F. Ravandi

M. Konopleva, M. Andreeff, H. Kantarjian, 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Long‐term follow‐up of a phase I study of high‐dose decitabine, busulfan, and cyclophosphamide plus allogeneic transplantation for the treatment of patients with leukemias

H. Kantarjian, F. Ravandi, B. Andersson, 2003, Cancer.

How I manage patients with hairy cell leukaemia

F. Ravandi, P. Thompson, 2017, British journal of haematology.

Inotuzumab ozogamicin with bosutinib for relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia or lymphoid blast phase of chronic myeloid leukemia

M. Konopleva, H. Kantarjian, J. Cortes, 2021, American journal of hematology.

Philadelphia-Positive Acute Lymphoblastic Leukemia: Current Treatment Options

H. Kantarjian, F. Ravandi, S. O'brien, 2012, Current Oncology Reports.

Targeted next-generation sequencing of circulating cell-free DNA vs bone marrow in patients with acute myeloid leukemia.

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2020, Blood advances.

How close are we to incorporating measurable residual disease into clinical practice for acute myeloid leukemia?

F. Ravandi, N. Short, 2019, Haematologica.

Effect of NPM1 and FLT3 mutations on the outcomes of elderly patients with acute myeloid leukemia receiving standard chemotherapy.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2013, Clinical lymphoma, myeloma & leukemia.

Frontline therapy with high-dose imatinib versus second generation tyrosine kinase inhibitor in patients with chronic-phase chronic myeloid leukemia – a propensity score analysis

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2016, Haematologica.

Evolutionary Action Score of TP53 Mutations: Integrated Clinico-pathologic And Protein Structural Analysis in Myelodysplastic Syndromes

O. Lichtarge, K. Do, M. Andreeff, 2020, bioRxiv.

Dynamic acquisition of FLT3 or RAS alterations drive a subset of patients with lower risk MDS to secondary AML

Z. Estrov, G. Garcia-Manero, J. Cortes, 2013, Leukemia.

Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System

J. Issa, H. Kantarjian, G. Garcia-Manero, 2008, Cancer.

Editorial: Acute Promyelocytic Leukemia — Towards A Chemotherapy-Free Approach to Cure in All Patients

F. Ravandi, Y. Kwong, H. Gill, 2022, Frontiers in Oncology.

Acute promyelocytic leukemia current treatment algorithms

F. Ravandi, H. Kantarjian, M. Yilmaz, 2021, Blood Cancer Journal.

Value of measurable residual disease monitoring in patients with acute promyelocytic leukemia in the era of frontline ‘chemotherapy-free’ therapy

M. Konopleva, M. Andreeff, H. Kantarjian, 2021, Leukemia & lymphoma.

The cure of leukemia through the optimist's prism

H. Kantarjian, G. Garcia-Manero, F. Ravandi, 2021, Cancer.

Acute Promyelocytic Leukemia: A Perspective.

F. Ravandi, R. Stone, 2017, Clinical lymphoma, myeloma & leukemia.

Time to abandon traditional chemotherapy for acute promyelocytic leukaemia?

F. Ravandi, H. Kantarjian, 2015, The Lancet. Oncology.

Clinical characteristics and outcomes in patients with acute promyelocytic leukaemia and hyperleucocytosis

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2015, British journal of haematology.

"It's effective therapy, stupid!".

F. Ravandi, 2013, Leukemia research.

Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Evolutionary action score identifies a subset of TP53 mutated myelodysplastic syndrome with favorable prognosis

O. Lichtarge, K. Do, M. Andreeff, 2021, Blood cancer journal.

Results of a Phase 1/2a dose–escalation study of FF-10501-01, an IMPDH inhibitor, in patients with acute myeloid leukemia or myelodysplastic syndromes

H. Kantarjian, G. Garcia-Manero, F. Ravandi, 2020, Leukemia & lymphoma.

Comparable outcomes of patients eligible vs ineligible for SWOG leukemia studies.

J. Radich, F. Ravandi, M. Othus, 2018, Blood.

Impact of the number of mutations in survival and response outcomes to hypomethylating agents in patients with myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms

M. Konopleva, Z. Estrov, S. Colla, 2018, Oncotarget.

Time to revise the revised-International Prognostic Scoring System?

F. Ravandi, C. Dinardo, 2015, Leukemia & lymphoma.

Prognostic factors associated with disease progression and overall survival in patients with myelodysplastic syndromes treated with decitabine.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2013, Clinical lymphoma, myeloma & leukemia.

The Search for Better Prognostic Models in Myelodysplastic Syndromes

H. Kantarjian, G. Garcia-Manero, F. Ravandi, 2011, Current hematologic malignancy reports.

Managing Philadelphia chromosome-positive acute lymphoblastic leukemia: role of tyrosine kinase inhibitors.

F. Ravandi, 2011, Clinical lymphoma, myeloma & leukemia.

Life after ponatinib failure: outcomes of chronic and accelerated phase CML patients who discontinued ponatinib in the salvage setting

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2018, Leukemia & lymphoma.

Integrative genomic analysis of adult mixed phenotype acute leukemia delineates lineage associated molecular subtypes

P. A. Futreal, Erika J. Thompson, M. Konopleva, 2018, Nature Communications.

The early achievement of measurable residual disease negativity in the treatment of adults with Philadelphia‐negative B‐cell acute lymphoblastic leukemia is a strong predictor for survival

M. Konopleva, Z. Estrov, H. Kantarjian, 2019, American journal of hematology.

Allogeneic Transplantation in First Remission Improves Outcome Irrespective of FLT3-ITD Allelic Ratio in FLT3-ITD positive AML Blood Marrow

E. Shpall, J. Cortes, K. Patel, 2018 .

Flotetuzumab as Salvage Immunotherapy for Refractory Acute Myeloid Leukemia.

S. Rutella, J. Dipersio, P. Chevallier, 2020, Blood.

Is acute myeloid leukemia a liquid tumor?

Z. Estrov, G. Garcia-Manero, J. Cortes, 2013, International journal of cancer.

To the editor: Ventricular arrhythmias and sudden death in patients taking ibrutinib

M. Konopleva, M. Andreeff, G. Garcia-Manero, 2017 .

The potential role of Bi-specific antibodies in acute myeloid leukemia.

F. Ravandi, M. Yilmaz, 2020, Best practice & research. Clinical haematology.

A clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trials

M. Konopleva, Z. Estrov, H. Kantarjian, 2017, Leukemia.

Update on Immunotherapy in AML and MDS: Monoclonal Antibodies and Checkpoint Inhibitors Paving the Road for Clinical Practice.

P. Sharma, G. Garcia-Manero, F. Ravandi, 2018, Advances in experimental medicine and biology.

Clinical and proteomic characterization of acute myeloid leukemia with mutated RAS

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2012, Cancer.

Timing of allogeneic hematopoietic cell transplantation (alloHCT) for chronic myeloid leukemia (CML) patients

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2020, Leukemia & lymphoma.

How I treat Philadelphia chromosome-positive acute lymphoblastic leukemia.

F. Ravandi, 2019, Blood.

Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitors.

Z. Estrov, H. Kantarjian, J. Cortes, 2016, Blood.

Investigational FMS-like tyrosine kinase 3 inhibitors in treatment of acute myeloid leukemia

M. Andreeff, H. Kantarjian, J. Cortes, 2014, Expert opinion on investigational drugs.

Acute promyelocytic leukemia in a patient with chronic lymphocytic leukemia-A case report.

T. Kadia, F. Ravandi, N. Pemmaraju, 2017, Hematology/oncology and stem cell therapy.

Factors associated with risk of central nervous system relapse in patients with non‐core binding factor acute myeloid leukemia

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2017, American journal of hematology.

T-cell large granular lymphocyte leukemia associated with myelodysplastic syndrome: a clinicopathologic study of nine cases.

F. Ravandi, L. Medeiros, J. Jorgensen, 2009, American journal of clinical pathology.

Survivorship in AML – a landmark analysis on the outcomes of acute myelogenous leukemia patients after maintaining complete remission for at least 3 years

M. Konopleva, M. Andreeff, H. Kantarjian, 2020, Leukemia & lymphoma.

Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials.

M. Konopleva, H. Kantarjian, J. Cortes, 2015, The Lancet. Haematology.

Long‐term results of frontline dasatinib in chronic myeloid leukemia

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2020, Cancer.

Phase I/II study of dasatinib in combination with decitabine in patients with accelerated or blast phase chronic myeloid leukemia

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2020, American journal of hematology.

Management of chronic myeloid leukemia during pregnancy among patients treated with a tyrosine kinase inhibitor: a single-Center experience

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2020, Leukemia & lymphoma.

Efficacy and safety of generic imatinib after switching from original imatinib in patients treated for chronic myeloid leukemia in the United States

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2019, Cancer medicine.

Prediction for sustained deep molecular response of BCR‐ABL1 levels in patients with chronic myeloid leukemia in chronic phase

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2018, Cancer.

Phase II trial of homoharringtonine with imatinib in chronic, accelerated, and blast phase chronic myeloid leukemia

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2017, Leukemia & lymphoma.

Malignancies occurring during therapy with tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML) and other hematologic malignancies.

H. Kantarjian, J. Cortes, A. Quintás-Cardama, 2008, Blood.

Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: retrospective analysis of patient data from five clinical trials.

H. Kantarjian, J. Cortes, S. Verstovsek, 2015, The Lancet. Haematology.

Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission.

H. Döhner, H. Dombret, B. Skikne, 2020, The New England journal of medicine.

A phase 1b/2 study of vosaroxin in combination with cytarabine in patients with relapsed or refractory acute myeloid leukemia

M. Maris, F. Ravandi, J. Karp, 2015, Haematologica.

Multivariate and subgroup analyses of a randomized, multinational, phase 3 trial of decitabine vs treatment choice of supportive care or cytarabine in older patients with newly diagnosed acute myeloid leukemia and poor- or intermediate-risk cytogenetics

H. Kantarjian, F. Ravandi, X. Thomas, 2014, BMC Cancer.

and T315I mutation following failure of imatinib mesylate therapy Characteristics and outcomes of patients with chronic myeloid leukemia

H. Kantarjian, G. Garcia-Manero, F. Ravandi, 2013 .

Dasatinib early intervention after cytogenetic or hematologic resistance to imatinib in patients with chronic myeloid leukemia

H. Kantarjian, J. Cortes, A. Quintás-Cardama, 2009, Cancer.

Bleeding diathesis in patients with chronic myelogenous leukemia receiving dasatinib therapy

H. Kantarjian, J. Cortes, A. Quintás-Cardama, 2009, Cancer.

Impact of treatment end point definitions on perceived differences in long-term outcome with tyrosine kinase inhibitor therapy in chronic myeloid leukemia.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A pilot study of imatinib, low-dose cytarabine and idarubicin for patients with chronic myeloid leukemia in myeloid blast phase

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2007, Leukemia & lymphoma.

Nasal-Type T/NK Lymphomas: A Clinicopathologic Study of 13 Cases

J. Manning, F. Cabanillas, F. Ravandi, 2000, Leukemia & lymphoma.

A phase I study of a combination of anti‐CD19 and anti‐CD22 immunotoxins (Combotox) in adult patients with refractory B‐lineage acute lymphoblastic leukaemia

A. Verma, F. Ravandi, S. Parekh, 2011, British journal of haematology.

Moxetumomab pasudotox for the treatment of relapsed and/or refractory hairy cell leukemia

F. Ravandi, I. Abou Dalle, 2019, Expert review of hematology.

Biological and clinical features of trisomy 21 in adult patients with acute myeloid leukemia.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2013, Clinical lymphoma, myeloma & leukemia.

Infections associated with purine analogs and monoclonal antibodies.

F. Ravandi, S. O'brien, 2005, Blood reviews.

Phase 1 study of anti-CD 33 immunotoxin HUM-195 / rGEL in patients with advanced myeloid malignancies

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2012 .

Ph-like acute lymphoblastic leukemia: a high-risk subtype in adults.

C. Mullighan, M. Konopleva, H. Kantarjian, 2017, Blood.

Frontline hyper-CVAD plus ponatinib for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: Updated results of a phase II study.

M. Konopleva, Z. Estrov, H. Kantarjian, 2017 .

Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients ≤60 years with newly diagnosed acute myeloid leukemia

M. Konopleva, Z. Estrov, M. Andreeff, 2013, American journal of hematology.

Minimal residual disease eradication with epigenetic therapy in core binding factor acute myeloid leukemia

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2017, American journal of hematology.

A randomized phase 2 study of idarubicin and cytarabine with clofarabine or fludarabine in patients with newly diagnosed acute myeloid leukemia

M. Konopleva, Z. Estrov, H. Kantarjian, 2017, Cancer.

US Intergroup Study of Chemotherapy Plus Dasatinib and Allogeneic Stem Cell Transplant in Philadelphia Chromosome Positive ALL.

J. Radich, F. Appelbaum, H. Kantarjian, 2016, Blood advances.

Long‐term follow‐up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome–positive acute lymphoblastic leukemia

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2015, Cancer.

Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia

H. Kantarjian, J. Cortes, F. Ravandi, 2013, Cancer.

Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study.

M. Konopleva, Z. Estrov, H. Kantarjian, 2015, The Lancet. Oncology.

Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia.

Jeffrey A Jones, M. Grever, E. Montserrat, 2017, Blood.

Phase 2 study of cladribine followed by rituximab in patients with hairy cell leukemia.

H. Kantarjian, F. Ravandi, S. Pierce, 2011, Blood.

Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study.

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2018, The Lancet. Oncology.

A phase 1 trial of vadastuximab talirine combined with hypomethylating agents in patients with CD33-positive AML.

F. Ravandi, D. DeAngelo, J. Lancet, 2018, Blood.

Efficacy of tosedostat, a novel, oral agent for elderly patients with relapsed or refractory acute myeloid leukemia: a review of the Phase II OPAL trial.

F. Ravandi, M. Mathisen, 2012, Future oncology.

Twice-daily fludarabine and cytarabine combination with or without gentuzumab ozogamicin is effective in patients with relapsed/refractory acute myeloid leukemia, high-risk myelodysplastic syndrome, and blast- phase chronic myeloid leukemia.

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2012, Clinical lymphoma, myeloma & leukemia.

Safety and clinical activity of 5‐aza‐2′‐deoxycytidine (decitabine) with or without Hyper‐CVAD in relapsed/refractory acute lymphocytic leukaemia

H. Kantarjian, G. Garcia-Manero, F. Ravandi, 2014, British journal of haematology.

Outcome of adults with acute lymphocytic leukemia in second or subsequent complete remission

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2010, Leukemia & lymphoma.

The combination of hyper-CVAD plus nelarabine as frontline therapy in adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma: MD Anderson Cancer Center experience

M. Konopleva, H. Kantarjian, T. Kadia, 2014, Leukemia.

Experience with 2 Dose Schedules of Inotuzumab Ozogamicin, Single Dose, and Weekly, in Refractory-Relapsed Acute Lymphocytic Leukemia (ALL)

H. Kantarjian, J. Cortes, F. Ravandi, 2012 .

Final Report Of Single-Center Study Of Chemotherapy Plus Dasatinib For The Initial Treatment Of Patients With Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia

H. Kantarjian, J. Cortes, F. Ravandi, 2013 .

Phase II Study Of Combination Of Hyper-CVAD With Ponatinib In Front Line Therapy Of Patients (pts) With Philadelphia Chromosome (Ph) Positive Acute Lymphoblastic Leukemia (ALL)

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2008 .

Augmented hyper-CVAD based on dose-intensified vincristine, dexamethasone, and asparaginase in adult acute lymphoblastic leukemia salvage therapy.

H. Kantarjian, G. Garcia-Manero, S. Verstovsek, 2011, Clinical lymphoma, myeloma & leukemia.

Anthracycline dose intensification in adult acute lymphoblastic leukemia

H. Kantarjian, J. Cortes, F. Ravandi, 2010, Cancer.

Salvage Therapy Outcomes in a Historical Cohort of Patients with Relapsed or Refractory Acute Myeloid Leukemia

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2018, Blood.

Prognostic impact of RAS mutations in patients with myelodysplastic syndrome

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2013, American journal of hematology.

Flow cytometric immunophenotypic alterations of persistent clonal haematopoiesis in remission bone marrows of patients with NPM1‐mutated acute myeloid leukaemia

M. Konopleva, H. Kantarjian, K. Patel, 2021, British journal of haematology.

Clonal hematopoiesis of indeterminate potential–associated mutations and risk of comorbidities in patients with myelodysplastic syndrome

H. Kantarjian, G. Garcia-Manero, K. Patel, 2019, Cancer.

Clearance of Somatic Mutations at Remission and the Risk of Relapse in Acute Myeloid Leukemia.

P. A. Futreal, M. Konopleva, M. Andreeff, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clonal chromosomal abnormalities appearing in Philadelphia chromosome-negative metaphases during CML treatment.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2017, Blood.

Distinct Immunophenotypes of T Cells in Bronchoalveolar Lavage Fluid From Leukemia Patients With Immune Checkpoint Inhibitors-Related Pulmonary Complications

L. Bashoura, S. Faiz, Linghua Wang, 2021, Frontiers in Immunology.

Phase I/II study of continuous-infusion troxacitabine in refractory acute myeloid leukemia.

M. Kelner, H. Kantarjian, F. Ravandi, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A randomized study of 2 dose levels of intravenous clofarabine in the treatment of patients with higher‐risk myelodysplastic syndrome

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2012, Cancer.

A phase I study of vorinostat in combination with idarubicin in relapsed or refractory leukaemia

H. Kantarjian, G. Garcia-Manero, T. Kadia, 2010, British journal of haematology.

Clinical experience with the BCL2‐inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies

M. Konopleva, K. Bhalla, H. Kantarjian, 2018, American journal of hematology.

Declining rates of treatment-related mortality in patients with newly diagnosed AML given ‘intense’ induction regimens: a report from SWOG and MD Anderson

E. Estey, F. Appelbaum, F. Ravandi, 2014, Leukemia.

Phase I clinical and pharmacokinetic study of oral sapacitabine in patients with acute leukemia and myelodysplastic syndrome.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Significance of thrombocytopenia in myelodysplastic syndromes: associations and prognostic implications.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2011, Clinical lymphoma, myeloma & leukemia.

Survival Outcome of Patients with Acute Myeloid Leukemia Transformed from Myeloproliferative Neoplasms

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2016 .

Phase I trial of alpha-particle immunotherapy with 225Ac-lintuzumab and low-dose cytarabine in patients age 60 or older with untreated acute myeloid leukemia.

E. Estey, D. Scheinberg, H. Kantarjian, 2017 .

Survival is poorer in patients with secondary core‐binding factor acute myelogenous leukemia compared with de novo core‐binding factor leukemia

H. Kantarjian, J. Cortes, F. Ravandi, 2009, Cancer.

Chronic myeloid leukemia 2011: Successes, challenges, and strategies—Proceedings of the 5th annual BCR‐ABL1 positive and BCR‐ABL1 negative myeloproliferative neoplasms workshop

J. Radich, G. Martinelli, A. Quintás-Cardama, 2011, American journal of hematology.

Treatment of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

F. Ravandi, E. Jabbour, N. Short, 2017, Current Treatment Options in Oncology.

A phase I and pharmacodynamic study of AT9283, a small-molecule inhibitor of aurora kinases in patients with relapsed/refractory leukemia or myelofibrosis.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2014, Clinical lymphoma, myeloma & leukemia.

FLT3 inhibitor based induction and allogeneic stem cell transplant in complete remission 1 improve outcomes in patients with newly diagnosed Acute Myeloid Leukemia with very low FLT3 allelic burden

M. Konopleva, H. Kantarjian, K. Patel, 2021, American journal of hematology.

Expression of ARC (apoptosis repressor with caspase recruitment domain), an antiapoptotic protein, is strongly prognostic in AML.

K. Coombes, Nianxiang Zhang, M. Andreeff, 2011, Blood.

Quizartinib in the treatment of FLT3-internal-tandem duplication-positive acute myeloid leukemia.

T. Kadia, F. Ravandi, S. Paul, 2019, Future oncology.

Differential characteristics of TP53 alterations in pure erythroid leukemia arising after exposure to cytotoxic therapy.

T. Kadia, F. Ravandi, N. Daver, 2022, Leukemia research.

Natural history of chronic myelomonocytic leukemia treated with hypomethylating agents

M. Konopleva, Z. Estrov, H. Kantarjian, 2017, American journal of hematology.

Importance of minimal residual disease in hairy cell leukemia: monoclonal antibodies as a therapeutic strategy

H. Kantarjian, F. Ravandi, M. Keating, 2009, Leukemia & lymphoma.

Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients

M. Konopleva, Z. Estrov, H. Kantarjian, 2017, Cancer.

Alemtuzumab Therapy for Hypereosinophilic Syndrome and Chronic Eosinophilic Leukemia

H. Kantarjian, J. Cortes, T. Manshouri, 2009, Clinical Cancer Research.

Phase I Study of XK469R (NSC 698215), a Quinoxaline Phenoxypropionic Acid Derivative, in Patients with Refractory Hematological Malignancies.

M. Ratain, R. Larson, S. Verstovsek, 2006 .

Post-transplantation cyclophosphamide reduces the incidence of acute graft-versus-host disease in patients with acute myeloid leukemia/myelodysplastic syndromes who receive immune checkpoint inhibitors after allogeneic hematopoietic stem cell transplantation

M. Suarez‐Almazor, M. Konopleva, G. Garcia-Manero, 2021, Journal for ImmunoTherapy of Cancer.

Targeted therapies in hematology and their impact on patient care: chronic and acute myeloid leukemia.

H. Kantarjian, J. Cortes, F. Ravandi, 2013, Seminars in hematology.

University of Birmingham Evaluating measurable residual disease in acute myeloid leukemia

F. Ravandi, R. Walter, S. Freeman, 2018 .

TP53 copy number and protein expression inform mutation status across risk categories in acute myeloid leukemia

K. Bhalla, H. Kantarjian, F. Khodakarami, 2022, Blood.

Clinical outcomes and influence of mutation clonal dominance in oligomonocytic and classical chronic myelomonocytic leukemia

M. Konopleva, Z. Estrov, H. Kantarjian, 2020, American journal of hematology.

Outcome of patients with FLT3-mutated acute myeloid leukemia in first relapse.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2010, Leukemia research.

Phase II trial of HyperCVAD and Dasatinib in patients with relapsed Philadelphia chromosome positive acute lymphoblastic leukemia or blast phase chronic myeloid leukemia

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2014, American journal of hematology.

2021 Update Measurable Residual Disease in Acute Myeloid Leukemia: European LeukemiaNet Working Party Consensus Document.

K. Döhner, M. Heuser, F. Thol, 2021, Blood.

2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party

M. Heuser, F. Thol, T. Haferlach, 2021 .

Ruxolitinib in combination with lenalidomide as therapy for patients with myelofibrosis

H. Kantarjian, J. Cortes, S. Verstovsek, 2015, Haematologica.

Current paradigms in the management of Philadelphia chromosome positive acute lymphoblastic leukemia in adults

H. Kantarjian, F. Ravandi, E. Jabbour, 2018, American journal of hematology.

Clinical impact of dose reductions and interruptions of second‐generation tyrosine kinase inhibitors in patients with chronic myeloid leukaemia

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2010, British journal of haematology.

The distribution of T‐cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia

P. Sharma, M. Konopleva, M. Andreeff, 2018, Cancer.

Proposed criteria for response assessment in patients treated in clinical trials for myeloproliferative neoplasms in blast phase (MPN-BP): formal recommendations from the post-myeloproliferative neoplasm acute myeloid leukemia consortium.

O. Abdel-Wahab, V. Najfeld, R. Levine, 2012, Leukemia research.

Implications of discrepancy in morphologic diagnosis of myelodysplastic syndrome between referral and tertiary care centers.

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2011, Blood.

A prospective analysis of symptom burden for patients with chronic myeloid leukemia in chronic phase treated with frontline second‐ and third‐generation tyrosine kinase inhibitors

C. Cleeland, Z. Estrov, H. Kantarjian, 2018, Cancer medicine.

Analysis of 2013 European LeukaemiaNet (ELN) responses in chronic phase CML across four frontline TKI modalities and impact on clinical outcomes

H. Kantarjian, J. Cortes, S. Verstovsek, 2016, British journal of haematology.

Analysis of long term responses and their impact on outcomes in patients with chronic phase CML treated with four different TKI modalities – analysis of 5 prospective clinical trials

H. Kantarjian, J. Cortes, S. Verstovsek, 2016 .

Ponatinib as first-line treatment for patients with chronic myeloid leukaemia in chronic phase: a phase 2 study.

H. Kantarjian, J. Cortes, P. Jain, 2015, The Lancet. Haematology.

Patient-driven discontinuation of tyrosine kinase inhibitors: single institution experience

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2014, Leukemia & lymphoma.

HCVAD plus imatinib or dasatinib in lymphoid blastic phase chronic myeloid leukemia

H. Kantarjian, J. Cortes, A. Quintás-Cardama, 2014, Cancer.

Assessment at 6 months may be warranted for patients with chronic myeloid leukemia with no major cytogenetic response at 3 months

H. Kantarjian, J. Cortes, A. Quintás-Cardama, 2013, Haematologica.

Outcome after failure of second generation tyrosine kinase inhibitors treatment as first-line therapy for patients with chronic myeloid leukemia.

M. Konopleva, E. Burton, H. Kantarjian, 2013, Clinical lymphoma, myeloma & leukemia.

Low Risk of Infectious Events in Patients (Pts) with Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) Treated with Dasatinib.

E. Burton, H. Kantarjian, J. Cortes, 2009 .

Activating internal tandem duplication mutations of the fms-like tyrosine kinase-3 (FLT3-ITD) at complete response and relapse in patients with acute myeloid leukemia

H. Kantarjian, J. Cortes, R. Luthra, 2012, Haematologica.

Alemtuzumab in CLL and Other Lymphoid Neoplasms

F. Ravandi, S. O'brien, 2006, Cancer investigation.

Valganciclovir prevents cytomegalovirus reactivation in patients receiving alemtuzumab-based therapy.

H. Kantarjian, Xuelin Huang, F. Ravandi, 2008, Blood.

Activity of decitabine, a hypomethylating agent, in chronic myelomonocytic leukemia

H. Kantarjian, J. Cortes, F. Ravandi, 2007, Cancer.

Novel monoclonal antibody-based treatment strategies in adults with acute lymphoblastic leukemia

H. Kantarjian, F. Ravandi, E. Jabbour, 2019, Therapeutic advances in hematology.

Quantifying the Survival Benefit for Allogeneic Stem Cell Transplantation in Relapsed Acute Myeloid Leukemia

F. Ravandi, S. Pierce, M. Lima, 2014 .

Prognostic impact of conventional cytogenetics in acute myeloid leukemia treated with venetoclax and decitabine

M. Konopleva, H. Kantarjian, T. Kadia, 2021, Leukemia & lymphoma.

Comparison of Multiparameter Flow Cytometry Immunophenotypic Analysis and Quantitative RT-PCR for the Detection of Minimal Residual Disease of Core Binding Factor Acute Myeloid Leukemia.

F. Ravandi, G. Borthakur, N. Daver, 2016, American journal of clinical pathology.

Improvement in clinical outcome of FLT3 ITD mutated acute myeloid leukemia patients over the last one and a half decade

M. Konopleva, M. Andreeff, H. Kantarjian, 2015, American journal of hematology.

Acute Myeloid Leukemia Biological and Clinical Features of Trisomy 21 in Adult Patients With Acute Myeloid Leukemia

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2013 .

myeloid leukemia (AML) in patients 50 years of age or older Clofarabine and cytarabine combination as induction therapy for acute

Z. Estrov, J. Cortes, S. Verstovsek, 2013 .

Hypocellular acute myeloid leukemia in adults: analysis of the clinical outcome of 123 patients

H. Kantarjian, J. Cortes, T. Kadia, 2011, Haematologica.

Persistence of cytogenetic abnormalities at complete remission after induction in patients with acute myeloid leukemia: prognostic significance and the potential role of allogeneic stem-cell transplantation.

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Intensively timed combination chemotherapy for the induction of adult patients with acute myeloid leukemia

E. Estey, H. Kantarjian, G. Garcia-Manero, 2010, Cancer.

Superior outcome with hypomethylating therapy in patients with acute myeloid leukemia and high‐risk myelodysplastic syndrome and chromosome 5 and 7 abnormalities

J. Issa, H. Kantarjian, G. Garcia-Manero, 2009, Cancer.

Validation of the European Prognostic Index for younger adult patients with acute myeloid leukaemia in first relapse

H. Kantarjian, G. Garcia-Manero, S. Verstovsek, 2006, British journal of haematology.

Comprehensive analysis of CBFbeta-MYH11 fusion transcripts in acute myeloid leukemia by RT-PCR analysis.

F. Ravandi, S. Kadkol, C. Dodge, 2004, The Journal of molecular diagnostics : JMD.

Phase I study of sorafenib in patients with refractory or relapsed acute leukemias

M. Konopleva, M. Andreeff, H. Kantarjian, 2011, Haematologica.

Outcome of patients with chronic myeloid leukemia with multiple ABL1 kinase domain mutations receiving tyrosine kinase inhibitor therapy

H. Kantarjian, J. Cortes, A. Quintás-Cardama, 2011, Haematologica.

Characteristics, outcomes, prognostic factors and treatment of patients with T-cell prolymphocytic leukemia (T-PLL)

Z. Estrov, H. Kantarjian, J. Cortes, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Low-level expression of SAMHD1 in acute myeloid leukemia (AML) blasts correlates with improved outcome upon consolidation chemotherapy with high-dose cytarabine-based regimens

M. Andreeff, H. Kantarjian, T. Schaller, 2018, Blood Cancer Journal.

CD56 expression predicts occurrence of CNS disease in acute lymphoblastic leukemia.

Z. Estrov, H. Kantarjian, J. Cortes, 2002, Leukemia research.

Contemporary outcomes in IDH‐mutated acute myeloid leukemia: The impact of co‐occurring NPM1 mutations and venetoclax‐based treatment

G. Garcia-Manero, K. Patel, T. Kadia, 2022, American journal of hematology.

Activity of decitabine as maintenance therapy in core binding factor acute myeloid leukemia

G. Garcia-Manero, K. Patel, T. Kadia, 2020, American journal of hematology.

Rapid and reliable confirmation of acute promyelocytic leukemia by immunofluorescence staining with an antipromyelocytic leukemia antibody

H. Kantarjian, J. Cortes, F. Ravandi, 2010, Cancer.

Immune modulation of minimal residual disease in early chronic phase chronic myelogenous leukemia

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2011, Cancer.

Results from a randomized phase III trial of decitabine versus supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed AML.

H. Kantarjian, F. Ravandi, X. Thomas, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Very High Rates of Clinical and Cytogenetic Response with the Combination of the Histone Deacetylase Inhibitor Pracinostat (SB939) and 5-Azacitidine in High-Risk Myelodysplastic Syndrome

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2012 .

Phase I/II Study of MGCD0103, an Oral Isotype-Selective Histone Deacetylase (HDAC) Inhibitor, in Combination with 5-Azacitidine in Higher-Risk Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML).

A. Yang, H. Kantarjian, G. Garcia-Manero, 2007 .

Comparable Outcomes of Patients Eligible Versus Ineligible for Southwest Oncology Group (SWOG) Leukemia Studies

J. Radich, F. Ravandi, M. Othus, 2016 .

A prognostic model of therapy-related myelodysplastic syndrome for predicting survival and transformation to acute myeloid leukemia.

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2014, Clinical lymphoma, myeloma & leukemia.

Decitabine in older adults with acute myeloid leukemia: why was the dream broken?

W. Wilson, E. Estey, H. Kantarjian, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Randomized Phase II Study of Low-Dose Decitabine Versus Azacitidine in Patients with Low- or Intermediate-1-Risk Myelodysplastic Syndromes: A Report on Behalf of the MDS Clinical Research Consortium

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2016 .

Phase II study of rabbit anti-thymocyte globulin, cyclosporine and granulocyte colony-stimulating factor in patients with aplastic anemia and myelodysplastic syndrome

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2009, Leukemia.

Urgent cytoreduction for newly diagnosed acute myeloid leukemia patients allows acquisition of pretreatment genomic data and enrollment on investigational clinical trials

G. Garcia-Manero, T. Kadia, F. Ravandi, 2022, American journal of hematology.

Survival Outcomes in Relapsed/Refractory Acute Myeloid Leukemia Patients Who Achieve Less-than-Complete Response After First Salvage Therapy

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2014 .

Resistance to targeted therapies: delving into FLT3 and IDH

M. Konopleva, T. Kadia, F. Ravandi, 2022, Blood Cancer Journal.

Oral (po) and Intravenous (iv) Clofarabine for Patients (pts) with Myelodysplastic Syndrome (MDS)

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2008 .

Low-Dose Decitabine versus Low-Dose Azacitidine in Lower-Risk MDS

K. Do, H. Kantarjian, G. Garcia-Manero, 2022, NEJM Evidence.

Time to response and survival in hypomethylating agent-treated acute myeloid leukemia

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2018, Leukemia & lymphoma.

Effect of haematological improvement on survival in patients given targeted therapy as initial treatment of acute myeloid leukaemia or high‐risk myelodysplastic syndrome

J. Issa, H. Kantarjian, G. Garcia-Manero, 2007, British journal of haematology.

A phase 1‐2 study of a farnesyltransferase inhibitor, tipifarnib, combined with idarubicin and cytarabine for patients with newly diagnosed acute myeloid leukemia and high‐risk myelodysplastic syndrome

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2011, Cancer.

Hypomethylating Therapy in Patients with AML and High-Risk MDS and Chromosome 5 and 7 Abnormalities Is Associated with An Improved Outcome Compared to Conventional Chemotherapy

J. Issa, H. Kantarjian, G. Garcia-Manero, 2008 .

The Addition of All-Trans Retinoic Acid to Chemotherapy May Not Improve the Outcome of Patient with NPM1 Mutated Acute Myeloid Leukemia

H. Kantarjian, J. Cortes, F. Ravandi, 2013, Front. Oncol..

Retrospective comparison of survival and responses to Fludarabine, Cytarabine, GCSF (FLAG) in combination with gemtuzumab ozogamicin (GO) or Idarubicin (IDA) in patients with newly diagnosed core binding factor (CBF) acute myelogenous leukemia: MD Anderson experience in 174 patients

G. Garcia-Manero, K. Patel, T. Kadia, 2022, American journal of hematology.

Venetoclax combined with FLAG‐IDA induction and consolidation in newly diagnosed acute myeloid leukemia

M. Konopleva, M. Andreeff, H. Kantarjian, 2021, American journal of hematology.

Phase 2 study of lenalidomide maintenance for patients with high‐risk acute myeloid leukemia in remission

Z. Estrov, M. Andreeff, H. Kantarjian, 2021, Cancer.

Vosaroxin: innovative anticancer quinolone for the treatment of acute myelogenous leukemia

H. Kantarjian, F. Ravandi, K. Marx, 2016 .

Relapse risk and survival in patients with FLT3 mutated acute myeloid leukemia undergoing stem cell transplantation

M. Andreeff, D. Marin, E. Shpall, 2017, American journal of hematology.

The effect of eltrombopag in managing thrombocytopenia associated with tyrosine kinase therapy in patients with chronic myeloid leukemia and myelofibrosis.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2019, Journal of Clinical Oncology.

The heterogeneous prognosis of patients with myelodysplastic syndrome and chromosome 5 abnormalities

J. Issa, H. Kantarjian, G. Garcia-Manero, 2009, Cancer.

The Heterogeneous Prognosis of Patients with Myelodysplastic Syndrome (MDS) and Chromosome 5 Abnormalities: How Does It Relate to the Original Lenalidomide Experience in MDS?.

J. Issa, H. Kantarjian, G. Garcia-Manero, 2008 .

Activity of 9‐nitro‐camptothecin, an oral topoisomerase I inhibitor, in myelodysplastic syndrome and chronic myelomonocytic leukemia

H. Kantarjian, J. Cortes, A. Quintás-Cardama, 2006, Cancer.

Activity of Venetoclax-Based Therapy in Myelodysplastic Syndrome (MDS)

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2019, Blood.

A Bayesian Phase II Randomized Trial of Azacitidine Versus Azacitidine + Vorinostat in Patients with Newly Diagnosed AML or High-Risk MDS with Poor Performance Status, Organ Dysfunction, or Other Comorbidities

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2014 .

Final Report of a Phase II Study of 5-Azacitidine and Vorinostat in Patients (pts) with Newly Diagnosed Myelodysplastic Syndrome (MDS) or Acute Myelogenous Leukemia (AML) Not Eligible for Clinical Trials Because Poor Performance and Presence of Other Comorbidities

E. Estey, M. Konopleva, Z. Estrov, 2010 .

A Prognostic Model of Therapy-Related Myelodysplastic Syndrome for Predicting Survival and Transformation to Acute Myeloid Leukemia

H. Kantarjian, G. Garcia-Manero, A. Quintás-Cardama, 2011 .

Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study.

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2018, The Lancet. Haematology.

Current management of Philadelphia chromosome positive ALL and the role of stem cell transplantation.

F. Ravandi, 2017, Hematology. American Society of Hematology. Education Program.

Which tyrosine kinase inhibitor should we use to treat Philadelphia chromosome-positive acute lymphoblastic leukemia?

H. Kantarjian, F. Ravandi, E. Jabbour, 2017, Best practice & research. Clinical haematology.

The role of ponatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia

H. Kantarjian, J. Cortes, F. Ravandi, 2015, Expert review of anticancer therapy.

Role of Tyrosine Kinase Inhibitors in the Management of Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia

H. Kantarjian, J. Cortes, F. Ravandi, 2011, Current hematologic malignancy reports.

Outcome after Frontline Therapy with the Hyper-CVAD and Imatinib Mesylate Regimen for Adults with De Novo or Minimally Treated Philadelphia Chromosome (Ph) Positive Acute Lymphoblastic Leukemia (ALL)

H. Kantarjian, J. Cortes, F. Ravandi, 2008 .

Long‐term results of low‐intensity chemotherapy with clofarabine or cladribine combined with low‐dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia

M. Konopleva, Z. Estrov, H. Kantarjian, 2021, American journal of hematology.

Oral azacitidine prolongs survival of patients with AML in remission independent of measurable residual disease status.

H. Döhner, F. Thol, H. Dombret, 2022, Blood.

Is Maintenance Therapy Necessary in AML

F. Ravandi, 2021 .

Nivolumab maintenance in high-risk acute myeloid leukemia patients: a single-arm, open-label, phase II study

M. Konopleva, H. Kantarjian, J. Cortes, 2021, Blood Cancer Journal.

Final results of the phase II study of rabbit anti‐thymocyte globulin, ciclosporin, methylprednisone, and granulocyte colony‐stimulating factor in patients with aplastic anaemia and myelodysplastic syndrome

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2012, British journal of haematology.

Characteristics and outcomes of patients with multiple myeloma (MM) who develop therapy (t)-related myelodysplastic syndrome (MDS), t-chronic myelomonocytic leukemia (CMML), or t-acute myeloid leukemia (AML) patients underwent high-dose chemotherapy and autologous hematopoietic stem cell

J. Cortes, S. Verstovsek, F. Ravandi, 2015 .

Decitabine improves response rate and prolongs progression‐free survival in older patients with newly diagnosed acute myeloid leukemia and with monosomal karyotype: A subgroup analysis of the DACO‐016 trial

H. Kantarjian, F. Ravandi, A. Oriol, 2018, American journal of hematology.

Clinical, genomic, and transcriptomic differences between myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN‐RS‐T) and myelodysplastic syndrome with ring sideroblasts (MDS‐RS)

K. Do, H. Kantarjian, G. Garcia-Manero, 2021, American journal of hematology.

Predicting survival of patients with hypocellular myelodysplastic syndrome

H. Kantarjian, G. Garcia-Manero, A. Quintás-Cardama, 2012, Cancer.

Retrospective analysis of prognostic factors associated with response and overall survival by baseline marrow blast percentage in patients with myelodysplastic syndromes treated with decitabine.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2013, Clinical lymphoma, myeloma & leukemia.

A multi-arm phase Ib/II study designed for rapid, parallel evaluation of novel immunotherapy combinations in relapsed/refractory acute myeloid leukemia

M. Konopleva, Z. Estrov, M. Andreeff, 2022, Leukemia & lymphoma.

Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial.

M. Konopleva, Z. Estrov, H. Kantarjian, 2019, The Lancet. Haematology.

Factors associated with outcome of secondary MDS and AML: Review of 2,182 patients at MDACC.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2012 .

Decitabine (DAC) Can Be Safely Reduced After Achievement of Best Response In Patients (pts) with Myelodysplastic Syndrome (MDS)

H. Kantarjian, J. Cortes, T. Kadia, 2010 .

Venetoclax for Children and Adolescents with Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma

M. Konopleva, H. Kantarjian, F. Ravandi, 2021, Cancers.

An Update on the Clinical Evaluation of Antibody-Based Therapeutics in Acute Myeloid Leukemia

F. Ravandi, N. Daver, S. Venugopal, 2021, Current Hematologic Malignancy Reports.

A phase 1 trial of vadastuximab talirine as monotherapy in patients with CD33-positive acute myeloid leukemia.

F. Ravandi, D. DeAngelo, J. Lancet, 2018, Blood.

Enhancing cytotoxicity of immunotoxins in AML.

F. Ravandi, N. Daver, 2016, Blood.

Clinical and Molecular Response in Core Binding Factor Acute Myelogenous Leukemia with Fludarabine, Cytarabine, G-CSF and Gemtuzumab Ozogamicin.

Z. Estrov, H. Kantarjian, S. Verstovsek, 2008 .

Optimizing Risk Stratification in Acute Myeloid Leukemia: Dynamic Models for a Dynamic Therapeutic Landscape.

M. Tallman, F. Ravandi, N. Short, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical Outcomes of Patients With Chronic Myeloid Leukemia With Concurrent Core Binding Factor Rearrangement and Philadelphia Chromosome.

G. Garcia-Manero, J. Cortes, F. Ravandi, 2021, Clinical lymphoma, myeloma & leukemia.

Myeloid sarcoma.

F. Ravandi, O. Shahin, 2020, Current opinion in hematology.

Outcome of patients with therapy-related acute myeloid leukemia with or without an antecedent history of myelodysplasia

G. Garcia-Manero, J. Cortes, T. Kadia, 2017 .

The clinical significance of negative flow cytometry immunophenotypic results in a morphologically scored positive bone marrow in patients following treatment for acute myeloid leukemia

M. Routbort, F. Ravandi, N. Daver, 2015, American journal of hematology.

Induction Therapy in Acute Myeloid Leukemia

T. Kadia, F. Ravandi, 2014 .

Novel treatment options for acute myelocytic leukemia

H. Kantarjian, J. Cortes, F. Ravandi, 2013 .

Prognostic significance of 11q23 aberrations in adult acute myeloid leukemia and the role of allogeneic stem cell transplantation

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2013, Leukemia.

Monitoring minimal residual disease in acute myeloid leukemia: ready for prime time?

F. Ravandi, J. Jorgensen, 2012, Journal of the National Comprehensive Cancer Network : JNCCN.

New treatments and strategies in acute myeloid leukemia.

F. Ravandi, 2011, Clinical lymphoma, myeloma & leukemia.

Acute Myeloid Leukemia S 60 New Treatments and Strategies in Acute Myeloid Leukemia

F. Ravandi, 2011 .

Quizartinib with Decitabine +/- Venetoclax Is Highly Active in Patients (Pts) with FLT3-ITD Mutated (mut) Acute Myeloid Leukemia (AML): Clinical Report and Signaling Cytof Profiling from a Phase IB/II Trial

M. Konopleva, M. Andreeff, H. Kantarjian, 2020 .

The Combination of Quizartinib with Azacitidine or Low Dose Cytarabine is Highly Active in Patients (Pts) with FLT3‐ITD Mutated Myeloid Leukemias: Interim Report of a Phase I/II Trial: Abstract: AML‐014

M. Konopleva, Z. Estrov, M. Andreeff, 2017 .

The Combination of Quizartinib with Azacitidine or Low Dose Cytarabine Is Highly Active in Patients (Pts) with FLT3-ITD Mutated Myeloid Leukemias: Interim Report of a Phase I/II Trial

M. Konopleva, M. Andreeff, H. Kantarjian, 2014 .

Characteristics and outcome of patients with acute myeloid leukemia refractory to 1 cycle of high-dose cytarabine-based induction chemotherapy.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2009, Blood.

Hyper‐CVAD plus nelarabine in newly diagnosed adult T‐cell acute lymphoblastic leukemia and T‐lymphoblastic lymphoma

M. Konopleva, G. Garcia-Manero, J. Cortes, 2018, American journal of hematology.

Clinical characteristics and outcomes of previously untreated patients with adult onset T‐acute lymphoblastic leukemia and T‐lymphoblastic lymphoma with hyper‐CVAD based regimens

M. Konopleva, Z. Estrov, H. Kantarjian, 2017, American journal of hematology.

Modern treatment programs for adults with acute lymphoblastic leukemia

H. Kantarjian, F. Ravandi, S. Faderl, 2007, Current hematologic malignancy reports.

Philadelphia chromosome-positive acute lymphoblastic leukemia.

F. Ravandi, P. Kebriaei, 2009, Hematology/oncology clinics of North America.

Philadelphia Chromosome -P ositive Acute Lymphoblastic Leukemia

F. Ravandi, P. Kebriaei, 2009 .

Reversal of Acquired Drug Resistance in FLT3-Mutated Acute Myeloid Leukemia Cells via Distinct Drug Combination Strategies

M. Konopleva, M. Andreeff, J. Cortes, 2014, Clinical Cancer Research.

Improved Survival in Patients with First Relapsed or Refractory Acute Myeloid Leukemia (AML) Treated with Vosaroxin Plus Cytarabine Versus Placebo Plus Cytarabine: Results of a Phase 3 Double-Blind Randomized Controlled Multinational Study (VALOR)

Jennifer A. Smith, G. Acton, H. Kantarjian, 2014 .

A Phase 2 Dose Regimen Optimization Study of Three Schedules of Voreloxin as Single Agent Therapy for Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia.

M. Maris, H. Kantarjian, S. Dakhil, 2009 .

SNS-595 Demonstrates Clinical Responses in a Phase 1 Study in Acute Leukemia.

H. Kantarjian, F. Ravandi, J. Karp, 2007 .

Clinical value of event-free survival in acute myeloid leukemia.

M. Konopleva, M. Andreeff, H. Kantarjian, 2020, Blood advances.

Venetoclax combined with induction chemotherapy in patients with newly diagnosed acute myeloid leukaemia: a post-hoc, propensity score-matched, cohort study.

G. Garcia-Manero, E. Shpall, T. Kadia, 2022, The Lancet. Haematology.

Outcome of therapy‐related acute promyelocytic leukemia with or without arsenic trioxide as a component of frontline therapy

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2011, Cancer.

Azacitidine plus venetoclax in patients with high-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: phase 1 results of a single-centre, dose-escalation, dose-expansion, phase 1-2 study.

M. Andreeff, S. Colla, G. Garcia-Manero, 2022, The Lancet. Haematology.

Outcomes with lower intensity therapy in TP53-mutated acute myeloid leukemia

M. Konopleva, M. Andreeff, H. Kantarjian, 2018, Leukemia & lymphoma.

Improving outcomes for patients with acute myeloid leukemia in first relapse: A single center experience

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2015, American journal of hematology.

Discontinuation of hypomethylating agent therapy in patients with myelodysplastic syndromes or acute myelogenous leukemia in complete remission or partial response: retrospective analysis of survival after long-term follow-up.

H. Kantarjian, G. Garcia-Manero, F. Ravandi, 2015, Leukemia research.

Outcomes of patients with myelodysplatic syndrome and chronic myelomonocytic leukemia post clofarabine failure

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2014, Therapeutic advances in hematology.

Decitabine can be safely reduced after achievement of best objective response in patients with myelodysplastic syndrome.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2013, Clinical lymphoma, myeloma & leukemia.

Phase I-II study of bendamustine in patients with acute leukemia and high risk myelodysplastic syndrome.

Z. Estrov, H. Kantarjian, J. Cortes, 2012, Clinical lymphoma, myeloma & leukemia.

Oral clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome.

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Next-Generation Sequencing of DDX41 in Myeloid Neoplasms Leads to Increased Detection of Germline Alterations

K. Bhalla, H. Kantarjian, G. Garcia-Manero, 2018, Frontiers in Oncology.

A Phase II Study of Azacitidine, Venetoclax, and Trametinib in Relapsed or Refractory Acute Myeloid Leukemia Harboring RAS Pathway-Activating Mutations

M. Konopleva, T. Kadia, F. Ravandi, 2022, Acta Haematologica.

Phase II Study of Venetoclax Added to Cladribine Plus Low-Dose Cytarabine Alternating With 5-Azacitidine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia

M. Konopleva, M. Andreeff, K. Bhalla, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Hypomethylating agent and venetoclax with FLT3 inhibitor “triplet” therapy in older/unfit patients with FLT3 mutated AML

M. Konopleva, M. Andreeff, G. Garcia-Manero, 2022, Blood Cancer Journal.

Prediction of survival with intensive chemotherapy in acute myeloid leukemia

G. Garcia-Manero, K. Patel, T. Kadia, 2022, American journal of hematology.

Outcomes in patients with newly diagnosed TP53‐mutated acute myeloid leukemia with or without venetoclax‐based therapy

M. Konopleva, M. Andreeff, H. Kantarjian, 2021, Cancer.

Duration of cytopenias with concomitant venetoclax and azole antifungals in acute myeloid leukemia

M. Konopleva, H. Kantarjian, T. Kadia, 2021, Cancer.

An effective chemotherapy‐free regimen of ponatinib plus venetoclax for relapsed/refractory Philadelphia chromosome‐positive acute lymphoblastic leukemia

M. Konopleva, H. Kantarjian, Xuelin Huang, 2021, American journal of hematology.

Decitabine and venetoclax for IDH1/2‐mutated acute myeloid leukemia

M. Konopleva, H. Kantarjian, T. Kadia, 2021, American journal of hematology.

Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia

M. Konopleva, H. Kantarjian, T. Kadia, 2021, Blood Cancer Journal.

Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemia.

M. Konopleva, M. Andreeff, H. Kantarjian, 2020, Blood advances.

Results From the Dose Escalation Phase of a Randomized Phase 1–2 First-in-Human (FIH) Study of SGI-110, a Novel Low Volume Stable Subcutaneous (SQ) Second Generation Hypomethylating Agent (HMA) in Patients with Relapsed/Refractory MDS and AML

J. Issa, W. Chung, H. Kantarjian, 2012 .

Decitabine with allogeneic peripheral blood stem cell transplantation in the therapy of leukemia relapse following a prior transplant: results of a phase I study

H. Kantarjian, F. Ravandi, S. Giralt, 2001, Bone Marrow Transplantation.

Relapsed Refractory BRAF-Negative, IGHV4-34-Positive Variant of Hairy Cell Leukemia: A Distinct Entity?

Z. Estrov, H. Kantarjian, R. Luthra, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I Study of Cloretazine (VNP40101M), a Novel Sulfonylhydrazine Alkylating Agent, Combined with Cytarabine in Patients with Refractory Leukemia

M. Sznol, H. Kantarjian, G. Garcia-Manero, 2005, Clinical Cancer Research.

Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia.

Susan O'Brien, Weiqiang Zhao, Gautam Borthakur, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalities.

H. Kantarjian, J. Cortes, A. Quintás-Cardama, 2013, Blood.

inhibitor modalities diagnosed chronic myeloid leukemia : results with four tyrosine kinase Early responses predict better outcomes in patients with newly

H. Kantarjian, P. Jain, F. Ravandi, 2013 .

The clinical significance of achieving different levels of cytogenetic response in patients with chronic phase chronic myeloid leukemia after failure to front-line therapy: is complete cytogenetic response the only desirable endpoint?

E. Burton, H. Kantarjian, G. Garcia-Manero, 2011, Clinical lymphoma, myeloma & leukemia.

Feasibility of allografting in patients with advanced acute lymphoblastic leukemia after salvage therapy with inotuzumab ozogamicin.

H. Kantarjian, F. Ravandi, S. O'brien, 2013, Clinical lymphoma, myeloma & leukemia.

positive leukemias - Philadelphia chromosome secondary genetic changes in determining the phenotype of BCR-ABL fusion transcript types and levels and their interaction with

H. Kantarjian, J. Cortes, F. Ravandi, 2013 .

BCR-ABL fusion transcript types and levels and their interaction with secondary genetic changes in determining the phenotype of Philadelphia chromosome-positive leukemias.

H. Kantarjian, J. Cortes, F. Ravandi, 2008, Blood.

Survival beneﬁt with imatinib mesylate versus interferon- (cid:1) –based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia

H. Kantarjian, G. Garcia-Manero, F. Ravandi, 2006 .

Outcome of patients with chronic myeloid leukemia in lymphoid blastic phase and Philadelphia chromosome–positive acute lymphoblastic leukemia treated with hyper‐CVAD and dasatinib

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2021, Cancer.

Outcomes of patients with chronic phase chronic myeloid leukemia (CML-CP) after discontinuation of frontline ponatinib therapy

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2019, Leukemia & lymphoma.

Tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: a single-institution experience

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2019, Journal of Hematology & Oncology.

Cladribine and low-dose cytarabine alternating with decitabine as front-line therapy for elderly patients with acute myeloid leukaemia: a phase 2 single-arm trial.

Susan O'Brien, Koji Sasaki, Naveen Pemmaraju, 2018, The Lancet. Haematology.

Posttransplantation cyclophosphamide improves transplantation outcomes in patients with AML/MDS who are treated with checkpoint inhibitors

P. Sharma, M. Konopleva, H. Kantarjian, 2020, Cancer.

Defining the Immune Checkpoint Landscape in Patients (pts) with Acute Myeloid Leukemia (AML)

P. Sharma, M. Konopleva, M. Andreeff, 2016 .

Phase IB/II Study of Nivolumab in Combination with Azacytidine (AZA) in Patients (pts) with Relapsed Acute Myeloid Leukemia (AML)

P. Sharma, M. Konopleva, M. Andreeff, 2016 .

chronic myeloid leukemia in accelerated or blast phase inhibitors is associated with a poor prognosis among patients with major cytogenetic response with second-generation tyrosine kinase Failure to achieve a complete hematologic response at the time of a

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2013 .

Failure to achieve a complete hematologic response at the time of a major cytogenetic response with second-generation tyrosine kinase inhibitors is associated with a poor prognosis among patients with chronic myeloid leukemia in accelerated or blast phase.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2009, Blood.

Failure to achieve a major cytogenetic response by 12 months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemia.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2008, Blood.

A phase I/II randomized trial of clofarabine or fludarabine added to idarubicin and cytarabine for adults with relapsed or refractory acute myeloid leukemia

M. Konopleva, Z. Estrov, H. Kantarjian, 2018, Leukemia & lymphoma.

Elacytarabine (CP-4055) in the treatment of acute myeloid leukemia.

F. Ravandi, C. Dinardo, S. O'brien, 2013, Future oncology.

A phase I study of the combination of a DNA topoisomerase inhibitor, idarubicin, with the histone deacetylase inhibitor vorinostat, in advanced acute leukemia

G. Garcia-Manero, T. Kadia, F. Ravandi, 2007 .

Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation.

Jorge Cortes, Guillermo Garcia-Manero, Gautam Borthakur, 2013, Blood.

Correction to: Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML

M. Konopleva, M. Andreeff, H. Kantarjian, 2021, Journal of Hematology & Oncology.

Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML

M. Konopleva, M. Andreeff, H. Kantarjian, 2020, Journal of Hematology & Oncology.

Salvage Therapy Outcomes in a Historical Cohort of Patients With Relapsed or Refractory Acute Myeloid Leukemia.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2020, Clinical lymphoma, myeloma & leukemia.

Prognostic factors for progression in patients with Philadelphia chromosome‐positive acute lymphoblastic leukemia in complete molecular response within 3 months of therapy with tyrosine kinase inhibitors

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2021, Cancer.

Philadelphia chromosome‐positive acute lymphoblastic leukemia at first relapse in the era of tyrosine kinase inhibitors

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2019, American journal of hematology.

Impact of complete molecular response on survival in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.

G. Garcia-Manero, J. Cortes, K. Patel, 2016, Blood.

Phase II study of methotrexate, vincristine, pegylated‐asparaginase, and dexamethasone (MOpAD) in patients with relapsed/refractory acute lymphoblastic leukemia

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2015, American journal of hematology.

Detection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapy.

Z. Estrov, H. Kantarjian, J. Cortes, 2013, Blood.

Secondary myelodysplastic syndrome in a patient with Philadelphia-positive acute lymphoblastic leukemia after achieving a major molecular response with hyperCVAD plus imatinib mesylate.

H. Kantarjian, A. Vega-Ruiz, J. Cortes, 2008, Leukemia research.

Acute myeloid leukemia with t(9;11)(p21-22;q23): common properties of dysregulated ras pathway signaling and genomic progression characterize de novo and therapy-related cases.

H. Kantarjian, G. Garcia-Manero, F. Ravandi, 2010, American journal of clinical pathology.

Prognostic significance of additional chromosomal abnormalities at the time of diagnosis in patients with chronic myeloid leukemia treated with frontline tyrosine kinase inhibitors

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2018, American journal of hematology.

Prognostic impact of persistent cytogenetic abnormalities at complete remission in adult patients with acute lymphoblastic leukemia

M. Konopleva, H. Kantarjian, J. Cortes, 2016, American journal of hematology.

Molecular identification of CBFβ-MYH11 fusion transcripts in an AML M4Eo patient in the absence of inv16 or other abnormality by cytogenetic and FISH analyses – a rare occurrence

F. Ravandi, S. Kadkol, C. Dodge, 2003, Leukemia.

Prognostic and therapeutic impacts of mutant TP53 variant allelic frequency in newly diagnosed acute myeloid leukemia.

M. Konopleva, M. Andreeff, H. Kantarjian, 2020, Blood advances.

Cause of death in patients with lower-risk myelodysplastic syndrome (MDS)

H. Kantarjian, J. Cortes, F. Ravandi, 2008 .

Myeloid Sarcoma of the Orbit and Ocular Adnexae

Z. Estrov, J. Cortes, A. Quintás-Cardama, 2012 .

Incidence of extramedullary disease in patients with acute promyelocytic leukemia: a single-institution experience

Z. Estrov, H. Kantarjian, A. Vega-Ruiz, 2009, International journal of hematology.

Emergence of BCR–ABL1 Fusion in AML Post–FLT3 Inhibitor-Based Therapy: A Potentially Targetable Mechanism of Resistance – A Case Series

M. Konopleva, K. Patel, T. Kadia, 2020, Frontiers in Oncology.

Clinical impact of change of FLT3 mutation status in acute myeloid leukemia patients

H. Kantarjian, J. Cortes, F. Ravandi, 2012, Modern Pathology.

Venetoclax (Ven) added to intensive chemo with cladribine, idarubicin, and AraC (CLIA) achieves high rates of durable complete remission with low rates of measurable residual disease (MRD) in pts with newly diagnosed acute myeloid leukemia (AML).

M. Konopleva, Z. Estrov, M. Andreeff, 2020 .

Discrepancy In Diagnosis of Myelodysplastic Syndrome (MDS) Between Referral and Tertiary Care Centers: Experience at MD Anderson Cancer Center (MDACC)

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2010 .

Achievement of a negative minimal residual disease state after hypomethylating agent therapy in older patients with AML reduces the risk of relapse

H. Kantarjian, T. Kadia, F. Ravandi, 2018, Leukemia.

Phase II study of alemtuzumab in combination with pentostatin in patients with T-cell neoplasms.

H. Kantarjian, S. Verstovsek, Xuelin Huang, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Venetoclax and BCR-ABL Tyrosine Kinase Inhibitor Combinations: Outcome in Patients with Philadelphia Chromosome-Positive Advanced Myeloid Leukemias

M. Konopleva, H. Kantarjian, J. Cortes, 2020, Acta Haematologica.

Isavuconazole as Primary Antifungal Prophylaxis in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome: An Open-label, Prospective, Phase 2 Study

M. Konopleva, Z. Estrov, Xuelin Huang, 2021 .

Isavuconazole as Primary Anti-Fungal Prophylaxis in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome: An Open-Label, Prospective, Phase II Study.

M. Konopleva, H. Kantarjian, Xuelin Huang, 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Predictive Factors for Response and Outcome in Patients (pts) Treated with Second Generation Tyrosine Kinase Inhibitors (2-TKI) for Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Post Imatinib Failure.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2009 .

Acute Myeloid Leukemia, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology.

F. Appelbaum, K. Gregory, M. Tallman, 2019, Journal of the National Comprehensive Cancer Network : JNCCN.

Neurologic complications associated with intrathecal liposomal cytarabine given prophylactically in combination with high-dose methotrexate and cytarabine to patients with acute lymphocytic leukemia.

H. Kantarjian, G. Garcia-Manero, F. Ravandi, 2007, Blood.

Running title: Sorafenib in hematologic malignancies

M. Konopleva, M. Andreeff, H. Kantarjian, 2010 .

Clofarabine and Clofarabine Plus Low-Dose Cytarabine (ara-C) as Induction Therapy for Patients (pts) ≥ 60 Years with Newly Diagnosed Acute Myeloid Leukemia (AML).

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2005 .

Novel Tyrosine Kinase Inhibitor Therapy Before Allogeneic Stem Cell Transplantation in Patients with Chronic Myeloid Leukemia.

H. Kantarjian, J. Cortes, F. Ravandi, 2008 .

Mobilization and elimination of FLT3-ITD+ acute myelogenous leukemia (AML) stem/progenitor cells by plerixafor, G-CSF, and sorafenib: Phase I trial results in relapsed/refractory AML patients.

M. Konopleva, M. Andreeff, H. Kantarjian, 2014 .

Association of hematologic response and assay sensitivity on the prognostic impact of measurable residual disease in acute myeloid leukemia: a systematic review and meta-analysis

D. Berry, C. Hourigan, Xuelin Huang, 2022, Leukemia.

Clofarabine combinations as acute myeloid leukemia salvage therapy

Z. Estrov, H. Kantarjian, S. Verstovsek, 2008, Cancer.

Development of TP53 mutations over the course of therapy for acute myeloid leukemia

M. Konopleva, T. Kadia, F. Ravandi, 2021, American journal of hematology.

Activity of venetoclax-based therapy in TP53-mutated acute myeloid leukemia.

M. Konopleva, M. Andreeff, K. Bhalla, 2019, Journal of Clinical Oncology.

Biphenotypic acute leukaemia: a case series

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2007, British journal of haematology.

Impact of CD33 and ABCB1 single nucleotide polymorphisms in patients with acute myeloid leukemia and advanced myeloid malignancies treated with decitabine plus gemtuzumab ozogamicin

M. Konopleva, H. Kantarjian, K. Patel, 2020, American journal of hematology.

Patterns of Resistance Differ in Patients with Acute Myeloid Leukemia Treated with Type I versus Type II FLT3 inhibitors.

M. Konopleva, M. Andreeff, K. Bhalla, 2020, Blood cancer discovery.

Crenolanib besylate, a type I pan-FLT3 inhibitor, to demonstrate clinical activity in multiply relapsed FLT3-ITD and D835 AML.

R. Collins, M. Konopleva, Z. Estrov, 2016 .

Results of a Phase II Study of Crenolanib in Relapsed/Refractory Acute Myeloid Leukemia Patients (Pts) with Activating FLT3 Mutations

Z. Estrov, H. Kantarjian, J. Cortes, 2014 .

Hyper-CVAD and sequential blinatumomab for newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: a single-arm, single-centre, phase 2 trial.

G. Garcia-Manero, Xuelin Huang, K. Patel, 2022, The Lancet. Haematology.

Characteristics and outcomes of patients with therapy-related acute myeloid leukemia with normal karyotype

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2020, Blood Cancer Journal.

Acute promyelocytic leukemia at time of relapse commonly demonstrates cytogenetic evidence of clonal evolution and variability in blast immunophenotypic features.

F. Ravandi, L. Medeiros, C. Bueso-Ramos, 2010, American journal of clinical pathology.

Alemtuzumab

F. Ravandi, S. O'brien, 2005 .

Ultra-accurate Duplex Sequencing for the assessment of pretreatment ABL1 kinase domain mutations in Ph+ ALL

J. Radich, J. Pritchard, M. Konopleva, 2020, Blood Cancer Journal.

Novel Therapies for Older Adults With Acute Lymphoblastic Leukemia

H. Kantarjian, F. Ravandi, E. Jabbour, 2018, Current Hematologic Malignancy Reports.

Phase I study of s-trans, trans-farnesylthiosalicylic acid (FTS), a novel oral Ras inhibitor, in patients with refractory hematologic malignancies

F. Ravandi, G. Borthakur, F. Giles, 2007 .

Allogeneic Hematopoietic Stem Cell Transplant (HSCT) Versus Conventional Chemotherapy in Patients with Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS) Attaining Complete Remission (CR1) Post Induction Chemotherapy: a Retrospective Case Control Study.

H. Kantarjian, F. Ravandi, G. Borthakur, 2008 .

Horse versus rabbit antithymocyte globulin in aplastic anemia.

F. Ravandi, M. Mathisen, 2011, The New England journal of medicine.

Single-agent liposomal all-trans-retinoic Acid as initial therapy for acute promyelocytic leukemia: 13-year follow-up data.

H. Kantarjian, J. Cortes, P. Jain, 2014, Clinical lymphoma, myeloma & leukemia.

Alemtuzumab in T-cell large granular lymphocyte leukaemia.

T. Kadia, F. Ravandi, 2016, The Lancet. Haematology.

A Phase I Study of the Combination of the Histone Deacetylase Inhibitor Vorinostat with Idarubicin in Advanced Acute Leukemia.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2007 .

Chronic lymphocytic leukemia (B-CLL) occurring with human immunodeficiency virus (HIV) infection: implications.

A. Verma, F. Ravandi, K. Pursell, 2003, Leukemia research : a Forum for Studies on Leukemia and Normal Hemopoiesis.

Clonal evolution of acute myeloid leukemia relapsed after 19 years of remission

Annette S. Kim, P. A. Futreal, L. Chin, 2015, American journal of hematology.

Prognostic significance of day 14 bone marrow evaluation in adults with Philadelphia chromosome–negative acute lymphoblastic leukemia

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2016, Cancer.

Kinetics of bone marrow blasts during induction and achievement of complete remission in acute myeloid leukemia

F. Ravandi, G. Borthakur, C. Bueso-Ramos, 2008, Haematologica.

A phase II study of lenalidomide alone in relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes with chromosome 5 abnormalities.

Z. Estrov, H. Kantarjian, J. Cortes, 2012, Clinical Lymphoma, Myeloma & Leukemia.

Therapeutic benefit of decitabine, a hypomethylating agent, in patients with high-risk primary myelofibrosis and myeloproliferative neoplasm in accelerated or blastic/acute myeloid leukemia phase.

H. Kantarjian, J. Cortes, S. Verstovsek, 2015, Leukemia research.

TP53 mutation does not confer a poor outcome in adult patients with acute lymphoblastic leukemia who are treated with frontline hyper‐CVAD‐based regimens

M. Konopleva, Z. Estrov, H. Kantarjian, 2017, Cancer.

Blood counts at time of complete remission provide additional independent prognostic information in acute myeloid leukemia.

H. Kantarjian, G. Garcia-Manero, F. Ravandi, 2008, Leukemia research.

Inotuzumab ozogamicin (IO; CMC544), a CD22 monoclonal antibody attached to calicheamycin, produces complete response (CR) plus complete marrow response (mCR) of greater than 50% in refractory relapse (R-R) acute lymphocytic leukemia (ALL).

C. Wilson, H. Kantarjian, G. Garcia-Manero, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II study of the hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with CD-20 positive ALL.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2014 .

The QUAZAR AML-001 Maintenance Trial: Results of a Phase III International, Randomized, Double-Blind, Placebo-Controlled Study of CC-486 (Oral Formulation of Azacitidine) in Patients with Acute Myeloid Leukemia (AML) in First Remission

H. Döhner, H. Dombret, B. Skikne, 2019 .

Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia.

Kim-Anh Do, Susan O'Brien, Jorge Cortes, 2007, Blood.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2009, Cancer.

Phase I/II Study of the Mammalian Target of Rapamycin Inhibitor Everolimus (RAD001) in Patients with Relapsed or Refractory Hematologic Malignancies

M. Konopleva, M. Andreeff, S. Verstovsek, 2006, Clinical Cancer Research.

Implications of RAS mutational status in subsets of patients with newly diagnosed acute myeloid leukemia across therapy subtypes

K. Bhalla, G. Garcia-Manero, T. Kadia, 2022, American journal of hematology.

Differential prognostic impact of RUNX1 mutations according to frontline therapy in patients with acute myeloid leukemia

K. Bhalla, K. Patel, T. Kadia, 2022, American journal of hematology/oncology.

Clinical and molecular profiling of AML patients with chromosome 7 or 7q deletions in the context of TP53 alterations and venetoclax treatment

M. Konopleva, M. Andreeff, G. Garcia-Manero, 2022, Leukemia & lymphoma.

A dynamic 3‐factor survival model for acute myeloid leukemia that accounts for response to induction chemotherapy

T. Kadia, F. Ravandi, C. Dinardo, 2022, American journal of hematology.

Validation of ALFA 1200 score in patients with AML >60 years treated with double nucleoside–based low-intensity therapy

M. Konopleva, G. Garcia-Manero, T. Kadia, 2022, Blood advances.

Acquired WT1 mutations contribute to relapse of NPM1-mutated acute myeloid leukemia following allogeneic hematopoietic stem cell transplant

M. Routbort, K. Patel, F. Ravandi, 2022, Bone Marrow Transplantation.

Translocation t(1;19)(q23;p13) in adult acute lymphoblastic leukemia – a distinct subtype with favorable prognosis

M. Konopleva, Z. Estrov, H. Kantarjian, 2020, Leukemia & lymphoma.

Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens.

J. Welch, M. Konopleva, M. Andreeff, 2020, Haematologica.

Impact of numerical variation, allele burden, mutation length and co-occurring mutations on the efficacy of tyrosine kinase inhibitors in newly diagnosed FLT3- mutant acute myeloid leukemia

H. Kantarjian, J. Cortes, K. Patel, 2020, Blood Cancer Journal.

HCL: insights into biology.

F. Ravandi, 2011, Blood.

Predictors and outcome of acute kidney injury in patients with acute myelogenous leukemia or high‐risk myelodysplastic syndrome

H. Kantarjian, J. Cortes, F. Ravandi, 2010, Cancer.

Final Report of a Phase II Study of Guadecitabine (SGI-110) in Patients (pts) with Previously Untreated Myelodysplastic Syndrome (MDS)

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2018, Blood.

A Phase II Study of Nivolumab or Ipilimumab with or without Azacitidine for Patients with Myelodysplastic Syndrome (MDS)

M. Konopleva, S. Colla, H. Kantarjian, 2018, Blood.

Influence of IDH on FLT3-ITD status in newly diagnosed AML

H. Kantarjian, F. Ravandi, N. Daver, 2017, Leukemia.

Co-occurrence of FLT3-TKD and NPM1 mutations defines a highly favorable prognostic AML group.

M. Andreeff, H. Kantarjian, J. Cortes, 2017, Blood advances.

Forodesine: review of preclinical and clinical data.

F. Ravandi, M. Keating, V. Gandhi, 2010, Future oncology.

Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial.

K. Rezvani, G. Garcia-Manero, Xuelin Huang, 2022, The Lancet. Haematology.

Incidence of adverse effects in patients receiving ponatinib with concomitant azole antifungals

F. Ravandi, E. Jabbour, N. Jain, 2022, Leukemia & lymphoma.

Proposal for a new risk model in myelodysplastic syndrome (MDS) that accounts for events not considered in the original International Prognostic Scoring System (IPSS)

J. Issa, H. Kantarjian, J. Cortes, 2008 .

Phase I Trial Of The Targeted Alpha-Particle Nano-Generator Actinium-225 (225Ac)-Lintuzumab (Anti-CD33) In Combination With Low-Dose Cytarabine (LDAC) For Older Patients With Untreated Acute Myeloid Leukemia (AML)

E. Estey, D. Scheinberg, H. Kantarjian, 2013 .

Novel treatments in acute myeloid leukemia.

F. Ravandi, 2011, Clinical advances in hematology & oncology : H&O.

Updated Results of Combination Cytokine Immunotherapy In the Treatment of Aplastic Anemia and Myelodysplastic Syndrome (MDS)

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2010 .

Response kinetics and factors predicting survival in core-binding factor leukemia

H. Kantarjian, G. Garcia-Manero, K. Patel, 2018, Leukemia.

Results of a phase I/II study of the combination of 5-aza-2’-deoxycytidine and valproic acid in patients with acute myeloid leukemia and myelodysplastic syndrome

G. Rosner, Hushan Yang, J. Issa, 2005 .

Feasibility of therapy with hypomethylating agents in patients with renal insufficiency.

J. Issa, H. Kantarjian, G. Garcia-Manero, 2010, Clinical Lymphoma, Myeloma & Leukemia.

Haploidentical Transplantation for Older Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome.

M. Konopleva, K. Rezvani, S. Parmar, 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Lenalidomide promotes the development of TP53-mutated therapy-related myeloid neoplasms

Andrew T Nguyen, B. Ebert, Jianhua Zhang, 2022, Blood.

Salvage therapy using FLT3 inhibitors may improve long‐term outcome of relapsed or refractory AML in patients with FLT3‐ITD

Z. Estrov, M. Andreeff, H. Kantarjian, 2013, British journal of haematology.

Interim Results of the Phase I/II Study of the Ponatinib, Venetoclax and Dexamethasone for Patients with Relapsed or Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

M. Konopleva, T. Kadia, F. Ravandi, 2020 .

Inotuzumab ozogamicin (INO) plus bosutinib (BOS) in R/R PH+ ALL or CML in lymphoid blast phase (CML LBP).

M. Konopleva, H. Kantarjian, J. Cortes, 2020 .

Long-Term Safety and Efficacy of Hyper-CVAD Plus Ponatinib As Frontline Therapy for Adults with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2019, Blood.

Poor outcomes associated with +der(22)t(9;22) and −9/9p in patients with Philadelphia chromosome‐positive acute lymphoblastic leukemia receiving chemotherapy plus a tyrosine kinase inhibitor

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2017, American journal of hematology/oncology.

Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome.

Jorge Cortes, Guillermo Garcia-Manero, E. Estey, 2007, Blood.

Preliminary Results from a Phase 1 First-in-Human Study of AMG 673, a Novel Half-Life Extended (HLE) Anti-CD33/CD3 BiTE® (Bispecific T-Cell Engager) in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

F. Ravandi, A. Wei, R. Walter, 2019, Blood.

A Phase 1 First-in-Human Study of AMG 330, an Anti-CD33 Bispecific T-Cell Engager (BiTE®) Antibody Construct, in Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)

P. Paschka, H. Kantarjian, M. Jongen‐Lavrencic, 2018, Blood.

Activity and tolerability of SL-401, a targeted therapy directed to the interleukin-3 receptor on cancer stem cells and tumor bulk, as a single agent in patients with advanced hematologic malignancies.

M. Konopleva, M. Andreeff, H. Kantarjian, 2013 .

Clinical activity of Crenolanib in patients with D835 mutant FLT3-positive relapsed/refractory acute myeloid leukemia (AML).

R. Collins, H. Kantarjian, J. Cortes, 2014 .

Update of the Modified Hyper-CVAD Regimen with or without Rituximab in Newly Diagnosed Adult Acute Lymphocytic Leukemia (ALL).

M. Andreeff, H. Kantarjian, G. Garcia-Manero, 2005 .

F. Ravandi, 2009, Leukemia & lymphoma.

Evolutionary action score identifies a subset of TP53 mutated myelodysplastic syndrome with favorable prognosis

O. Lichtarge, K. Do, M. Andreeff, 2020, Blood Cancer Journal.

Comment on Poletto et al , page 3112 GR SNP helps transform myelofibrosis

Nakatake, F. Ravandi, Jj, 2022 .

Common kinase mutations do not impact optimal molecular responses in core binding factor acute myeloid leukemia treated with fludarabine, cytarabine, and G‐CSF based regimens

T. Kadia, F. Ravandi, G. Borthakur, 2022, American journal of hematology.

Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet.

E. Estey, H. Döhner, T. Naoe, 2019, Blood.

Identification of a novel fusion gene, IRF2BP2-RARA, in acute promyelocytic leukemia.

L. Chin, A. Protopopov, A. Futreal, 2015, Journal of the National Comprehensive Cancer Network : JNCCN.

T. Kadia, F. Ravandi, E. Jabbour, 2020, Leukemia & lymphoma.

Preclinical and clinical evaluation of forodesine in pediatric and adult B-cell acute lymphoblastic leukemia.

F. Ravandi, V. Gandhi, S. Bantia, 2013, Clinical lymphoma, myeloma & leukemia.

Survival and Efficacy of Decitabine in Myelodysplastic Syndromes (MDS), Analysis of the 5-Day IV Dosing Regimen.

J. Issa, Z. Estrov, H. Kantarjian, 2007 .

Differential impact of minimal residual disease negativity according to the salvage status in patients with relapsed/refractory B‐cell acute lymphoblastic leukemia

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2017, Cancer.

Clinical activity of arsenic trioxide in Burkitt-like lymphoma

F. Ravandi, K. Besien, 2003, Leukemia.

A randomized study of decitabine versus conventional care for maintenance therapy in patients with acute myeloid leukemia in complete remission

J. Issa, Z. Estrov, H. Kantarjian, 2012, Leukemia.

Clinical characteristics and outcomes in patients with acute myeloid leukemia with concurrent FLT3‐ITD and IDH mutations

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2020, Cancer.

Phase I Study of Suberoylanilide Hydroxamic Acid (SAHA) and Decitabine in Patients with Relapsed, Refractory or Poor Prognosis Leukemia.

J. Issa, H. Kantarjian, G. Garcia-Manero, 2007 .

TdT expression in acute myeloid leukemia with minimal differentiation is associated with distinctive clinicopathological features and better overall survival following stem cell transplantation

K. Patel, F. Ravandi, S. Pierce, 2013, Modern Pathology.

Final Update of Phase I-II Study of the Farnesyltransferase Inhibitor Tipifarnib in Combination with Idarubicin and Cytarabine for Patients with Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome.

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2007 .

Safety and outcome after fludarabine–thiotepa–TBI conditioning for allogeneic transplantation: a prospective study of 30 patients with hematologic malignancies

J. Sosman, R. Hoffman, F. Ravandi, 2003, Bone Marrow Transplantation.

A Prospective Multicenter Study of Paroxysmal Nocturnal Hemoglobinuria Cells in Patients with Bone Marrow Failure

F. Ravandi, A. Rastogi, A. Raza, 2013, Cytometry. Part B, Clinical cytometry.

Comparing Outcomes of Patients with Secondary AML: Treatment-Related MDS/AML, AML Secondary to Myeloproliferative Neoplasms (t-MPN), and AML with Prior Malignancies

M. Konopleva, M. Andreeff, H. Kantarjian, 2012 .

Azacitidine (AZA) with Nivolumab (Nivo), and AZA with Nivo + Ipilimumab (Ipi) in Relapsed/Refractory Acute Myeloid Leukemia: A Non-Randomized, Prospective, Phase 2 Study

P. Sharma, M. Konopleva, Z. Estrov, 2019, Blood.

Results of a Phase 2, Open-Label Study of Idarubicin (I), Cytarabine (A) and Nivolumab (Nivo) in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)

P. Sharma, M. Konopleva, Z. Estrov, 2018, Blood.

Results From a Randomized Trial of Salvage Chemotherapy Followed by Lestaurtinib for FLT3 Mutant AML Patients in First Relapse

W. Jędrzejczak, M. Baccarani, L. Tremmel, 2009 .

R. Hoffman, F. Ravandi, W. Stock, 2003, Bone Marrow Transplantation.

Cytopenias in Patients (pts) with Chronic Myelogenous Leukemia (CML) in Chronic Phase (CP) Treated with Dasatinib (SPRYCEL®): Clinical Features and Management, Including Outcome after Hematopoietic Growth Factor Therapy.

H. Kantarjian, G. Garcia-Manero, A. Quintás-Cardama, 2006 .

MRD in HCL: does it matter?

F. Ravandi, 2018, Blood.

Prognostic impact of ASXL1 mutations in chronic phase chronic myeloid leukemia

K. Patel, F. Ravandi, E. Jabbour, 2022, Blood Cancer Journal.

SGN-CD33A Plus Hypomethylating Agents: A Novel, Well-Tolerated Regimen with High Remission Rate in Frontline Unfit AML

F. Ravandi, D. DeAngelo, J. Lancet, 2015 .

Distinguishing thymoma from T-lymphoblastic leukaemia/lymphoma: a case-based evaluation

T. Kadia, F. Ravandi, E. Jabbour, 2018, Journal of Clinical Pathology.

Prognostic significance of baseline FLT3‐ITD mutant allele level in acute myeloid leukemia treated with intensive chemotherapy with/without sorafenib

M. Konopleva, M. Andreeff, H. Kantarjian, 2019, American journal of hematology.

Validation of the 2017 European LeukemiaNet classification for acute myeloid leukemia with NPM1 and FLT3‐internal tandem duplication genotypes

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2018, Cancer.

Next-generation sequencing-based multigene mutational screening for acute myeloid leukemia using MiSeq: applicability for diagnostics and disease monitoring

H. Kantarjian, J. Cortes, M. Routbort, 2014, Haematologica.

Secondary mutations as mediators of resistance to targeted therapy in leukemia.

M. Konopleva, H. Kantarjian, K. Patel, 2015, Blood.

Phase I/II Study of Vosaroxin and Decitabine in Newly Diagnosed Older Patients (pts) with Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2014 .

Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia.

M. Minden, H. Kantarjian, F. Ravandi, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older.

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2006, Blood.

Evaluating measurable residual disease in acute myeloid leukemia.

F. Ravandi, R. Walter, S. Freeman, 2018, Blood advances.

A mind map for managing minimal residual disease in acute myeloid leukemia.

F. Ravandi, C. Benton, 2017, Clinical advances in hematology & oncology : H&O.

Acute myeloid leukemia.

M. Millenson, F. Appelbaum, M. Tallman, 2008, Journal of the National Comprehensive Cancer Network : JNCCN.

Clinical outcomes and impact of therapeutic intervention in patients with acute myeloid leukemia who experience measurable residual disease (MRD) recurrence following MRD‐negative remission

H. Kantarjian, E. Shpall, K. Patel, 2022, American journal of hematology.

Prognostic and therapeutic implications of measurable residual disease in acute myeloid leukemia

K. Patel, F. Ravandi, N. Short, 2021, Journal of Hematology & Oncology.

The Role of Acute Myeloid Leukemia Minimal Residual Disease in Regulatory Decision-making-Reply.

Shouhao Zhou, F. Ravandi, N. Short, 2021, JAMA oncology.

Association of Measurable Residual Disease With Survival Outcomes in Patients With Acute Myeloid Leukemia: A Systematic Review and Meta-analysis.

D. Berry, H. Kantarjian, Shouhao Zhou, 2020, JAMA oncology.

Clinical practice recommendation on hematopoietic stem cell transplantation for acute myeloid leukemia patients with FLT3-internal tandem duplication: a position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

J. Esteve, H. Döhner, F. Baron, 2020, Haematologica.

Acute Myeloid Leukemia , Version 3 . 2019

Donnell, F. Appelbaum, K. Gregory, 2019 .

Is it time to routinely incorporate MRD into practice?

F. Ravandi, 2018, Best practice & research. Clinical haematology.

Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology.

F. Appelbaum, K. Gregory, D. Arber, 2017, Journal of the National Comprehensive Cancer Network : JNCCN.

Resistance Prediction in AML: Analysis of 4,601 Patients from MRC/NCRI, HOVON/SAKK, SWOG, and MD Anderson Cancer Center

Bob Löwenberg, Elihu H. Estey, Megan Othus, 2014, Leukemia.

Advances in the Treatment of Acute Myeloid Leukemia: New Drugs and New Challenges.

M. Konopleva, T. Kadia, F. Ravandi, 2020, Cancer discovery.

Characteristics of Sweet Syndrome in patients with acute myeloid leukemia.

Philip R. Cohen, H. Kantarjian, G. Garcia-Manero, 2015, Clinical lymphoma, myeloma & leukemia.

Relapsed Acute Myeloid Leukemia: Need for Innovative Treatment Strategies to Improve Outcome.

F. Ravandi, T. Badar, Talha Badar, 2015, Clinical lymphoma, myeloma & leukemia.

Role of cytokines in the treatment of acute leukemias: a review

F. Ravandi, 2006, Leukemia.

Cytokines in the treatment of acute leukemias.

F. Ravandi, P. Kebriaei, 2005, Cancer treatment and research.

Phase I study of S-trans, trans-farnesylthiosalicylic acid (salirasib), a novel oral RAS inhibitor in patients with refractory hematologic malignancies.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2015, Clinical lymphoma, myeloma & leukemia.

Characterization of IDH1 p.R132H Mutant Clones Using Mutation-specific Antibody in Myeloid Neoplasms

M. Routbort, K. Patel, F. Ravandi, 2017, The American journal of surgical pathology.

Open-Label Phase II Prospective, Randomized, Controlled Study of Romyelocel-L Myeloid Progenitor Cells to Reduce Infection During Induction Chemotherapy for Acute Myeloid Leukemia

O. Frankfurt, S. Kambhampati, H. Kantarjian, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Treating Leukemia in the Time of COVID-19

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2020, Acta Haematologica.

Forodesine, an inhibitor of purine nucleoside phosphorylase, induces apoptosis in chronic lymphocytic leukemia cells.

F. Ravandi, M. Keating, V. Gandhi, 2006, Blood.

Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs.

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2019, Blood advances.

The anti-angiogenesis agent, AG-013736, has minimal activity in elderly patients with poor prognosis acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).

Z. Estrov, S. Verstovsek, P. Bycott, 2006, Leukemia research.

Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trial.

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2021, The Lancet. Haematology.

Acute Myeloid Leukemia: Historical Perspective and Progress in Research and Therapy Over 5 Decades.

H. Kantarjian, M. Tallman, F. Ravandi, 2021, Clinical lymphoma, myeloma & leukemia.

Acute myeloid leukemia: Treatment and research outlook for 2021 and the MD Anderson approach

H. Kantarjian, T. Kadia, F. Ravandi, 2021, Cancer.

Acute myeloid leukemia: current progress and future directions

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2021, Blood Cancer Journal.

NCCN Acute Myeloid Leukemia , Version 3 . 2017 Clinical Practice Guidelines in Oncology

F. Appelbaum, K. Gregory, D. Arber, 2017 .

Design of the randomized, Phase III, QUAZAR AML Maintenance trial of CC-486 (oral azacitidine) maintenance therapy in acute myeloid leukemia

M. Voso, B. Skikne, H. Kantarjian, 2016, Future oncology.

Progress in acute myeloid leukemia.

H. Kantarjian, J. Cortes, T. Kadia, 2015, Clinical lymphoma, myeloma & leukemia.

Acute myeloid leukemia in the elderly: do we know who should be treated and how?

F. Ravandi, A. Nazha, 2014, Leukemia & lymphoma.

Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2010, Blood.

Results of a Phase I/II Study of the Combination of 5-aza-2′-Deoxycytidine (DAC) and Valproic Acid (VPA) in Patients (pts) with Leukemia.

G. Rosner, J. Issa, H. Kantarjian, 2004 .

Decitabine improves outcomes in older patients with acute myeloid leukemia and higher blast counts

M. Minden, H. Kantarjian, T. Kadia, 2015, American journal of hematology.

Decitabine improves patient outcomes in myelodysplastic syndromes

John M Bennett, J. Issa, Lanlan Shen, 2006, Cancer.

Novel purine nucleoside analogues for T-cell-lineage acute lymphoblastic leukaemia and lymphoma

Varsha Gandhi, F. Ravandi, V. Gandhi, 2006, Expert opinion on investigational drugs.

Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia.

J. Issa, Y. Oki, Z. Estrov, 2007, Blood.

Frontline treatment of acute myeloid leukemia in adults.

M. Konopleva, H. Kantarjian, J. Cortes, 2017, Critical reviews in oncology/hematology.

Targeting acute myeloid leukemia with TP53-independent vosaroxin.

F. Ravandi, C. Benton, Christopher B. Benton, 2017, Future oncology.

The safety and efficacy of vosaroxin in patients with first relapsed or refractory acute myeloid leukemia - a critical review

F. Ravandi, N. Short, 2016, Expert review of hematology.

Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study.

Arnaud Pigneux, Gary Acton, Michael Heuser, 2015, The Lancet. Oncology.

A phase II study of voreloxin as single agent therapy for elderly patients (pts) with newly diagnosed acute myeloid leukemia (AML).

M. Maris, F. Ravandi, W. Stock, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2007, Blood.

Acute myeloid leukemia, version 2.2013.

M. Millenson, F. Appelbaum, K. Gregory, 2013, Journal of the National Comprehensive Cancer Network : JNCCN.

Phase I clinical, pharmacokinetic, and pharmacodynamic study of the Akt-inhibitor triciribine phosphate monohydrate in patients with advanced hematologic malignancies.

H. Kantarjian, G. Garcia-Manero, S. Verstovsek, 2013, Leukemia research.

Effect of food on the oral bioavailability of UFT and leucovorin in cancer patients.

R. Pazdur, F. Ravandi, D. Alberts, 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

Elacytarabine has single‐agent activity in patients  with advanced acute myeloid leukaemia

D. Berry, M. Dennis, F. Ravandi, 2012, British journal of haematology.

Elacytarabine, a novel 5'-elaidic acid derivative of cytarabine, and idarubicin combination is active in refractory acute myeloid leukemia.

F. Ravandi, S. O'brien, F. Giles, 2012, Leukemia research.

Phase I and pharmacokinetic study of elacytarabine, a novel 5′-elaidic acid derivative of cytarabine, in adults with refractory hematological malignancies

F. Ravandi, F. Giles, N. Vey, 2012, Leukemia.

Improved outcomes among newly diagnosed patients with FMS‐like tyrosine kinase 3 internal tandem duplication mutated acute myeloid leukemia treated with contemporary therapy: Revisiting the European LeukemiaNet adverse risk classification

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2022 .

Haploidentical transplantation for acute myeloid leukemia patients with minimal/measurable residual disease at transplantation

M. Konopleva, H. Kantarjian, F. Ravandi, 2019, American journal of hematology.

Acute promyelocytic leukemia: A population‐based study on incidence and survival in the United States, 1975‐2008

H. Kantarjian, J. Cortes, F. Ravandi, 2012, Cancer.

Long‐term prognostic impact of the use of erythropoietic‐stimulating agents in patients with chronic myeloid leukemia in chronic phase treated with imatinib

H. Kantarjian, J. Cortes, F. Ravandi, 2011, Cancer.

Results of a randomized phase 3 study of oral sapacitabine in elderly patients with newly diagnosed acute myeloid leukemia (SEAMLESS)

P. Venugopal, M. Buyse, G. Gaidano, 2021, Cancer.

untreated patients with chronic lymphocytic leukemia Prognostic nomogram and index for overall survival in previously

K. Do, H. Kantarjian, G. Garcia-Manero, 2013 .

A phase I trial of the human double minute 2 inhibitor (MK-8242) in patients with refractory/recurrent acute myelogenous leukemia (AML).

M. Minden, H. Kantarjian, F. Ravandi, 2015, Leukemia research.

An Inv(16)(p13.3q24.3)-encoded CBFA2T3-GLIS2 fusion protein defines an aggressive subtype of pediatric acute megakaryoblastic leukemia.

Heather L. Mulder, S. Ranade, R. Wilson, 2012, Cancer cell.

Eradication of Leukemia Stem Cells as a New Goal of Therapy in Leukemia

Z. Estrov, F. Ravandi, 2006, Clinical Cancer Research.

Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia.

M. Andreeff, H. Kantarjian, G. Garcia-Manero, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Treatment with FLT3 inhibitor in patients with FLT3‐mutated acute myeloid leukemia is associated with development of secondary FLT3–tyrosine kinase domain mutations

M. Konopleva, Z. Estrov, M. Andreeff, 2014, Cancer.

Progress in the treatment of acute myeloid leukemia

H. Kantarjian, F. Ravandi, A. Burnett, 2007, Cancer.

Flt3 in aml

F. Ravandi, N. Daver, 2015 .

Impact of numerical variation in FMS‐like tyrosine kinase receptor 3 internal tandem duplications on clinical outcome in normal karyotype acute myelogenous leukemia

H. Kantarjian, R. Luthra, K. Patel, 2012, Cancer.

Buparlisib, a PI3K inhibitor, demonstrates acceptable tolerability and preliminary activity in a phase I trial of patients with advanced leukemias

M. Konopleva, M. Andreeff, H. Kantarjian, 2017, American journal of hematology.

Long-term follow-up of allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: impact of tyrosine kinase inhibitors on treatment outcomes.

H. Kantarjian, E. Shpall, F. Ravandi, 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Prognostic significance of alterations in IDH enzyme isoforms in patients with AML treated with high‐dose cytarabine and idarubicin

M. Konopleva, M. Andreeff, H. Kantarjian, 2012, Cancer.

Acute myeloid leukemia with IDH1 or IDH2 mutation: frequency and clinicopathologic features.

Rajyalakshmi Luthra, K. Patel, F. Ravandi, 2011, American journal of clinical pathology.

Modulation of cellular signaling pathways: prospects for targeted therapy in hematological malignancies.

Z. Estrov, F. Ravandi, M. Talpaz, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Final results of a single institution experience with a pediatric‐based regimen, the augmented Berlin–Frankfurt–Münster, in adolescents and young adults with acute lymphoblastic leukemia, and comparison to the hyper‐CVAD regimen

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2016, American journal of hematology.

A phase 1/2 study of ruxolitinib and decitabine in patients with post-myeloproliferative neoplasm acute myeloid leukemia

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2020, Leukemia.

Impact of the variant allele frequency of ASXL1, DNMT3A, JAK2, TET2, TP53, and NPM1 on the outcomes of patients with newly diagnosed acute myeloid leukemia

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2019, Cancer.

Phase 2, randomized, double‐blind study of pracinostat in combination with azacitidine in patients with untreated, higher‐risk myelodysplastic syndromes

J. Reeves, M. Maris, H. Kantarjian, 2017, Cancer.

Hypomethylation of TET2 Target Genes Identifies a Curable Subset of Acute Myeloid Leukemia.

J. Issa, J. Jelinek, H. Kantarjian, 2016, Journal of the National Cancer Institute.

Clinical features of De Novo acute myeloid leukemia with concurrent DNMT3A, FLT3 and NPM1 mutations

F. Stingo, H. Kantarjian, J. Cortes, 2014, Journal of Hematology & Oncology.

Decitabine in the treatment of myelodysplastic syndromes

J. Issa, H. Kantarjian, G. Garcia-Manero, 2010, Expert review of anticancer therapy.

Advances in treatment of chronic myelogenous leukemia – new treatment options with tyrosine kinase inhibitors

F. Ravandi, F. P. Santos, 2009, Leukemia & lymphoma.

Adults with acute lymphoblastic leukemia and translocation (1;19) abnormality have a favorable outcome with hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with methotrexate and high‐dose cytarabine chemotherapy

H. Kantarjian, F. Ravandi, S. Pierce, 2009, Cancer.

Identification of clinically important chromosomal aberrations in acute myeloid leukemia by array-based comparative genomic hybridization

K. Patel, F. Ravandi, L. Medeiros, 2014, Leukemia & lymphoma.

CELLULAR SIGNALLING PATHWAYS: NEW TARGETS IN LEUKAEMIA THERAPY

Z. Estrov, F. Ravandi, M. Talpaz, 2002, British journal of haematology.

A phase II study of 5-azacitidine for patients with primary and post-essential thrombocythemia/polycythemia vera myelofibrosis

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2008, Leukemia.

Early T-cell precursor acute lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) in adolescents and adults: a high-risk subtype.

M. Konopleva, H. Kantarjian, J. Cortes, 2016, Blood.

Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics

P. A. Futreal, Erika J. Thompson, N. Navin, 2020, Nature Communications.

Investigational agents in myeloid disorders.

J. Cortes, F. Ravandi, 2004, Advances in pharmacology.

Pre-leukemic clonal hematopoiesis and the risk of therapy-related myeloid neoplasms: a case-control study

Erika J. Thompson, Xifeng Wu, S. Colla, 2016, The Lancet. Oncology.

Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials

Z. Ju, M. Konopleva, F. Meric-Bernstam, 2023, Nature Medicine.

Late relapses in acute myeloid leukemia: analysis of characteristics and outcome

H. Kantarjian, J. Cortes, F. Ravandi, 2010, Leukemia & lymphoma.

Outcomes of TP53‐mutant acute myeloid leukemia with decitabine and venetoclax

M. Konopleva, H. Kantarjian, T. Kadia, 2021, Cancer.

10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial.

J. Welch, M. Konopleva, Z. Estrov, 2020, The Lancet. Haematology.

NPM1 mutations define a specific subgroup of MDS and MDS/MPN patients with favorable outcomes with intensive chemotherapy.

M. Konopleva, S. Colla, H. Kantarjian, 2019, Blood advances.

Late relapse in acute myeloid leukemia (AML): clonal evolution or therapy-related leukemia?

Z. Estrov, Jianhua Zhang, Xingzhi Song, 2019, Blood Cancer Journal.

Persistent IDH1/2 mutations in remission can predict relapse in patients with acute myeloid leukemia

H. Kantarjian, M. Routbort, K. Patel, 2018, Haematologica.

Impact of frontline treatment approach on outcomes of myeloid blast phase CML

M. Konopleva, J. Cortes, T. Kadia, 2021, Journal of Hematology & Oncology.

Phase II evaluation of IPI-926, an oral Hedgehog inhibitor, in patients with myelofibrosis

J. Kutok, H. Kantarjian, J. Cortes, 2015, Leukemia & lymphoma.

New agents in acute myeloid leukemia and other myeloid disorders

H. Kantarjian, J. Cortes, F. Ravandi, 2004, Cancer.

A potential role of ruxolitinib in leukemia

S. Verstovsek, F. Ravandi, H. Kantarjian, 2011, Expert opinion on investigational drugs.

Therapeutic implications of menin inhibition in acute leukemias

M. Andreeff, H. Kantarjian, F. Ravandi, 2021, Leukemia.

Translocation t(17;18)(q10;q10)

H. Kantarjian, J. Cortes, F. Ravandi, 2001, Cancer.

Safety and tolerability of lurbinectedin (PM01183) in patients with acute myeloid leukemia and myelodysplastic syndrome

H. Kantarjian, G. Garcia-Manero, F. Ravandi, 2018, Hematological oncology.

Outcome of T‐cell acute lymphoblastic leukemia/lymphoma: Focus on near‐ETP phenotype and differential impact of nelarabine

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2021, American journal of hematology.

High-sensitivity next-generation sequencing MRD assessment in ALL identifies patients at very low risk of relapse

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2022, Blood advances.

Minimal residual disease assessed by multi‐parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia

Xuelin Huang, Guillermo Garcia-Manero, Gautam Borthakur, 2016, British journal of haematology.

Clinical Experience With Venetoclax Combined With Chemotherapy for Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia.

M. Konopleva, H. Kantarjian, F. Ravandi, 2019, Clinical lymphoma, myeloma & leukemia.

A Multicenter Phase I Study Combining Venetoclax with Mini-Hyper-CVD in Older Adults with Untreated and Relapsed/Refractory Acute Lymphoblastic Leukemia

Jeremy M. Stewart, A. Letai, D. Neuberg, 2019, Blood.

A Phase I Study of the Pan Bcl-2 Family Inhibitor Obatoclax Mesylate in Patients with Advanced Hematologic Malignancies

B. Cheson, M. Minden, M. Berger, 2008, Clinical Cancer Research.

MYC protein expression is an important prognostic factor in acute myeloid leukemia

Z. Estrov, M. Andreeff, K. Bhalla, 2019, Leukemia & lymphoma.

More than 1 TP53 abnormality is a dominant characteristic of pure erythroid leukemia.

M. Konopleva, M. Andreeff, H. Kantarjian, 2017, Blood.

The Role of JAK Pathway Dysregulation in the Pathogenesis and Treatment of Acute Myeloid Leukemia

H. Kantarjian, S. Verstovsek, F. Ravandi, 2012, Clinical Cancer Research.

Treatment of Acute Myeloid Leukemia and Myelodysplastic Syndromes

F. Ravandi, 2010 .

The Role of Leukemia Inhibitory Factor in Cancer and Cancer Metastasis

Z. Estrov, F. Ravandi, 2001 .

Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia.

Michael Rytting, Jorge Cortes, Guillermo Garcia-Manero, 2006, Blood.

Phase IB/II study of nivolumab with azacytidine (AZA) in patients (pts) with relapsed AML.

P. Sharma, M. Konopleva, M. Andreeff, 2017 .

Report of a phase 1/2 study of a combination of azacitidine and cytarabine in acute myelogenous leukemia and high-risk myelodysplastic syndromes

D. Berry, J. Issa, H. Kantarjian, 2010, Leukemia & lymphoma.

Phase II trial of vorinostat with idarubicin and cytarabine for patients with newly diagnosed acute myelogenous leukemia or myelodysplastic syndrome.

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome

J. Issa, H. Kantarjian, G. Garcia-Manero, 2007, Cancer.

Addition of eltrombopag to immunosuppressive therapy in patients with newly diagnosed aplastic anemia

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2018, Cancer.

Salvage Chemoimmunotherapy With Inotuzumab Ozogamicin Combined With Mini–Hyper-CVD for Patients With Relapsed or Refractory Philadelphia Chromosome–Negative Acute Lymphoblastic Leukemia: A Phase 2 Clinical Trial

M. Konopleva, Z. Estrov, D. Marin, 2017, JAMA oncology.

A CpG island methylator phenotype in acute myeloid leukemia independent of IDH mutations and associated with a favorable outcome

J. Issa, J. Jelinek, H. Kantarjian, 2016, Leukemia.

A phase I study of recombinant interferon-beta in patients with advanced malignant disease.

Z. Estrov, R. Kurzrock, F. Ravandi, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

A pathway-based gene signature correlates with therapeutic response in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia

Susan O'Brien, Dan Jones, Rajyalakshmi Luthra, 2010, Modern Pathology.

Clofarabine Plus Low-Dose Cytarabine Induction Followed by Consolidation with Clofarabine Plus Low-Dose Cytarabine Alternating with Decitabine as Frontline Therapy for Patients (pts) with Acute Myeloid Leukemia (AML) ≥ 60 Years (yrs).

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2009 .

Incidence of and risk factors for involvement of the central nervous system in acute myeloid leukemia

Z. Estrov, G. Garcia-Manero, J. Cortes, 2015, Leukemia & lymphoma.

Gemtuzumab ozogamicin with fludarabine, cytarabine, and granulocyte colony stimulating factor (FLAG‐GO) as front‐line regimen in patients with core binding factor acute myelogenous leukemia

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2014, American journal of hematology.

Phase I/II trial of the combination of midostaurin (PKC412) and 5‐azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome

M. Konopleva, Z. Estrov, M. Andreeff, 2015, American journal of hematology.

FLT3 mutations in myelodysplastic syndrome and chronic myelomonocytic leukemia

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2013, American journal of hematology.

Characteristics and outcome of chronic myeloid leukemia patients with E255K/V BCR–ABL kinase domain mutations

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2018, International Journal of Hematology.

Predictive factors for outcome and response in patients treated with second-generation tyrosine kinase inhibitors for chronic myeloid leukemia in chronic phase after imatinib failure.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2011, Blood.

Novel therapeutic options for relapsed hairy cell leukemia

P. Jain, F. Ravandi, A. Polliack, 2015, Leukemia & lymphoma.

Update on the Biology and Treatment Options for Hairy Cell Leukemia

P. Jain, F. Ravandi, N. Pemmaraju, 2014, Current Treatment Options in Oncology.

Frontline combination of ponatinib and hyper‐CVAD in Philadelphia chromosome‐positive acute lymphoblastic leukemia: 80‐months follow‐up results

G. Garcia-Manero, Xuelin Huang, F. Ravandi, 2023, American journal of hematology.

Hyper‐CVAD plus ponatinib versus hyper‐CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome‐positive acute lymphoblastic leukemia: A propensity score analysis

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2016, Cancer.

Significance of recurrence of minimal residual disease detected by multi‐parameter flow cytometry in patients with acute lymphoblastic leukemia in morphological remission

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2017, American journal of hematology.

First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2010, Blood.

Clinical and molecular characterization of myeloid sarcoma without medullary leukemia

M. Konopleva, G. Garcia-Manero, T. Kadia, 2021, Leukemia & lymphoma.

Prediction of survival with lower intensity therapy among older patients with acute myeloid leukemia

H. Kantarjian, G. Garcia-Manero, K. Patel, 2023, Cancer.

Hyper‐CVAD plus ofatumumab versus hyper‐CVAD plus rituximab as frontline therapy in adults with Philadelphia chromosome–negative acute lymphoblastic leukemia: A propensity score analysis

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2021, Cancer.

De novo acute myeloid leukemia: A population‐based study of outcome in the United States based on the Surveillance, Epidemiology, and End Results (SEER) database, 1980 to 2017

H. Kantarjian, T. Kadia, F. Ravandi, 2021, Cancer.

Acute lymphoblastic leukemia: A population‐based study of outcome in the United States based on the surveillance, epidemiology, and end results (SEER) database, 1980–2017

C. Pui, H. Kantarjian, F. Ravandi, 2021, American journal of hematology.

Results of second salvage therapy in 673 adults with acute myelogenous leukemia treated at a single institution since 2000

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2018, Cancer.

Peripheral blood blast clearance is an independent prognostic factor for survival and response to acute myeloid leukemia induction chemotherapy

P. Qiu, M. Konopleva, M. Andreeff, 2016, American journal of hematology.

Outcomes in patients with relapsed or refractory acute promyelocytic leukemia treated with or without autologous or allogeneic hematopoietic stem cell transplantation.

V. Baladandayuthapani, H. Kantarjian, J. Cortes, 2013, Clinical lymphoma, myeloma & leukemia.

Clofarabine plus low‐dose cytarabine followed by clofarabine plus low‐dose cytarabine alternating with decitabine in acute myeloid leukemia frontline therapy for older patients

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2012, Cancer.

Prognostic value of FLT3 mutations among different cytogenetic subgroups in acute myeloid leukemia

H. Kantarjian, J. Cortes, F. Ravandi, 2011, Cancer.

Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy

J. Issa, H. Kantarjian, G. Garcia-Manero, 2010, Cancer.

Quantifying the survival benefit for allogeneic hematopoietic stem cell transplantation in relapsed acute myelogenous leukemia.

P. Thall, E. Estey, H. Kantarjian, 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Treatment of core‐binding‐factor in acute myelogenous leukemia with fludarabine, cytarabine, and granulocyte colony‐stimulating factor results in improved event‐free survival

E. Estey, H. Kantarjian, G. Garcia-Manero, 2008, Cancer.

A prognostic score for patients with lower risk myelodysplastic syndrome

H. Kantarjian, G. Garcia-Manero, Xuelin Huang, 2008, Leukemia.

Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome

J. Issa, H. Kantarjian, G. Garcia-Manero, 2007, Cancer.

CD33 is frequently expressed in cases of myelodysplastic syndrome and chronic myelomonocytic leukemia with elevated blast count

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2016, Leukemia & lymphoma.

Soluble phosphorylated fms-like tyrosine kinase III. FLT3 protein in patients with acute myeloid leukemia (AML).

E. Estey, H. Kantarjian, F. Ravandi, 2007, Leukemia research.

Clofarabine plus cytarabine compared to cytarabine alone in older patients with relapsed or refractory (R/R) acute myelogenous leukemia (AML): Results from the phase III CLASSIC 1 trial.

R. Collins, P. Hari, M. Maris, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome.

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2008, Blood.

Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study.

H. Kantarjian, J. Cortes, F. Ravandi, 2012, The Lancet Oncology.

Potential role of sorafenib in the treatment of acute myeloid leukemia

H. Kantarjian, J. Cortes, F. Ravandi, 2008, Leukemia & lymphoma.

Clinicopathologic and molecular features in hairy cell leukemia-variant: single institutional experience

K. Patel, F. Ravandi, R. Kanagal-Shamanna, 2018, Modern Pathology.

Activity of decitabine in patients with myelodysplastic syndrome previously treated with azacitidine

J. Issa, H. Kantarjian, F. Ravandi, 2008, Leukemia & lymphoma.

Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms

R. Collins, D. Bottomly, S. McWeeney, 2019, Nature Communications.

Patient Characteristics and Outcomes in Adolescents and Young Adults (AYA) With Acute Myeloid Leukemia (AML).

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2016, Clinical lymphoma, myeloma & leukemia.

Phase I and extension study of clofarabine plus cyclophosphamide in patients with relapsed/refractory acute lymphoblastic leukemia.

H. Kantarjian, J. Cortes, T. Kadia, 2014, Clinical lymphoma, myeloma & leukemia.

Phase 1 and Extension Study of Clofarabine plus Cyclophosphamide in Patients with Relapsed / Refractory Acute Lymphoblastic Leukemia ( ALL )

J. Cortes, T. Kadia, F. Ravandi, 2014 .

Dasatinib, an immunomodulator?

F. Ravandi, 2010, Blood.

Treated secondary acute myeloid leukemia: a distinct high-risk subset of AML with adverse prognosis.

M. Konopleva, Z. Estrov, M. Andreeff, 2017, Blood advances.

NCCN Clinical Practice Guidelines Acute myeloid leukemia.

M. Millenson, F. Appelbaum, K. Gregory, 2012, Journal of the National Comprehensive Cancer Network : JNCCN.

A phase II study of decitabine and gemtuzumab ozogamicin in newly diagnosed and relapsed acute myeloid leukemia and high-risk myelodysplastic syndrome

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2016, Leukemia.

T-cell large granular lymphocytic (T-LGL) leukemia: experience in a single institution over 8 years.

H. Kantarjian, F. Ravandi, M. Keating, 2007, Leukemia research.

Janus kinase 2 variants associated with the transformation of myeloproliferative neoplasms into acute myeloid leukemia

M. Konopleva, M. Andreeff, H. Kantarjian, 2019, Cancer.

Long‐term durable remission by cladribine followed by rituximab in patients with hairy cell leukaemia: update of a phase II trial

H. Kantarjian, P. Jain, F. Ravandi, 2016, British journal of haematology.

Chemoimmunotherapy for hairy cell leukemia.

F. Ravandi, 2015, Best practice & research. Clinical haematology.

Hairy cell leukemia.

F. Ravandi, 2009, Clinical lymphoma & myeloma.

Eradication of minimal residual disease in hairy cell leukemia.

H. Kantarjian, S. Verstovsek, Xuelin Huang, 2006, Blood.

Chronic lymphoid leukemias other than chronic lymphocytic leukemia: diagnosis and treatment.

F. Ravandi, S. O'brien, 2005, Mayo Clinic proceedings.

Infections in chronic leukemias and other hematological malignancies

E. Anaissie, F. Ravandi, S. O'brien, 2003 .

Phase II Trial of MEK Inhibitor Binimetinib (MEK162) in RAS‐mutant Acute Myeloid Leukemia

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2019, Clinical lymphoma, myeloma & leukemia.

Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia

W. Wilson, I. Pastan, J. Delgado, 2018, Leukemia.

Clinical outcomes in adult patients with aplastic anemia: A single institution experience

S. Parmar, H. Kantarjian, G. Garcia-Manero, 2017, American journal of hematology.

Estimated glomerular filtration rate changes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors

H. Kantarjian, J. Cortes, F. Ravandi, 2015, Cancer.

Predictors of outcomes in adults with acute myeloid leukemia and KMT2A rearrangements

M. Konopleva, M. Andreeff, H. Kantarjian, 2021, Blood Cancer Journal.

Phase I/II Study of Azacitidine (AZA) with Venetoclax (VEN) and Magrolimab (Magro) in Patients (pts) with Newly Diagnosed Older/Unfit or High-Risk Acute Myeloid Leukemia (AML) and Relapsed/Refractory (R/R) AML

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2021, Blood.

A Phase II Study of 5-Azacytidine (AZA) and Venetoclax As Maintenance Therapy in Patients with Acute Myeloid Leukemia (AML) in Remission

M. Konopleva, G. Garcia-Manero, T. Kadia, 2021, Blood.

Prognostic Impact of NPM1 and FLT3 Mutations at Diagnosis and Presence of Measurable Residual Disease (MRD) after Intensive Chemotherapy (IC) for Patients with Acute Myeloid Leukemia (AML) in Remission: Outcomes from the QUAZAR AML-001 Trial of Oral Azacitidine (Oral-AZA) Maintenance

H. Döhner, F. Thol, H. Dombret, 2021, Blood.

Outcome of patients with relapsed/refractory acute lymphoblastic leukemia after blinatumomab failure: No change in the level of CD19 expression

H. Einsele, M. Konopleva, H. Kantarjian, 2018, American journal of hematology.

Phase II trial of hyper CVAD and dasatinib in patients with relapsed Philadelphia chromosome positive acute lymphoblastic leukemia or blast phase chronic myeloid leukemia.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2014, American journal of hematology.

Role of the p38 Mitogen-activated Protein Kinase Pathway in the Generation of the Effects of Imatinib Mesylate (STI571) in BCR-ABL-expressing Cells*

A. Verma, S. Parmar, L. Platanias, 2004, Journal of Biological Chemistry.

The p38 MAPK Pathway Mediates the Growth Inhibitory Effects of Interferon-α in BCR-ABL-expressing Cells*

Amit Verma, L. Platanias, F. Ravandi, 2001, The Journal of Biological Chemistry.

Efficacy of Ponatinib Versus Earlier Generation Tyrosine Kinase Inhibitors for Front‐line Treatment of Newly Diagnosed Philadelphia‐positive Acute Lymphoblastic Leukemia

H. Kantarjian, F. Ravandi, E. Jabbour, 2018, Clinical lymphoma, myeloma & leukemia.

Treating adults with acute lymphoblastic leukemia: it is time to grow up

F. Ravandi, P. Kebriaei, 2013 .

Adult acute megakaryocytic leukemia: an analysis of 37 patients treated at M.D. Anderson Cancer Center.

E. Estey, Y. Oki, H. Kantarjian, 2006, Blood.

Prophylactic intrathecal chemotherapy in acute promyelocytic leukemia (APL)

F. Ravandi, 2004, Leukemia.

Activation of Rac1 and the p38 Mitogen-activated Protein Kinase Pathway in Response to Arsenic Trioxide*

S. Minucci, A. Verma, S. Kambhampati, 2002, The Journal of Biological Chemistry.

Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin.

E. Estey, Z. Estrov, H. Kantarjian, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes.

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2020, Blood advances.

Immunotherapy in Acute Myeloid Leukemia: Where We Stand

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2021, Frontiers in Oncology.

Harnessing the Immune System Against Leukemia: Monoclonal Antibodies and Checkpoint Strategies for AML.

P. Sharma, F. Ravandi, N. Daver, 2017, Advances in experimental medicine and biology.

Prognostic implications of chromosome 17 abnormalities in the context of monosomal karyotype in patients with acute myeloid leukemia and complex cytogenetics.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2011, Clinical lymphoma, myeloma & leukemia.

Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2011, Blood.

First Clinical Results Of a Randomized Phase 2 Study Of SGI-110, a Novel Subcutaneous (SQ) Hypomethylating Agent (HMA), In Adult Patients With Acute Myeloid Leukemia (AML)

J. Issa, W. Chung, H. Kantarjian, 2013 .

Phase II study of the IDH2-inhibitor enasidenib in patients with high-risk IDH2-mutated myelodysplastic syndromes (MDS).

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2021 .

Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab.

E. Estey, M. Konopleva, Z. Estrov, 2017, Blood.

Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignment.

E. Estey, F. Appelbaum, J. Cortes, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Selective, novel spleen tyrosine kinase (Syk) inhibitors suppress chronic lymphocytic leukemia B-cell activation and migration

F. Ravandi, A. Pandey, M. Keating, 2012, Leukemia.

Adult acute erythroleukemia: an analysis of 91 patients treated at a single institution

H. Kantarjian, F. Ravandi, G. Borthakur, 2009, Leukemia.

Molecular Insights in Patient Care Identification of a Novel Fusion Gene , IRF 2 BP 2-RARA , in Acute Promyelocytic Leukemia

L. Chin, A. Protopopov, Jianhua Zhang, 2015 .

Treatment with Combination of Dabrafenib and Trametinib in Patients with Recurrent/Refractory BRAF V600E-Mutated Hairy Cell Leukemia (HCL)

J. Blay, Z. Wainberg, F. Ravandi, 2018, Blood.

Outcomes of older patients with NPM1-mutated AML: current treatments and the promise of venetoclax-based regimens.

M. Konopleva, M. Andreeff, H. Kantarjian, 2020, Blood advances.

Fludarabine, Cytarabine, G-CSF and Gemtuzumab Ozogamicin (FLAG-GO) Regimen Results in Better Molecular Response and Relapse-Free Survival in Core Binding Factor Acute Myeloid Leukemia Than FLAG and Idarubicin (FLAG-Ida)

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2019, Blood.

Clinical Outcomes and Co-Occurring Mutations in Patients with RUNX1-Mutated Acute Myeloid Leukemia

M. Konopleva, K. Bhalla, H. Kantarjian, 2017, International journal of molecular sciences.

The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia.

H. Kantarjian, J. Cortes, S. Verstovsek, 2007, British journal of haematology.

Characteristics and outcomes of older patients with secondary acute myeloid leukemia according to treatment approach

M. Konopleva, K. Bhalla, H. Kantarjian, 2017, Cancer.

Management of Newly Diagnosed Acute Myeloid Leukemia in the Elderly: Current Strategies and Future Directions

F. Ravandi, D. Sanford, 2015, Drugs & Aging.

Management of Relapsed/Refractory Acute Myeloid Leukemia

H. Kantarjian, F. Ravandi, E. Jabbour, 2020 .

Usefulness of CD11a and CD18 in flow cytometric immunophenotypic analysis for diagnosis of acute promyelocytic leukemia.

H. Kantarjian, J. Cortes, F. Ravandi, 2012, American journal of clinical pathology.

Results of phase 2 randomized study of low‐dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia

J. Issa, H. Kantarjian, G. Garcia-Manero, 2015, Cancer.

Feasibility of allo-SCT after hypomethylating therapy with decitabine for myelodysplastic syndrome

J. Issa, H. Kantarjian, G. Garcia-Manero, 2009, Bone Marrow Transplantation.

Blinatumomab Is Well Tolerated Maintenance Therapy Following Allogeneic Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia

K. Rezvani, D. Marin, H. Kantarjian, 2019, Biology of Blood and Marrow Transplantation.

Mature T‐cell leukemias

H. Kantarjian, F. Ravandi, C. Dearden, 2005, Cancer.

Phase 2 Study of Ibrutinib in Classic and Variant Hairy Cell Leukemia.

Jeffrey A Jones, M. Grever, G. Lozanski, 2021, Blood.

Immune therapies in acute myeloid leukemia: a focus on monoclonal antibodies and immune checkpoint inhibitors

H. Kantarjian, F. Ravandi, N. Daver, 2017, Current opinion in hematology.

Outcome Of Patients (pts) With Low and Intermediate-1 Risk Myelodysplastic Syndrome (MDS) After Hypomethylating Agent (HMA) Failure

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2012 .

Long-term outcome of hyper-CVAD-R for Burkitt leukemia/lymphoma and high-grade B-cell lymphoma: focus on CNS relapse

H. Kantarjian, F. Ravandi, E. Jabbour, 2021, Blood advances.

Phase 2 and pharmacodynamic study of oral forodesine in patients with advanced, fludarabine-treated chronic lymphocytic leukemia.

H. Kantarjian, F. Ravandi, M. Keating, 2010, Blood.

Clonal evolution and treatment outcomes in hematopoietic neoplasms arising in patients with germline RUNX1 mutations

K. Bhalla, H. Kantarjian, G. Garcia-Manero, 2020, American journal of hematology.

Approaching the Treatment of AML from a Biological Perspective

F. Ravandi, F. Giles, 2007 .

Novel Agents in Acute Myeloid Leukemia

F. Ravandi, F. Giles, A. Aribi, 2006, Cancer journal.

Hairy cell leukemia and COVID-19 adaptation of treatment guidelines

M. Grever, A. Saven, B. Falini, 2021, Leukemia.

Blinatumomab Maintenance After Allogeneic Hematopoietic Cell Transplantation for B-lineage Acute Lymphoblastic Leukemia.

R. Başar, K. Rezvani, D. Marin, 2021, Blood.

Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trial.

E. Rock, J. Issa, H. Kantarjian, 2017, The Lancet. Oncology.

Relapsed acute myeloid leukemia: why is there no standard of care?

F. Ravandi, 2013, Best practice & research. Clinical haematology.

Chromosomal Abnormalities and Prognosis in NPM1-Mutated Acute Myeloid Leukemia: A Pooled Analysis of Individual Patient Data From Nine International Cohorts.

E. Estey, G. Lenz, H. Dombret, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Acute myeloid leukemia after myelodysplastic syndrome and failure of therapy with hypomethylating agents: an emerging entity with a poor prognosis.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2013, Clinical lymphoma, myeloma & leukemia.

AML-348 A Phase Ib/II Study of Ivosidenib With Venetoclax +/- Azacitidine in IDH1-Mutated Hematologic Malignancies.

P. Vyas, H. Kantarjian, T. Kadia, 2022, Clinical lymphoma, myeloma & leukemia.

Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapy

M. Konopleva, M. Andreeff, H. Kantarjian, 2022, Blood cancer journal.

A Triplet Combination of Azacitidine, Venetoclax and Gilteritinib for Patients with FLT3-Mutated Acute Myeloid Leukemia: Results from a Phase I/II Study

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2021, Blood.

Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia

M. Konopleva, M. Andreeff, H. Kantarjian, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Ten-Day Decitabine with Venetoclax Versus Intensive Chemotherapy in Relapsed or Refractory Acute Myeloid Leukemia: A Propensity Score Matched Analysis

M. Konopleva, H. Kantarjian, T. Kadia, 2020, Blood.

Interactions and relevance of blast percentage and treatment strategy among younger and older patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS)

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2016, American journal of hematology/oncology.

Impact of numerical variation, allele burden, mutation length and co-occurring mutations on the efficacy of tyrosine kinase inhibitors in newly diagnosed FLT3- mutant acute myeloid leukemia

H. Kantarjian, J. Cortes, K. Patel, 2020, Blood Cancer Journal.

Allogeneic Transplantation in First Remission Improves Outcomes Irrespective of FLT3-ITD Allelic Ratio in FLT3-ITD-Positive Acute Myelogenous Leukemia.

H. Kantarjian, E. Shpall, J. Cortes, 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

FLT3 inhibitors in the treatment of acute myeloid leukemia

H. Kantarjian, J. Cortes, F. Ravandi, 2011, Cancer.

Age and Modified European LeukemiaNet Classification to Predict Transplant Outcomes: An Integrated Approach for Acute Myelogenous Leukemia Patients Undergoing Allogeneic Stem Cell Transplantation.

E. Shpall, J. Cortes, F. Ravandi, 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: Position on Standards of Care and Areas of Need.

M. Konopleva, H. Kantarjian, A. Lane, 2022, Blood.

Characteristics and outcomes of patients with blastic plasmacytoid dendritic cell neoplasm treated with frontline HCVAD

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2022, Blood advances.

Complete Responses in Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients on a Weekly Dosing Schedule of Vibecotamab (XmAb14045), a CD123 x CD3 T Cell-Engaging Bispecific Antibody; Initial Results of a Phase 1 Study

F. Ravandi, W. Stock, A. Pastore, 2020, Blood.

TP53 abnormalities correlate with immune infiltration and associate with response to flotetuzumab immunotherapy in AML.

T. Yau, S. Rutella, J. Dipersio, 2020, Blood advances.

Phase 1 Cohort Expansion of Flotetuzumab, a CD123×CD3 Bispecific Dart® Protein in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)

S. Rutella, J. Dipersio, J. Wigginton, 2018, Blood.

Complete Responses in Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients on a Weekly Dosing Schedule of XmAb14045, a CD123 x CD3 T Cell-Engaging Bispecific Antibody: Initial Results of a Phase 1 Study

H. Kantarjian, F. Ravandi, Koichi Takahashi, 2018, Blood.

A phase Ib/II study of ivosidenib with venetoclax +/- azacitidine in IDH1-mutated myeloid malignancies.

P. Vyas, M. Konopleva, H. Kantarjian, 2021, Blood cancer discovery.

Characteristics, clinical outcome, and prognostic significance of IDH mutations in AML

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2015, American journal of hematology.

Clinical outcomes associated with NPM1 mutations in patients with relapsed or refractory AML

M. Konopleva, M. Andreeff, K. Bhalla, 2022, Blood advances.

Outcomes of acute lymphoblastic leukemia with KMT2A (MLL) rearrangement: the MD Anderson experience

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2021, Blood advances.

FLT3 inhibitor quizartinib (AC220)

F. Ravandi, K. Naqvi, 2019, Leukemia & lymphoma.

FLT3 inhibitors in acute myeloid leukemia: Choosing the best when the optimal does not exist

F. Ravandi, R. Assi, 2018, American journal of hematology.

Targeted therapies in Acute Myeloid Leukemia: a focus on FLT-3 inhibitors and ABT199

M. Konopleva, F. Ravandi, K. Naqvi, 2017, Expert review of hematology.

Are adjuncts to induction chemotherapy worthwhile in the treatment of acute myeloid leukemia?

F. Ravandi, 2014, Best practice & research. Clinical haematology.

Vadastuximab Talirine Monotherapy in Older Patients with Treatment Naive CD33-Positive Acute Myeloid Leukemia (AML)

F. Ravandi, D. DeAngelo, J. Lancet, 2016 .

A Phase 1b Study of Vadastuximab Talirine As Maintenance and in Combination with Standard Consolidation for Patients with Acute Myeloid Leukemia (AML)

Scott E. Smith, B. Wood, M. Maris, 2016 .

A Phase 1b Study of Vadastuximab Talirine in Combination with 7+3 Induction Therapy for Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)

Scott E. Smith, B. Wood, M. Maris, 2016 .

Interim Analysis of the Phase 1b/2 Study of the BCL-2 Inhibitor Venetoclax in Combination with Standard Intensive AML Induction/Consolidation Therapy with FLAG-IDA in Patients with Newly Diagnosed or Relapsed/Refractory AML

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2020 .

Phase Ib/II study of the IDH1-mutant inhibitor ivosidenib with the BCL2 inhibitor venetoclax +/- azacitidine in IDH1-mutated hematologic malignancies.

P. Vyas, M. Konopleva, H. Kantarjian, 2020 .

Updated results from phase I dose-escalation study of AMG 330, a bispecific T-cell engager molecule, in patients with relapsed/refractory acute myeloid leukemia (R/R AML).

P. Paschka, H. Kantarjian, M. Jongen‐Lavrencic, 2020 .

The evolution of acute lymphoblastic leukemia research and therapy at MD Anderson over four decades

F. Ravandi, E. Jabbour, N. Jain, 2023, Journal of Hematology & Oncology.

Emerging treatment paradigms with FLT3 inhibitors in acute myeloid leukemia

H. Kantarjian, F. Ravandi, N. Daver, 2019, Therapeutic advances in hematology.

Long‐term survival with oral azacitidine for patients with acute myeloid leukemia in first remission after chemotherapy: Updated results from the randomized, placebo‐controlled, phase 3 QUAZAR AML‐001 trial

H. Döhner, H. Dombret, B. Skikne, 2023, American journal of hematology.

Oral azacitidine preserves favorable level of fatigue and health-related quality of life for patients with acute myeloid leukemia in remission: results from the phase III, placebo-controlled QUAZAR AML-001 trial

H. Döhner, H. Dombret, B. Skikne, 2021, Haematologica.

Prognostic impact of complete remission with MRD negativity in patients with relapsed or refractory AML.

M. Konopleva, H. Kantarjian, J. Cortes, 2020, Blood advances.

Spontaneous Hematologic and Cytogenetic Remission in a Case of Acute Myelogenous Leukemia with Inversion 16

F. Ravandi, L. Abruzzo, Dan M. Jones, 2007 .

FLT3 mutated acute myeloid leukemia: 2021 treatment algorithm

F. Ravandi, N. Daver, S. Venugopal, 2021, Blood Cancer Journal.

Prognostic impact of NPM1 and FLT3 mutations in patients with AML in first remission treated with oral azacitidine.

H. Döhner, F. Thol, H. Dombret, 2022, Blood.

Management of adverse events in patients with acute myeloid leukemia in remission receiving oral azacitidine: experience from the phase 3 randomized QUAZAR AML-001 trial

H. Döhner, T. Chevassut, H. Dombret, 2021, Journal of Hematology & Oncology.

Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN.

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2017, Blood.

CC-486 Prolongs Survival for Patients with Acute Myeloid Leukemia (AML) in Remission after Intensive Chemotherapy (IC) Independent of the Presence of Measurable Residual Disease (MRD) at Study Entry: Results from the QUAZAR AML-001 Maintenance Trial

H. Döhner, F. Thol, H. Dombret, 2020 .

CC-486 Improves Overall Survival (OS) and Relapse-Free Survival (RFS) for Patients with Acute Myeloid Leukemia (AML) in First Remission after Intensive Chemotherapy (IC), Regardless of Amount of Consolidation Received: Results from the Phase III QUAZAR AML-001 Maintenance Trial

H. Döhner, H. Dombret, B. Skikne, 2020 .

Blinatumomab is associated with favorable outcomes in patients with B‐cell lineage acute lymphoblastic leukemia and positive measurable residual disease at a threshold of 10−4 and higher

H. Kantarjian, G. Garcia-Manero, T. Kadia, 2022, American journal of hematology.

P365: INCORPORATION OF NELARABINE (NEL), PEGYLATED ASPARAGINASE (PEG) AND VENETOCLAX (VEN) IN THE FRONTLINE THERAPY OF ADULT PATIENTS WITH T-ACUTE LYMPHOBLASTIC LEUKEMIA/T-LYMPHOBLASTIC LYMPHOMA (T-ALL/LBL)

T. Kadia, F. Ravandi, E. Jabbour, 2022, HemaSphere.

P371: HYPER-CVAD WITH SEQUENTIAL BLINATUMOMAB, WITH OR WITHOUT INOTUZUMAB OZOGAMICIN, IN ADULTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-NEGATIVE B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA

T. Kadia, F. Ravandi, E. Jabbour, 2022, HemaSphere.

A phase II study of hyper-CVAD with sequential blinatumomab (Blina), with or without inotuzumab ozogamicin (INO), in adults with newly diagnosed B-cell acute lymphoblastic leukemia (ALL).

H. Kantarjian, T. Kadia, F. Ravandi, 2022, Journal of Clinical Oncology.

Updated results from a phase II study of mini-hyper-CVD (mini-HCVD) plus inotuzumab ozogamicin (INO), with or without blinatumomab (Blina), in older adults with newly diagnosed Philadelphia chromosome (Ph)-negative B-cell acute lymphoblastic leukemia (ALL).

M. Konopleva, H. Kantarjian, T. Kadia, 2022, Journal of Clinical Oncology.

Intrathecal prophylaxis with 12 versus 8 administrations reduces the incidence of central nervous system relapse in patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia

G. Garcia-Manero, T. Kadia, F. Ravandi, 2022, American journal of hematology.

Dismal outcomes of patients with relapsed/refractory Philadelphia chromosome‐negative B‐cell acute lymphoblastic leukemia after failure of both inotuzumab ozogamicin and blinatumomab

M. Konopleva, H. Kantarjian, T. Kadia, 2022, American journal of hematology.

A Phase II Study of Inotuzumab Ozogamicin for the Treatment of Measurable Residual Disease-Positive B-Cell Acute Lymphoblastic Leukemia

M. Konopleva, F. Ravandi, E. Jabbour, 2021, Blood.

Combination of ponatinib and blinatumomab in Philadelphia chromosome-positive acute lymphoblastic leukemia: Early results from a phase II study.

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2021 .

Ultrasensitive Next-Generation Sequencing-Based Measurable Residual Disease Assessment in Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia after Frontline Therapy: Correlation with Flow Cytometry and Impact on Clinical Outcomes

M. Konopleva, H. Kantarjian, K. Patel, 2020 .

Hyper-CVAD and Sequential Blinatumomab in Adults with Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia: Results from a Phase II Study

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2020 .

Reduced-Intensity Chemotherapy with Mini-Hyper-CVD Plus Inotuzumab Ozogamicin, with or without Blinatumomab, in Older Adults with Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: Results from a Phase II Study

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2020 .

Frontline HCVAD with Nelarabine and Peg-Asparaginase in T-Acute Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LBL): Updated Results of a Phase II Trial

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2020 .

Hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia: a single-arm, phase 2 trial.

C. Mullighan, M. Konopleva, H. Kantarjian, 2020, The Lancet. Haematology.

Title: 12 Versus 8 Prophylactic Intrathecal (IT) Chemotherapy Administration Decrease Incidence of Central Nervous System (CNS) Relapse in Patients (pts) with Newly Diagnosed Philadelphia (Ph)-Positive Acute Lymphocytic Leukemia (ALL)

H. Kantarjian, G. Garcia-Manero, T. Kadia, 2019, Blood.

Inotuzumab ozogamicin in combination with low‐intensity chemotherapy (mini‐HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVAD) as frontline therapy for older patients with Philadelphia chromosome‐negative acute lymphoblastic leukemia: A propensity score analysis

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2019, Cancer.

Recommendations for the assessment and management of measurable residual disease in adults with acute lymphoblastic leukemia: A consensus of North American experts

A. Logan, H. Kantarjian, F. Ravandi, 2018, American journal of hematology.

Chemoimmunotherapy with inotuzumab ozogamicin combined with mini‐hyper‐CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome–negative acute lymphoblastic leukemia in first salvage

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2018, Cancer.

Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2015, Haematologica.

Identifying effective drug combinations for patients with acute myeloid leukemia

T. Kadia, F. Ravandi, M. Yilmaz, 2020, Expert review of anticancer therapy.

Vadastuximab Talirine Plus Hypomethylating Agents: A Well-Tolerated Regimen with High Remission Rate in Frontline Older Patients with Acute Myeloid Leukemia (AML)

F. Ravandi, D. DeAngelo, J. Lancet, 2016 .

The microenvironment in hairy cell leukemia: pathways and potential therapeutic targets

F. Ravandi, J. Burger, M. Sivina, 2011, Leukemia & lymphoma.

Chemo-immunotherapy for hairy cell leukemia

F. Ravandi, 2011, Leukemia & lymphoma.

Survival benefit with imatinib mesylate versus interferon-alpha-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia.

Susan O'Brien, Jorge Cortes, Guillermo Garcia-Manero, 2006, Blood.

Monoclonal antibody therapy for hairy cell leukemia.

H. Kantarjian, F. Ravandi, D. Thomas, 2006, Hematology/oncology clinics of North America.

Safety, Efficacy, and Biomarkers of Response to Azacitidine (AZA) with Nivolumab (Nivo) and AZA with Nivo and Ipilimumab (Ipi) in Relapsed/Refractory Acute Myeloid Leukemia: A Non-Randomized, Phase 2 Study

P. Sharma, M. Konopleva, Z. Estrov, 2018, Blood.

TP53 abnormalities correlate with immune infiltration and are associated with response to flotetuzumab, an investigational immunotherapy, in acute myeloid leukemia

S. Rutella, J. Dipersio, Catherine Lai, 2020, bioRxiv.

Acute erythroleukemia: diagnosis and management

F. Ravandi, C. Bueso-Ramos, F. P. Santos, 2010, Expert review of hematology.

Outcome after Frontline Therapy with the Modified Hyper-CVAD Regimen with or without Rituximab for De Novo Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL).

M. Konopleva, Z. Estrov, H. Kantarjian, 2008 .

Leukemia stemness and co-occurring mutations drive resistance to IDH inhibitors in acute myeloid leukemia

Erika J. Thompson, M. Konopleva, K. Bhalla, 2020, Nature Communications.

Myeloablative Fractionated Busulfan Conditioning Regimen with Sorafenib in Patients with AML: Results of Phase I Clinical Trial

P. Thall, K. Rezvani, D. Marin, 2021, Blood.

Ten‐day decitabine with venetoclax versus intensive chemotherapy in relapsed or refractory acute myeloid leukemia: A propensity score‐matched analysis

M. Konopleva, H. Kantarjian, T. Kadia, 2021, Cancer.

A phase I/II study of the combination of quizartinib with azacitidine or low-dose cytarabine for the treatment of patients with acute myeloid leukemia or myelodysplastic syndrome

M. Konopleva, Z. Estrov, M. Andreeff, 2021, Haematologica.

Cladribine, Idarubicin, Cytarabine (ara-C), and Venetoclax in Treating Patients with Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome

M. Konopleva, Z. Estrov, M. Andreeff, 2020 .

Phase II trial of CPX-351 in patients with acute myeloid leukemia at high risk for induction mortality

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2020, Leukemia.

Phase II Study of Cladribine, Idarubicin, Cytarabine (CLIA) Plus Gilteritinib in Patients with FLT3 Mutated Acute Myeloid Leukemia (AML)

G. Garcia-Manero, T. Kadia, F. Ravandi, 2021, Blood.

Quizartinib (Quiz) with Decitabine (DAC) and Venetoclax (VEN) Is Highly Active in Patients (pts) with FLT3-ITD Mutated Acute Myeloid Leukemia (AML) - RAS/MAPK Mutations Continue to Drive Primary and Secondary Resistance

M. Konopleva, M. Andreeff, G. Garcia-Manero, 2021, Blood.

Long-Term Overall Survival (OS) with Oral Azacitidine (Oral-AZA) in Patients with Acute Myeloid Leukemia (AML) in First Remission after Intensive Chemotherapy (IC): Updated Results from the Phase 3 QUAZAR AML-001 Trial

H. Döhner, H. Dombret, B. Skikne, 2021, Blood.

A phase 1b/2 study of azacitidine with PD‐L1 antibody avelumab in relapsed/refractory acute myeloid leukemia

M. Konopleva, M. Andreeff, G. Garcia-Manero, 2021, Cancer.

Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study.

P. Sharma, M. Konopleva, Z. Estrov, 2019, The Lancet. Haematology.

Management of Cytokine Release Syndrome in AML Patients Treated with Flotetuzumab, a CD123 x CD3 Bispecific Dart® Molecule for T-Cell Redirected Therapy

C. Viero, J. Dipersio, J. Wigginton, 2018, Blood.

CASCADE: A phase 3, randomized, double-blind study of vadastuximab talirine (33A) versus placebo in combination with azacitidine or decitabine in the treatment of older patients with newly diagnosed acute myeloid leukemia (AML).

F. Ravandi, K. Kreuzer, L. Adès, 2017 .

Sorafenib plus intensive chemotherapy improves survival in patients with newly diagnosed, FLT3‐internal tandem duplication mutation–positive acute myeloid leukemia

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2019, Cancer.

Clonal Dynamics and clinical implications of Post-Remission Clonal Hematopoiesis in Acute Myeloid Leukemia (AML).

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2021, Blood.

Incorporating Tyrosine Kinase Inhibitors into Treatment Regimens for AML and ALL: Is There a Right or Wrong Way?

F. Ravandi, 2014, Current Hematologic Malignancy Reports.

First report of clinical response to venetoclax combination with pentostatin in T-cell-prolymphocytic leukemia (T-PLL)

T. Kadia, P. Jain, F. Ravandi, 2020, Leukemia & lymphoma.

Phase I trial of SAR103168, a novel multi-kinase inhibitor, in patients with refractory/relapsed acute leukemia or high-risk myelodysplastic syndrome

Wei Zheng, F. Ravandi, E. Jabbour, 2015, Leukemia & lymphoma.

Acute Myeloid Leukemia: Past, Present, and Prospects for the Future.

F. Ravandi, N. Short, 2016, Clinical lymphoma, myeloma & leukemia.

Outcome of Patients With Therapy-Related Acute Myeloid Leukemia With or Without a History of Myelodysplasia.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2016, Clinical Lymphoma, Myeloma & Leukemia.

Purine analogue combinations for indolent lymphomas.

F. Ravandi, N. D. Di Bella, 2006, Seminars in hematology.

Pooled Analysis of Elderly Patients with Newly Diagnosed AML Treated with Sapacitabine and Decitabine Administered in Alternating Cycles.

P. Venugopal, H. Kantarjian, T. Kadia, 2012 .

Phase 1/ 2 Study of Sapacitabine and Decitabine Administered Sequentially in Elderly Patients with Newly Diagnosed AML,

P. Venugopal, H. Kantarjian, G. Garcia-Manero, 2011 .

Phase I/II study of sapacitabine and decitabine administered sequentially in elderly patients with newly diagnosed acute myeloid leukemia.

G. Garcia-Manero, J. Cortes, T. Kadia, 2011, Journal of Clinical Oncology.

Durable Overall Survival Benefit in Patients ≥ 60 Years with Relapsed or Refractory AML Treated with Vosaroxin/Cytarabine Vs Placebo/Cytarabine: Updated Results from the Valor Trial

Jennifer A. Smith, H. Kantarjian, J. Cortes, 2016 .

Validation of the ALFA-1200 model in older patients with AML treated with intensive chemotherapy

M. Konopleva, T. Kadia, F. Ravandi, 2022, Blood advances.

Venetoclax with decitabine vs intensive chemotherapy in acute myeloid leukemia: A propensity score matched analysis stratified by risk of treatment‐related mortality

M. Konopleva, M. Andreeff, H. Kantarjian, 2020, American journal of hematology.

Long-Term Follow-Up after Frontline Therapy with the Hyper-CVAD and Imatinib Mesylate Regimen in Adults with Philadelphia (Ph) Positive Acute Lymphocytic Leukemia (ALL).

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2007 .

Prognostic factors for outcome in patients with refractory and relapsed acute lymphocytic leukemia treated with inotuzumab ozogamicin, a CD22 monoclonal antibody

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2015, American journal of hematology.

Characteristics and outcomes of patients with multiple myeloma who develop therapy-related myelodysplastic syndrome, chronic myelomonocytic leukemia, or acute myeloid leukemia.

V. Baladandayuthapani, H. Kantarjian, G. Garcia-Manero, 2015, Clinical lymphoma, myeloma & leukemia.

Outcomes of adults with relapsed or refractory Burkitt and high‐grade B‐cell leukemia/lymphoma

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2017, American journal of hematology.

Outcome of Patients (pts) with Myelodysplastic Syndrome (MDS) and Chronic Myelomonocytic Leukemia (CMML) Post Decitabine Failure.

J. Issa, H. Kantarjian, G. Garcia-Manero, 2008 .

A clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trials

M. Konopleva, Z. Estrov, H. Kantarjian, 2017, Leukemia.

Early T-Cell Precursor Acute Lymphoblastic Leukemia (ETP-ALL) Is a High-Risk Subtype in Adults

M. Konopleva, H. Kantarjian, J. Cortes, 2015 .

Impact of TKIs post–allogeneic hematopoietic cell transplantation in Philadelphia chromosome–positive ALL

D. Marin, H. Kantarjian, E. Shpall, 2020 .

Impact of TKI maintenance post-allogeneic transplant in Philadelphia positive acute lymphoblastic leukemia.

D. Marin, H. Kantarjian, E. Shpall, 2020, Blood.

Pan-Myeloid Leukemia Analysis: Machine Learning-Based Approach to Predict Phenotype and Clinical Outcomes Using Mutation Data

P. A. Futreal, S. Ogawa, Jianhua Zhang, 2018, Blood.

Failure is not fatal: long-term remission in refractory acute myeloid leukemia (AML) after graft failure of cord blood stem cells

H. Kantarjian, E. Shpall, F. Ravandi, 2010, Leukemia.

Inotuzumab Ozogamicin (Ino) May Overcome the Impact of Philadelphia Chromosome (Ph)-like Phenotype in Adult Patients (pts) with Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL)

Chunxu Qu, C. Mullighan, M. Konopleva, 2019, Blood.

Analysis of outcomes in adolescents and young adults with chronic myelogenous leukemia treated with upfront tyrosine kinase inhibitor therapy

H. Kantarjian, J. Cortes, A. Quintás-Cardama, 2012, Haematologica.

Evolving Therapies in Acute Myeloid Leukemia: Progress at Last?

F. Ravandi, D. DeAngelo, E. Stein, 2016, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

Clofarabine Plus Low-Dose Cytarabine Is as Effective as and Less Toxic Than Intensive Chemotherapy in Elderly AML Patients.

M. Konopleva, Z. Estrov, M. Andreeff, 2016, Clinical lymphoma, myeloma & leukemia.

Impact of frontline treatment approach on outcomes in patients with secondary AML with prior hypomethylating agent exposure

M. Konopleva, G. Garcia-Manero, E. Shpall, 2022, Journal of Hematology & Oncology.

Consensus opinion from an international group of experts on measurable residual disease in hairy cell leukemia

M. Grever, A. Saven, B. Falini, 2022, Blood cancer journal.

Flotetuzumab As Salvage Therapy for Primary Induction Failure and Early Relapse Acute Myeloid Leukemia

S. Rutella, J. Dipersio, M. Jongen‐Lavrencic, 2020 .

The Combination of Ruxolitinib (RUX) with Decitabine (DAC) in Patients (Pts) with Post-Myeloproliferative Neoplasm Acute Myeloid Leukemia (post-MPN AML): Interim Report of a Phase I/II Trial

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2017 .

Phase I/II Study of Ruxolitinib (RUX) with Decitabine (DAC) in Patients with Post-Myeloproliferative Neoplasm Acute Myeloid Leukemia (post-MPN AML): Phase I Results

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2016 .

Decitabine therapy for myeloproliferative neoplasm in accelerated (MPN-AP) or blastic (acute myeloid leukemia; MPN-AML) phase.

H. Kantarjian, J. Cortes, S. Verstovsek, 2014 .

Phase 2 study of arsenic trioxide in patients with relapsed or refractory multiple myeloma

F. Ravandi, R. Rifkin, M. Saleh, 2004, British journal of haematology.

Sequential azacitidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemia: a single-arm, phase 1/2 study.

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2015, The Lancet. Haematology.

Detection of nucleophosmin gene mutations in plasma from patients with acute myeloid leukemia: clinical significance and implications.

Amber C. Donahue, E. Estey, H. Kantarjian, 2009, Cancer biomarkers : section A of Disease markers.

The Clinical impact of PTPN11 mutations in adults with acute myeloid leukemia

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2020, Leukemia.

IDH1 and IDH2 mutations in myelodysplastic syndromes and role in disease progression

H. Kantarjian, G. Garcia-Manero, M. Routbort, 2015, Leukemia.

Return of gemtuzumab ozogamicin in acute myeloid leukemia—Is it for everyone with CD33+ disease?

F. Ravandi, P. Boddu, 2018, Advances in Cell and Gene Therapy.

Vosaroxin in combination with decitabine in newly diagnosed older patients with acute myeloid leukemia or high-risk myelodysplastic syndrome

M. Konopleva, M. Andreeff, H. Kantarjian, 2017, Haematologica.

Impact of achievement of complete cytogenetic response on outcome in patients with myelodysplastic syndromes treated with hypomethylating agents

Z. Estrov, S. Colla, H. Kantarjian, 2017, American journal of hematology.

Acute pulmonary failure during remission induction chemotherapy in adults with acute myeloid leukemia or high‐risk myelodysplastic syndrome

H. Kantarjian, S. Verstovsek, F. Ravandi, 2009, Cancer.

Outcomes of Chronic Myelomonocytic Leukemia (CMML) after Hypomethylating Agent (HMA) Failure

M. Konopleva, Z. Estrov, H. Kantarjian, 2020 .

Outcomes of TP53-Mutant Acute Myeloid Leukemia with Venetoclax and Decitabine

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2020 .

Phase II Study of CPX-351 Plus Venetoclax in Patients with Acute Myeloid Leukemia (AML)

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2020 .

Gastrointestinal Events and Management Strategies for Patients with Acute Myeloid Leukemia (AML) in First Remission Receiving CC-486 in the Randomized, Placebo-Controlled, Phase III QUAZAR AML-001 Maintenance Trial

T. Chevassut, H. Dombret, B. Skikne, 2020 .

Implications of RAS Mutational Status in Subsets of Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) across Therapy Groups

M. Konopleva, M. Andreeff, K. Bhalla, 2020 .

Only SF3B1 mutation involving K700E independently predicts overall survival in myelodysplastic syndromes

H. Kantarjian, G. Garcia-Manero, M. Routbort, 2021, Cancer.

Only SF3B1 Mutation involving K700E (And Not Other Codons), Independently Predicts Overall Survival in Myelodysplastic Syndromes

H. Kantarjian, G. Garcia-Manero, M. Routbort, 2020, bioRxiv.

Jumping Translocations in Myeloid Malignancies Associated With Treatment Resistance and Poor Survival.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2015, Clinical lymphoma, myeloma & leukemia.

Long-term results of a phase II trial of lenalidomide plus prednisone therapy for patients with myelofibrosis.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2016, Leukemia research.

Outcomes of acute myeloid leukemia with myelodysplasia related changes depend on diagnostic criteria and therapy

K. Do, M. Konopleva, H. Kantarjian, 2020, American journal of hematology.

Cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients age 60 years or older with previously untreated acute myeloid leukemia.

G. Mufti, H. Kantarjian, F. Ravandi, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Persistence of minimal residual disease assessed by multiparameter flow cytometry is highly prognostic in younger patients with acute myeloid leukemia

M. Konopleva, Z. Estrov, M. Andreeff, 2017, Cancer.

Monoclonal antibodies in acute lymphoblastic leukemia.

H. Kantarjian, F. Ravandi, E. Jabbour, 2015, Blood.

Relapse and death during first remission in acute myeloid leukemia

G. Garcia-Manero, F. Ravandi, G. Borthakur, 2008, Haematologica.

Tamibarotene in patients with acute promyelocytic leukaemia relapsing after treatment with all‐trans retinoic acid and arsenic trioxide

F. Lo‐Coco, H. Kantarjian, J. Cortes, 2015, British journal of haematology.

Prognostic significance of measurable residual disease in patients with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation in second or later complete remission

E. Shpall, F. Ravandi, U. Popat, 2022, American journal of hematology.

Toward Individualized Therapy in Acute Myeloid Leukemia: A Contemporary Review.

H. Kantarjian, J. Cortes, T. Kadia, 2015, JAMA oncology.

Phase 1 study of combinatorial sorafenib, G‐CSF, and plerixafor treatment in relapsed/refractory, FLT3‐ITD‐mutated acute myelogenous leukemia patients

M. Konopleva, M. Andreeff, H. Kantarjian, 2020, American journal of hematology.

Final results of a phase 2 trial of clofarabine and low‐dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2015, Cancer.

Phase II Study of the Frontline Hyper-CVAD in Combination with Ofatumumab for Adult Patients (pts) with CD-20 Positive Acute Lymphoblastic Leukemia (ALL)

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2015 .

Activity of alemtuzumab in patients with CD52‐positive acute leukemia

G. Garcia-Manero, J. Cortes, S. Verstovsek, 2006, Cancer.

Fatigue and physical activity in patients undergoing hematopoietic stem cell transplant.

F. Ravandi, K. van Besien, C. Ferrans, 2006, Oncology nursing forum.

Arsenic trioxide: expanding roles for an ancient drug?

F. Ravandi, 2004, Leukemia.

Phase II Study of the Frontline Hyper-CVAD in Combination with Ponatinib for Patients with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

M. Konopleva, Z. Estrov, H. Kantarjian, 2016 .

Frontline Inotuzumab Ozogamicin in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) for Older Patients with Acute Lymphoblastic Leukemia (ALL)

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2015 .

Outcomes of Patients With Relapsed Core Binding Factor‐Positive Acute Myeloid Leukemia

H. Kantarjian, J. Cortes, F. Ravandi, 2018, Clinical lymphoma, myeloma & leukemia.

Impact of splicing mutations in acute myeloid leukemia treated with hypomethylating agents combined with venetoclax.

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2021, Blood advances.

Bone marrow necrosis in acute leukemia: Clinical characteristic and outcome

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2015, American journal of hematology.

H. Kantarjian, F. Ravandi, X. Thomas, 2014, BMC Cancer.

The Role of Allogeneic Transplant for Adult Ph+ ALL in CR1 with Complete Molecular Remission: A Retrospective Analysis.

F. Gao, P. Westervelt, J. Dipersio, 2022, Blood.

Phase II Study of Combination of the HyperCVAD Regimen with Dasatinib in Patients with Philadelphia Chromosome (Ph) or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL) and Lymphoid Blast Phase Chronic Myeloid Leukemia (CML-LB).

H. Kantarjian, J. Cortes, F. Ravandi, 2007 .

Acute myeloid leukemia: advancing clinical trials and promising therapeutics

H. Kantarjian, J. Cortes, F. Ravandi, 2016, Expert review of hematology.

Genetic correlates in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with Hyper-CVAD plus dasatinib or ponatinib

P. A. Futreal, M. Konopleva, H. Kantarjian, 2022, Leukemia.

Phase 2 study of hyper‐CMAD with liposomal vincristine for patients with newly diagnosed acute lymphoblastic leukemia

M. Konopleva, Z. Estrov, H. Kantarjian, 2020, American journal of hematology.

Inotuzumab ozogamicin (CMC-544) compared to chemotherapy in patients (pts) with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL): A retrospective comparison.

H. Kantarjian, F. Ravandi, E. Jabbour, 2013 .

Results of a Phase II Trial of Dasatinib As Frontline Therapy for Chronic Myeloid Leukemia (CML) In Chronic Phase (CP)

E. Burton, H. Kantarjian, J. Cortes, 2011 .

Complete response in a patient with adult T-cell leukemia (ATL) treated with combination of alemtuzumab and pentostatin.

F. Ravandi, S. Faderl, 2006, Leukemia research.

Phase II Study of Cladribine and Low-Dose Cytarabine (AraC) Alternating with Decitabine in Older Patients with Acute Myeloid Leukemia (AML)

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2014 .

Phase II trial of cladribine and low-dose AraC alternating with decitabine in older patients with AML.

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2014 .

Significance of persistent cytogenetic abnormalities on myeloablative allogeneic stem cell transplantation in first complete remission.

G. Garcia-Manero, F. Ravandi, B. Andersson, 2013, Biology of Blood and Marrow Transplantation.

A Phase I/II Study of the mTOR Inhibitor Everolimus in Combination with HyperCVAD Chemotherapy in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia

K. Baggerly, M. Konopleva, Wenbin Liu, 2015, Clinical Cancer Research.

Rapid detection and quantitation of BRAF mutations in hairy cell leukemia using a sensitive pyrosequencing assay.

H. Kantarjian, K. Patel, F. Ravandi, 2012, American journal of clinical pathology.

Treatment of hairy cell leukemia during pregnancy: are purine analogues and rituximab viable therapeutic options.

H. Kantarjian, F. Ravandi, N. Daver, 2013, Clinical lymphoma, myeloma & leukemia.

The bruton tyrosine kinase inhibitor ibrutinib (PCI‐32765) blocks hairy cell leukaemia survival, proliferation and B cell receptor signalling: a new therapeutic approach

F. Ravandi, J. Burger, R. Kreitman, 2014, British journal of haematology.

Exome analysis of treatment‐related AML after APL suggests secondary evolution

Christopher A. Miller, J. Welch, S. Heath, 2018, British journal of haematology.

Case series of patients with acute myeloid leukemia receiving hypomethylation therapy and retrospectively found to have IDH1 or IDH2 mutations

D. Wheeler, P. Qiu, M. Konopleva, 2014, Leukemia and Lymphoma.

Atypical cases of necrotizing sweet syndrome in patients with myelodysplastic syndrome and acute myeloid leukaemia

G. Garcia-Manero, S. Verstovsek, F. Ravandi, 2020, British journal of haematology.

Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemia

Hoang Q. Nguyen, P. Thall, E. Estey, 2015, Haematologica.

Incidence of second malignancies in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitors

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2019, International Journal of Hematology.

Clonal chromosomal abnormalities in Philadelphia chromosome-negative metaphases (CCA/Ph-) emerge as patients with chronic phase chronic myeloid leukemia (CP-CML) are treated with tyrosine kinase

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2017 .

Efficacy of Frontline Nilotinib Therapy in Patients (Pts) with Newly Diagnosed Philadelphia Chromosome (Ph)-Positive Chronic Myeloid Leukemia in Early Chronic Phase (CML-CP)

M. Konopleva, E. Burton, H. Kantarjian, 2011 .

Results of salvage therapy with mini-hyper-CVD and inotuzumab ozogamicin with or without blinatumomab in pre-B acute lymphoblastic leukemia

G. Garcia-Manero, T. Kadia, F. Ravandi, 2023, Journal of Hematology & Oncology.

F. Ravandi, 2011, Haematologica.

Inotuzumab Ozogamicin In Combination With Low-Intensity Chemotherapy (Mini-hyper-CVD) As Frontline Therapy For Older Patients (≥60 years) With Acute Lymphoblastic Leukemia (ALL)

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2013 .

Ponatinib and Blinatumomab for Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Subgroup Analysis from a Phase II Study

G. Garcia-Manero, Xuelin Huang, T. Kadia, 2022, Blood.

A Prognostic Model of Therapy-Related Myelodysplastic syndrome .

Z. Estrov, G. Garcia-Manero, J. Cortes, 2009 .

Prognositc Factors and Survival in Patients with Hypocellular Myelodysplastic Syndrome: Development of a Disease Specific Prognostic Score.

H. Kantarjian, G. Garcia-Manero, T. Kadia, 2009 .

Modeling interactions between leukemia‐specific chromosomal changes, somatic mutations, and gene expression patterns during progression of core‐binding factor leukemias

H. Kantarjian, G. Garcia-Manero, F. Ravandi, 2009, Genes, chromosomes & cancer.

Acute promyelocytic leukemia (APL) with an IRF2BP2-RARA fusion transcript: an aggressive APL variant

M. Konopleva, A. Futreal, K. Patel, 2020, Leukemia & lymphoma.

Unrecognized fluid overload during induction therapy increases morbidity in patients with acute promyelocytic leukemia

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2019, Cancer.

Treatment of patients with acute promyelocytic leukemia: a consensus statement on risk-adapted approaches to therapy.

M. Tallman, F. Ravandi, M. Sanz, 2010, Clinical lymphoma, myeloma & leukemia.

Forodesine (FodosineTM), a PNP Inhibitor Active in Relapsed or Refractory T-Cell Leukemia Patients (Phase II Study).

F. Ravandi, L. Isola, G. Iosava, 2005 .

61st Annual Conference of Indian Society of Hematology & Blood Transfusion (ISHBT) November 2020

Marina, M. Andreeff, H. Kantarjian, 2020, Indian Journal of Hematology and Blood Transfusion.

A phase I study of moxetumomab pasudotox in adults with relapsed or refractory B‐cell acute lymphoblastic leukaemia

M. Konopleva, H. Kantarjian, J. Cortes, 2018, British journal of haematology.

Expression of apoptosis proteins in chronic myelogenous leukemia

M. Andreeff, H. Kantarjian, J. Cortes, 2001, Cancer.

Salvage Therapy with Combined Cyclophosphamide (C), Fludarabine (F), Alemtuzumab (A), and Rituximab (R) (CFAR) for Heavily Pre-Treated Patients with CLL.

M. Andreeff, G. Garcia-Manero, J. Cortes, 2005 .

Continuous Infusion/Subcutaneous Alemtuzumab (Campath-1H) Plus Rituximab Is Active for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL).

G. Garcia-Manero, F. Ravandi, M. Keating, 2005 .

A retrospective study of cladribine and low‐dose cytarabine–based regimens for the treatment of chronic myelomonocytic leukemia and secondary acute myeloid leukemia

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2022, Cancer.

NPM1 mutant variant allele frequency correlates with leukemia burden but does not provide prognostic information in NPM1‐mutated acute myeloid leukemia

M. Konopleva, H. Kantarjian, J. Cortes, 2019, American journal of hematology.

Clinical significance of MYC expression in acute myeloid leukemia.

Z. Estrov, P. Fox, H. Kantarjian, 2014 .

Prediction model for mortality after intracranial hemorrhage in patients with leukemia

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2011, American journal of hematology.

Phase II study of vorinostat (V) in combination with idarubicin and high-dose cytarabine (IA) as front-line therapy in patients (pts) with high-risk myelodyplsatic syndrome (MDS) or acute myeloid leukemia (AML).

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2009, Journal of Clinical Oncology.

Updated Results of a Phase II Study of Reduced-Intensity Chemotherapy with Mini-Hyper-CVD in Combination with Inotuzumab Ozogamicin, with or without Blinatumomab, in Older Adults with Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2019, Blood.

Updated Results from the Phase II Study of Hyper-CVAD in Sequential Combination with Blinatumomab in Newly Diagnosed Adults with B-Cell Acute Lymphoblastic Leukemia (B-ALL)

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2019, Blood.

Sequential Combination of Inotuzumab Ozogamicin (InO) with Low-Intensity Chemotherapy (Mini-hyper-CVD) with or without Blinatumomab Is Highly Effective in Patients (pts) with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL) in First Relapse

M. Konopleva, Z. Estrov, H. Kantarjian, 2019, Blood.

Sequential Combination of Low-Intensity Chemotherapy (Mini-hyper-CVD) Plus Inotuzumab Ozogamicin with or without Blinatumomab in Patients with Relapsed/Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL): A Phase 2 Trial

M. Konopleva, Z. Estrov, H. Kantarjian, 2018, Blood.

A phase 2 study of hyper-CVAD plus ofatumumab as frontline therapy in CD20+ acute lymphoblastic leukemia (ALL): Updated results.

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2018 .

Inotuzumab Ozogamicin in Combination with Bosutinib for Patients with Relapsed or Refractory Ph+ ALL or CML in Lymphoid Blast Phase

M. Konopleva, H. Kantarjian, J. Cortes, 2017 .

Conditional survival in patients with chronic myeloid leukemia in chronic phase in the era of tyrosine kinase inhibitors

M. Konopleva, H. Kantarjian, J. Cortes, 2016, Cancer.

Frontline Therapy for Older Patients (pts) with Acute Myeloid Leukemia (AML): Clofarabine Plus Low-Dose Cytarabine Induction Followed by Prolonged Consolidation with Clofarabine Plus Low-Dose Cytarabine Alternating with Decitabine

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2010 .

Efficacy of Dasatinib in Patients (pts) with Previously Untreated Chronic Myelogenous Leukemia (CML) in Early Chronic Phase (CML-CP).

H. Kantarjian, J. Cortes, F. Ravandi, 2007 .

Disease Patterns for Patients (pts) with Chronic Myeloid Leukemia (CML) That Have BCR-ABL Transcript Levels > 10% At 3 Month of Therapy with Tyrosine Kinase Inhibitors (TKIs)

H. Kantarjian, J. Cortes, A. Quintás-Cardama, 2012 .

Phase I and pharmacodynamic trial of AT9283, an aurora kinase inhibitor, in patients with refractory leukemia

H. Kantarjian, F. Ravandi, G. Borthakur, 2008 .

Purine analogues in advanced T-cell lymphoid malignancies.

R. Kurzrock, F. Ravandi, 2006, Seminars in hematology.

The achievement of an early complete cytogenetic response is a major determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2010, Blood.

Inotuzumab Ozogamicin in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) As Frontline Therapy for Older Patients with Acute Lymphoblastic Leukemia (ALL): Interim Result of a Phase II Clinical Trial

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2016 .

Salvage Chemotherapy with Inotuzumab Ozogamicin (INO) Combined with Mini-Hyper-CVD for Adult Patients with Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL)

M. Konopleva, Z. Estrov, H. Kantarjian, 2015 .

Very long‐term follow‐up results of imatinib mesylate therapy in chronic phase chronic myeloid leukemia after failure of interferon alpha therapy

Susan O'Brien, Jorge Cortes, H. Kantarjian, 2012, Cancer.

Single-Cell Mass Cytometry Reveals Phenotypic and Functional Heterogeneity In Acute Myeloid Leukemia At Diagnosis and In Remission

P. Qiu, M. Konopleva, M. Andreeff, 2013 .

Outcomes of adult patients with relapsed/refractory CRLF2 rearranged B‐cell acute lymphoblastic leukemia

C. Mullighan, T. Kadia, F. Ravandi, 2023, American journal of hematology.

Association of Pleural Effusion and Bleeding in Patients with Chronic Myelogenous Leukemia Receiving Dasatinib.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2008 .

Outcome Of Patients (pts) With Myelofibrosis (MF) After Ruxolutinib (Rux) Therapy

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2013 .

Detection of Minimal Residual Leukemia Predicts the Outcome of Patients with Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia Treated with Tyrosine Kinase Inhibitors Plus Chemotherapy

Z. Estrov, H. Kantarjian, J. Cortes, 2011 .

Long-Term Follow-up of Combined Hypercvad (hCVAD) Regimen with Dasatinib (Db) in the Front Line Therapy of Patients (pts) with Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)

H. Kantarjian, J. Cortes, F. Ravandi, 2011 .

Combination of the Hypercvad Regimen with Dasatinib Is Effective in Patients with Relapsed Philadelphia Chromosome (Ph) Positive Acute Lymphoblastic Leukemia (ALL) and Lymphoid Blast Phase Chronic Myeloid Leukemia (CML-LB).

H. Kantarjian, J. Cortes, F. Ravandi, 2009 .

Combination of the hyperCVAD Regimen with Dasatinib Is Effective in Patients with Relapsed Philadelphia Chromosome (Ph) Positive Acute Lymphoblastic Leukemia (ALL) and Lymphoid Blast Phase Chronic Meyloid Leukemia (CML-LB)

H. Kantarjian, J. Cortes, F. Ravandi, 2008 .

The effect of decitabine dose modification and myelosuppression on response and survival in patients with myelodysplastic syndromes

Guillermo Garcia-Manero, Angela Teng, H. Kantarjian, 2015, Leukemia & lymphoma.

Characteristics and Clinical Outcomes of Patients with Acute Lymphoblastic Leukemia with KMT2A (MLL) Rearrangement

M. Konopleva, Z. Estrov, H. Kantarjian, 2019, Blood.

Association between bariatric surgery and outcomes in chronic myeloid leukemia

H. Kantarjian, G. Garcia-Manero, T. Kadia, 2023, Cancer.

The LEukemia Artificial Intelligence Program (LEAP) in chronic myeloid leukemia in chronic phase: A model to improve patient outcomes

M. Konopleva, G. Garcia-Manero, J. Cortes, 2020, American journal of hematology.

Chronic myeloid leukemia among patients with a history of prior malignancies: A tale of dual survivorship

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2017, Cancer.

Patients with Chronic Myeloid Leukemia with Variant Philadelphia Chromosome (Ph) Translocations Have a Similar Outcome as Those with Classic Ph When Treated with Imatinib or 2nd Generation TKI

Z. Estrov, H. Kantarjian, J. Cortes, 2008 .

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2013, Clinical lymphoma, myeloma & leukemia.

Venetoclax Combined with Cladribine + Low Dose AraC (LDAC) Alternating with 5-Azacytidine Produces High Rates of Minimal Residual Disease (MRD) Negative Complete Remissions (CR) in Older Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)

M. Konopleva, Z. Estrov, M. Andreeff, 2019, Blood.

Detectable FLT3-ITD or RAS mutation at the time of transformation from MDS to AML predicts for very poor outcomes.

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2015, Leukemia research.

Phase II study of combination of the hyperCVAD regimen with dasatinib in patients (pts) with newly diagnosed Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL)

H. Kantarjian, J. Cortes, F. Ravandi, 2008 .

Outcome after frontline therapy with the hyper-CVAD and imatinib mesylate regimen for adults with de novo or minimally treated Philadelphia (Ph) positive acute lymphoblastic leukemia (ALL)

H. Kantarjian, J. Cortes, F. Ravandi, 2008 .

A Phase I/II Trial of Combination of Midostaurin (PKC412) and 5-Azacytidine (5-AZA) for the Treatment of Patients with Refractory or Relapsed (R/R) Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2012 .

Updated results from the phase II study of hyper-CVAD in combination with ofatumumab as frontline therapy for adults with CD20 positive (CD20+) acute lymphoblastic leukemia (ALL).

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2016 .

Ten-year follow up of patients with newly diagnosed chronic myeloid leukemia in chronic phase treated with 400 mg or 800 mg of imatinib daily.

H. Kantarjian, J. Cortes, S. Verstovsek, 2014 .

A Phase I Trial of AT9283, a Multitargeted Kinase Inhibitor, in Patients with Refractory Hematological Malignancies.

H. Kantarjian, J. Cortes, S. Verstovsek, 2007 .

Prognostic Factors for Progression in Patients (pts) with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) in Complete Molecular Response (CMR) within 3 Months of Therapy with Tyrosine Kinase Inhibitors (TKIs)

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2019, Blood.

Long term follow-up of frontline dasatinib in patients (pts) with early chronic phase chronic myeloid leukemia (CML-CP).

Z. Estrov, H. Kantarjian, J. Cortes, 2016 .

Checkpoint Expression By Acute Myeloid Leukemia (AML) and the Immune Microenvironment Suppresses Adaptive Immunity

P. Sharma, M. Konopleva, M. Andreeff, 2017 .

Clinicopathologic Correlates and Natural History of Atypical Chronic Myeloid Leukemia

M. Konopleva, Z. Estrov, H. Kantarjian, 2020, bioRxiv.

SL-401, A Targeted Therapy Directed to the Interleukin-3 Receptor Present On Leukemia Blasts and Cancer Stem Cells, Is Active As a Single Agent in Patients with Advanced AML

M. Konopleva, M. Andreeff, H. Kantarjian, 2012 .

Outcome of adults with relapsed/refractory T‐cell acute lymphoblastic leukemia or lymphoblastic lymphoma

M. Konopleva, H. Kantarjian, F. Ravandi, 2020, American journal of hematology.

Machine Learning Integrates Genomic Signatures for Subclassification Beyond Primary and Secondary Acute Myeloid Leukemia.

Jacob G. Scott, T. Haferlach, H. Kantarjian, 2021, Blood.

Pediatric-Based Therapy for Young Adults with Newly Diagnosed Lymphoblastic Leukemia.

H. Kantarjian, J. Cortes, T. Kadia, 2009 .

Outcome for Adolescents and Young Adults (AYA) with the Hyper-CVAD (with or without Rituximab) Regimens for De Novo Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma.

H. Kantarjian, J. Cortes, F. Ravandi, 2009 .

Phase I Study of the Combination of 5-Azacitidine Sequentially with High-Dose Lenalidomide in Higher-Risk Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)

M. Konopleva, Z. Estrov, H. Kantarjian, 2011 .

Ruxolitinib or Dasatinib in Combination with Chemotherapy for Patients with Relapsed/Refractory Philadelphia (Ph)-like Acute Lymphoblastic Leukemia: A Phase I-II Trial

C. Mullighan, M. Konopleva, H. Kantarjian, 2017 .

Clinical Significance of Deeper Molecular Responses with Four Modalities of Tyrosine Kinase Inhibitors As Frontline Therapy for Chronic Myeloid Leukemia

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2012 .

A phase I study of pemetrexed in patients with relapsed or refractory acute leukemia

H. Kantarjian, F. Ravandi, W. Plunkett, 2011, Investigational New Drugs.

Multi-Center US Intergroup Study of Intensive Chemotherapy Plus Dasatinib Followed By Allogeneic Stem Cell Transplant in Patients with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Younger Than 60

J. Radich, F. Appelbaum, H. Kantarjian, 2015 .

Inotuzumab Ozogamicin in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) Vs. Standard Intensive Chemotherapy (hyper-CVAD) As Frontline Therapy for Older Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL): A Propensity Score Analysis

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2018, Blood.

Prediction of Early (4-week) Mortality in Acute Myeloid Leukemia with Intensive Chemotherapy.

M. Konopleva, G. Garcia-Manero, T. Kadia, 2021, American journal of hematology.

Clonal Dynamics and Clinical Implications of Post-Remission Clonal Hematopoiesis in Acute Myeloid Leukemia (AML).

P. A. Futreal, M. Konopleva, H. Kantarjian, 2019, Blood.

Mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in the subgroup of older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: long-term results of an open-label phase 2 trial.

H. Kantarjian, G. Garcia-Manero, Xuelin Huang, 2023, The Lancet. Haematology.

Ultrasensitive NGS MRD assessment in Ph+ ALL: Prognostic impact and correlation with RT‐PCR for BCR::ABL1

K. Patel, F. Ravandi, E. Jabbour, 2023, American journal of hematology.

Characteristics and outcomes of patients with therapy-related acute myeloid leukemia with normal karyotype

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2020, Blood Cancer Journal.

Inotuzumab Ozogamycin (I0), a CD22 Monoclonal Antibody Conjugated to Calecheamicin, Is Active in Refractory-Relapse Acute Lymphocytic Leukemia (R-R ALL)

H. Kantarjian, J. Cortes, F. Ravandi, 2011 .

Venetoclax Dosing in Combination with Antifungal Agents: Real World Experience in Patients with Acute Myeloid Leukemia

M. Konopleva, H. Kantarjian, T. Kadia, 2019, Blood.

Phase II Study of Cladribine, Idarubicin, and Cytarabine (araC) in Patients with Acute Myeloid Leukemia (AML)

M. Konopleva, Z. Estrov, H. Kantarjian, 2015 .

Final Report of a Phase I/II Study of Hyper-CVAD Plus RAD001 (Everolimus) in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia

M. Konopleva, H. Kantarjian, Y. Boumber, 2012 .

Acute promyelocytic leukemia can be treated successfully without cytotoxic chemotherapy.

F. Ravandi, 2011, Oncology.

A propensity score matching analysis of dasatinib and nilotinib as a frontline therapy for patients with chronic myeloid leukemia in chronic phase

H. Kantarjian, G. Garcia-Manero, T. Kadia, 2016, Cancer.

Full Doses of Crenolanib, a Type I FLT3 Inhibitor, Can be Safely Administered in AML Patients Post Allogeneic Stem Cell Transplant

R. Collins, H. Kantarjian, J. Cortes, 2015 .

Hypomethylating Agent (HMA) Therapy and Venetoclax (VEN) with FLT3 Inhibitor "Triplet" Therapy Is Highly Active in Older/Unfit Patients with FLT3 Mutated AML

M. Konopleva, M. Andreeff, H. Kantarjian, 2021, Blood.

Venetoclax in Combination with FLAG-IDA Chemotherapy (FLAG-V-I) for Fit, Relapsed/Refractory AML Patients: Interim Results of a Phase 1b/2 Dose Escalation and Expansion Study

M. Konopleva, H. Kantarjian, J. Cortes, 2018, Blood.

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2022, American journal of hematology.

Senior adult oncology: three cases of advanced cancer in patients of advanced age.

F. Ravandi, A. Chapman, S. Lichtman, 2012, Seminars in oncology.

Current and emerging treatments for acute promyelocytic leukemia

F. Ravandi, K. Naqvi, M. Yilmaz, 2019, Expert Opinion on Orphan Drugs.

Intensive chemotherapy is more effective than hypomethylating agents for the treatment of younger patients with myelodysplastic syndrome and elevated bone marrow blasts

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2019, American journal of hematology.

Nivolumab (Nivo) maintenance (maint) in high-risk (HR) acute myeloid leukemia (AML) patients.

M. Konopleva, H. Kantarjian, J. Cortes, 2018 .

Prognosis of patients with intermediate risk IPSS‐R myelodysplastic syndrome indicates variable outcomes and need for models beyond IPSS‐R

M. Andreeff, H. Kantarjian, G. Garcia-Manero, 2018, American journal of hematology.

Dabrafenib plus trametinib in patients with relapsed/refractory BRAF V600E mutation–positive hairy cell leukemia

Z. Wainberg, F. Ravandi, S. Dietrich, 2022, Blood.

Revisiting Co-existing Chromosomal Abnormalities in NPM1-mutated AML in Light of the Revised ELN 2022 classification.

G. Juliusson, F. Ravandi, A. Wei, 2022, Blood.

Serum Beta-2 Microglobulin: The Universal Independent Prognostic Factor for Patients with CLL.

H. Kantarjian, J. Cortes, F. Ravandi, 2005 .

Development of a distributed international patient data registry for hairy cell leukemia

M. Grever, A. Saven, P. Zinzani, 2022, Leukemia & lymphoma.

Prognostic significance of hyperdiploidy in adult acute myeloid leukemia

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2018, American journal of hematology/oncology.

Phase IB/II study of lirilumab with azacytidine (AZA) in relapsed AML.

P. Sharma, M. Konopleva, M. Andreeff, 2017 .

A Phase 1 Trial of SGN-CD33A As Monotherapy in Patients with CD33-Positive Acute Myeloid Leukemia (AML)

F. Ravandi, D. DeAngelo, J. Lancet, 2015 .

Myeloid neoplasms with isolated isochromosome 17q demonstrate a high frequency of mutations in SETBP1, SRSF2, ASXL1 and NRAS

F. Stingo, P. Fox, G. Garcia-Manero, 2016, Oncotarget.

Outcome of Elderly Patients with Acute Myeloid Leukemia (AML) Post Hypomethylating Agent (HMA) Failure.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2012 .

Efficacy and safety of an anti-FLT3 antibody (LY3012218) in patients with relapsed acute myeloid leukemia.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2015 .

Phase I Study of Triciribine Phosphate Monohydrate, a Specific Inhibitor of AKt Phosphorylation, in Adult Patients with Advanced Hematologic Malignancies.

Z. Estrov, H. Kantarjian, F. Ravandi, 2007 .

Outcomes of patients with therapy‐related myeloid neoplasms after treatment with poly(ADP‐ribose) polymerase proteins inhibitors for solid tumours

H. Kantarjian, G. Garcia-Manero, T. Kadia, 2023, British journal of haematology.

MLL gene amplification in acute myeloid leukemia and myelodysplastic syndromes is associated with characteristic clinicopathological findings and TP53 gene mutation.

F. Ravandi, C. Dinardo, L. Medeiros, 2015, Human pathology.

Forodesine IV (Bcx-1777) Is Clinically Active in Relapsed/Refractory T-Cell Leukemia: Results of a Phase II Study (Interim Report).

F. Ravandi, R. Furman, D. Hoelzer, 2006 .

Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapy

M. Konopleva, M. Andreeff, H. Kantarjian, 2022, Blood Cancer Journal.

Memory Impairment in Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Patients (pts) Treated with Dasatinib Tyrosine Kinase Inhibitor (TKI) Therapy

E. Burton, H. Kantarjian, J. Cortes, 2011 .

NCCN CLINICAL PRACTICE GUIDELINES IN ONCOLOGY Acute Myeloid Leukemia, Version 3.2019

F. Appelbaum, K. Gregory, M. Tallman, 2019 .

Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms

R. Collins, D. Bottomly, S. McWeeney, 2019, Nature Communications.

Updated Results from a Phase I/II Study of the Triplet Combination of Azacitidine, Venetoclax and Gilteritinib for Patients with FLT3-Mutated Acute Myeloid Leukemia

G. Garcia-Manero, T. Kadia, F. Ravandi, 2022, Blood.

A Phase I/II Study of Combination of ASTX727, Gilteritinib and Venetoclax in Patients with Relapsed/Refractory FLT3 Mutated Acute Myeloid Leukemia (AML) and Frontline FLT3 Mutated AML Patients Unfit for Chemotherapy

G. Garcia-Manero, T. Kadia, F. Ravandi, 2022, Blood.

A Phase II Study of Azacitidine, Venetoclax and Trametinib in Relapsed/Refractory AML Harboring a Ras Pathway-Activating Mutation

M. Konopleva, H. Kantarjian, T. Kadia, 2021, Blood.

Azacitidine (AZA) with Nivolumab (Nivo), and AZA with Nivo + Ipilimumab (Ipi) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia: Clinical and Immune Biomarkers of Response

P. Sharma, M. Konopleva, M. Andreeff, 2020 .

Comprehensive immunophenotypic study of acute myeloid leukemia with KMT2A (MLL) rearrangement in adults: A single‐institution experience

F. Ravandi, L. Medeiros, Shaoying Li, 2021, Cytometry. Part B, Clinical cytometry.

Chemotherapy-free treatment of acute promyelocytic leukemia.

F. Ravandi, 2015, Clinical advances in hematology & oncology : H&O.

A randomized open label exploratory controlled trial of CLT-008 myeloid progenitor cells (MPC) to decrease infections during induction for AML.

O. Frankfurt, F. Ravandi, J. Pagel, 2018 .

Acute Myeloid Leukemia, Version 3.2023, NCCN Clinical Practice Guidelines in Oncology.

Deborah A. Freedman-Cass, F. Ravandi, G. Marcucci, 2023, Journal of the National Comprehensive Cancer Network : JNCCN.

Low-level expression of SAMHD1 in acute myeloid leukemia (AML) blasts correlates with improved outcome upon consolidation chemotherapy with high-dose cytarabine-based regimens

M. Andreeff, H. Kantarjian, T. Schaller, 2018, Blood Cancer Journal.

Acute lymphoblastic leukemia arising in post-polycythemic myelofibrosis: a rare entity

Z. Estrov, H. Kantarjian, S. Verstovsek, 2012, Leukemia & lymphoma.

Significant Activity of the JAK2 Inhibitor, INCB018424 in Patients with Secondary, Post-Myeloproliferative Disorder (MPD) Acute Myeloid Leukemia (sAML): Results of An Exploratory Phase II Study.

Z. Estrov, H. Kantarjian, S. Verstovsek, 2009 .

Can Measurable Residual Disease (MRD) assessment be reliably used to defer allogeneic stem cell transplant in patients with intermediate-risk acute myeloid leukemia?

F. Ravandi, M. Swaminathan, 2023, Haematologica.

Ocular extramedullary myeloid leukaemia

Z. Estrov, J. Manning, F. Ravandi, 2018, British journal of haematology.

Phase I Study of AVE9633, an AntiCD33-Maytansinoid Immunoconjugate, Administered as an Intravenous Infusion in Patients with Refractory/Relapsed CD33-Positive Acute Myeloid Leukemia (AML).

S. Verstovsek, F. Ravandi, D. DeAngelo, 2006 .

Treatment‐free remission in patients with chronic myeloid leukemia following the discontinuation of tyrosine kinase inhibitors

G. Garcia-Manero, J. Cortes, T. Kadia, 2022, American journal of hematology.

Characteristics and clinical outcomes of patients with acute myeloid leukemia with inv(3)(q21q26.2) or t(3;3)(q21;q26.2)

M. Konopleva, K. Bhalla, H. Kantarjian, 2023, Haematologica.

Proteomic Profiling of 150 Proteins in 511 Acute Myelogenous Leukemia (AML) Patient Samples Using Reverse Phase Proteins Arrays (RPPA) Reveals Recurrent Proteins Expression Signatures with Prognostic Implications

K. Coombes, Z. Ju, Nianxiang Zhang, 2008 .

Philadelphia-Like Genetic Rearrangements in Adults With B-Cell ALL: Refractoriness to Chemotherapy and Response to Tyrosine Kinase Inhibitor in ABL Class Rearrangements.

C. Mullighan, K. Patel, T. Kadia, 2023, JCO precision oncology.

A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agents

M. Andreeff, G. Garcia-Manero, J. Cortes, 2023, Journal of Hematology & Oncology.

AML-513 The Role of FLT3 Inhibitors in Patients With Acute Myeloid Leukemia (AML) and T(6;9)(P22;Q34).

G. Garcia-Manero, T. Kadia, F. Ravandi, 2022, Clinical lymphoma, myeloma & leukemia.

Prolonged survival in patients >= 60 years with first relapsed/refractory acute myeloid leukemia treated with vosaroxin plus cytarabine vs placebo plus cytarabine: Results from the phase 3 VALOR study

Jennifer A. Smith, G. Acton, H. Kantarjian, 2015 .

VALOR, an adaptive design, pivotal phase III trial of vosaroxin or placebo in combination with cytarabine in first relapsed or refractory acute myeloid leukemia

Michael Craig, Robert K. Stuart, Gary Acton, 2012 .

Updated results from DIAMOND-01 (CLI24-001) trial: A phase I/II study of SEL24/MEN1703, a first-in-class dual PIM/FLT3 kinase inhibitor, in acute myeloid leukemia.

A. Santoro, G. Martinelli, F. Ravandi, 2021 .

Venetoclax, FLT3 Inhibitor and Decitabine in FLT3mut Acute Myeloid Leukemia: Subgroup Analysis of a Phase II Trial

M. Konopleva, H. Kantarjian, T. Kadia, 2020 .

Phase I-II Study of Crenolanib Combined with Standard Salvage Chemotherapy and Crenolanib Combined with 5-Azacitidine in Acute Myeloid Leukemia Patients with FLT3 Activating Mutations

M. Konopleva, M. Andreeff, H. Kantarjian, 2018, Blood.

Additional Chromosomal Abnormalities in Philadelphia Chromosome-Negative Metaphases Appearing during Therapy with Imatinib, Dasatinib, Nilotinib and Ponatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2015 .

Long-Term Outcome after Hyper-CVAD and Rituximab Chemoimmunotherapy for Burkitt (BL) or Burkitt-Like (BLL) Leukemia/Lymphoma and Mature B-Cell Acute Lymphocytic Leukemia (ALL).

H. Kantarjian, J. Cortes, F. Ravandi, 2007 .

Phase I Studies

Farhad, M. Ratain, R. Larson, 2022 .

A Phase 1, Open-Label, Multicenter Study of HMPL-306 in Advanced Hematological Malignancies with Isocitrate Dehydrogenase (IDH) Mutations

F. Ravandi, V. Jayaprakash, A. Doraiswamy, 2021, Blood.

Undetectable measurable residual disease is associated with improved outcomes in AML irrespective of treatment intensity

M. Konopleva, M. Andreeff, H. Kantarjian, 2023, Blood advances.

Outcomes in Molecular Subgroups and Resistance Patterns with Ten-Day Decitabine and Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia

J. Welch, M. Konopleva, M. Andreeff, 2019, Blood.

Biologic features and clinical outcomes in newly diagnosed myelodysplastic syndrome with KMT2A rearrangements

G. Garcia-Manero, T. Kadia, F. Ravandi, 2023, American journal of hematology.

Updated results from phase II study of guadecitabine for patients with higher risk myelodysplastic syndromes or chronic myelomonocytic leukemia.

M. Andreeff, H. Kantarjian, G. Garcia-Manero, 2017 .

Natural history of newly diagnosed myelodysplastic syndrome with isolated inv(3)/t(3;3)

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2020, American journal of hematology/oncology.

Updated Results of a Phase II Study of Ponatinib and Blinatumomab for Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2021, Blood.

Cladribine Combined with Idarubicin and Ara-C (CLIA) As a Frontline and Salvage Treatment for Young Patients (≤65 yrs) with Acute Myeloid Leukemia

M. Konopleva, Z. Estrov, H. Kantarjian, 2016 .

Cardiovascular Events Among Patients with Chronic Myeloid Leukemia (CML) Treated with Tyrosine Kinase Inhibitors (TKIs)

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2016 .

Significance of FAB subclassification of "acute myeloid leukemia, NOS" in the 2008 WHO classification: analysis of 5848 newly diagnosed patients.

E. Estey, R. Hills, F. Appelbaum, 2013, Blood.

A New Nonrandom Chromosomal Translocation of Clonal Evolution in Chronic Myeloid Leukemia

H. Kantarjian, J. Cortes, F. Ravandi, 2001 .

Alemtuzumab

F. Ravandi, S. O'brien, 2005, Reactions Weekly.

A Phase I/II Study with CP-4055 in Patients with Haematologic Malignancies.

H. Kantarjian, F. Ravandi, F. Giles, 2007 .

Venetoclax for Acute Myeloid Leukemia in Pediatric Patients: A Texas Medical Center Collaboration

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2021, Blood.

FLT3 Inhibitor Treatment in FLT3-Mutated AML Is Associated with Development of Secondary FLT3-TKD Mutations

M. Konopleva, Z. Estrov, M. Andreeff, 2011 .

Acquired Point Mutations of TKD Are Responsible for Sorafenib Resistance in FLT3-ITD Mutant AML,

M. Konopleva, M. Andreeff, J. Cortes, 2011 .

PHF6 mutations in myelodysplastic syndromes, chronic myelomonocytic leukemia and acute myeloid leukemia.

G. Garcia-Manero, T. Kadia, F. Ravandi, 2023, Leukemia research.

Phase 2 Study of Combination of Cytarabine, Idarubicin, and Nivolumab for Initial Therapy of Patients with Newly Diagnosed Acute Myeloid Leukemia

P. Sharma, M. Konopleva, Z. Estrov, 2017 .

Venetoclax for Acute Myeloid Leukemia in Pediatric Patients: A Texas Medical Center Experience

G. Garcia-Manero, T. Kadia, F. Ravandi, 2023, Cancers.

Mutated NPM1 in patients with acute myeloid leukemia in remission and relapse

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2014, Leukemia & lymphoma.

Inotuzumab Ozogamicin (IO) in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) as Frontline Therapy for Older Patients (pts) and as Salvage Therapy for Adult with Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL)

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2015 .

Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib (PCI-32765) Blocks Hairy Cell Leukemia (HCL) Survival, Proliferation, and BCR Signaling: A New Therapeutic Approach for HCL

F. Ravandi, J. Burger, J. Buggy, 2012 .

Phase I trial of {alpha}-particle therapy with actinium-225 (225Ac)-lintuzumab (anti-CD33) and low-dose cytarabine (LDAC) in older patients with untreated acute myeloid leukemia (AML.

E. Estey, D. Scheinberg, H. Kantarjian, 2015 .

A Randomized Phase II Trial of 5-Day Versus 10-Day Schedules of Decitabine for Older Patients with Previously Untreated Acute Myeloid Leukemia

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2017 .

Phase 2 Study of ASTX727 (cedazuridine/decitabine) Plus Venetoclax in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) or Previously Untreated, Elderly Patients with AML Unfit for Chemotherapy

M. Konopleva, G. Garcia-Manero, T. Kadia, 2022, Blood.

Phase Ib/2 Study of Oral Decitabine/Cedazuridine (ASTX727) and Venetoclax in Combination with the Targeted Mutant IDH1 Inhibitor Ivosidenib or the Targeted Mutant IDH2 Inhibitor Enasidenib in IDH Mutated Acute Myeloid Leukemia

M. Konopleva, M. Andreeff, G. Garcia-Manero, 2022, Blood.

Targeted therapy with the mutant IDH2 inhibitor enasidenib for high-risk IDH2-mutant myelodysplastic syndrome

H. Kantarjian, G. Garcia-Manero, T. Kadia, 2022, Blood advances.

Impact of type of induction therapy on outcomes in older adults with AML after allogeneic stem cell transplantation

M. Konopleva, H. Kantarjian, E. Shpall, 2023, Blood advances.

Evolving trends and outcomes in older patients with acute myeloid leukemia including allogeneic stem cell transplantation.

G. Garcia-Manero, E. Shpall, T. Kadia, 2023, American journal of hematology.

Venetoclax Added to Cladribine (CLAD) + Low Dose AraC (LDAC) Alternating with Azacitidine (AZA) Is Highly Active As Frontline Therapy in Older Patients with Newly Diagnosed Acute Myeloid Leukemia in a Phase 2 Study

K. Bhalla, G. Garcia-Manero, T. Kadia, 2022, Blood.

Activity of venetoclax-based therapy in chronic myelomonocytic leukemia

M. Konopleva, Z. Estrov, H. Kantarjian, 2021, Leukemia.

Clinical Outcomes with Hypomethylating Agents in Patients with Myelodysplastic Syndrome/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T); A Case Series

H. Kantarjian, G. Garcia-Manero, S. Verstovsek, 2020 .

Updated Results of CPX-351 in Combination with Gemtuzumab Ozogamicin (GO) in Relapsed Refractory (R/R) Acute Myeloid Leukemia (AML) and Post-Hypomethylating Agent (Post-HMA) Failure High-Risk Myelodysplastic Syndrome (HR-MDS)

M. Konopleva, M. Andreeff, G. Garcia-Manero, 2022, Blood.

A Phase II Study of the Hyper-CVAD Regimen in Sequential Combination with Blinatumomab As Frontline Therapy for Adults with B-Cell Acute Lymphoblastic Leukemia (B-ALL)

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2018, Blood.

Chemoimmunotherapy with Inotuzumab Ozogamicin Combined with Mini-Hyper-CVD, with or without Blinatumomab, for Newly Diagnosed Older Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: Results from a Phase II Study

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2018, Blood.

Ultrasensitive Duplex Sequencing of Pretreatment ABL1 Kinase Domain Mutations in Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

J. Radich, M. Konopleva, H. Kantarjian, 2018, Blood.

Cladribine Combined with Idarubicin and High-Dose AraC (CLIA2) As a Frontline and Salvage Treatment for Young Patients (≤65 yrs) with Acute Myeloid Leukemia

M. Konopleva, Z. Estrov, H. Kantarjian, 2016, Blood.

Preliminary activity of AMN107, a novel potent oral selective Bcr-Abl tyrosine kinase inhibitor, in newly diagnosed Philadelphia chromosome (Ph)-positive chronic phase chronic myelogenous leukemia (CML-CP).

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical, pharmacokinetic and pharmacodynamic data for the MEK1/2 inhibitor pimasertib in patients with advanced hematologic malignancies

T. Kadia, F. Ravandi, D. DeAngelo, 2015, Blood Cancer Journal.

Neurologic complications associated with intrathecal liposomal cytarabine given prophylactically in combination with high-dose methotrexate and cytarabine to patients with acute lymphocytic leukemia.

H. Kantarjian, G. Garcia-Manero, F. Ravandi, 2007, Blood.

Phase I Study of Palbociclib Alone and in Combination in Patients with Relapsed and Refractory (R/R) Leukemias

M. Konopleva, K. Bhalla, H. Kantarjian, 2018, Blood.

A model for prediction of FLT3‐ITD and NPM1 (without FLT3‐ITD) positivity in patients with newly diagnosed acute myeloid leukaemia

E. Estey, S. Meshinchi, D. Stirewalt, 2013, British journal of haematology.

Declining Rates of Treatment-Related Mortality in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Given “Intensive” Induction Regimens: A Report From the Southwest Oncology Group (SWOG) and MD Anderson Cancer Center (MDA)

E. Estey, F. Appelbaum, H. Kantarjian, 2012 .

The distribution of T‐cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia

P. Sharma, M. Konopleva, M. Andreeff, 2018, Cancer.

era: analysis of patient from six trials.

M. Konopleva, P. Jain, F. Ravandi, 2016 .

Phase I Trial of Targeted Alpha-Particle Therapy with Actinium-225 (225Ac)-Lintuzumab and Low-Dose Cytarabine (LDAC) in Patients Age 60 or Older with Untreated Acute Myeloid Leukemia (AML)

E. Estey, D. Scheinberg, H. Kantarjian, 2016 .

Comparison of mold active triazoles as primary antifungal prophylaxis in patients with newly diagnosed acute myeloid leukemia in the era of molecularly targeted therapies.

T. Kadia, F. Ravandi, C. Dinardo, 2022, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Different Definitions of Progression-Free Survival (PFS) and Event-Free Survival (EFS) May Result In Perceived but Not Real Differences In Long-Term Outcome When Comparing Trials In Chronic Myeloid Leukemia (CML)

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2010 .

Integrative genomic analysis of adult mixed phenotype acute leukemia delineates lineage associated molecular subtypes

P. A. Futreal, Erika J. Thompson, M. Konopleva, 2018, Nature Communications.

Decitabine Is Effective In Patients with Myelodysplastic Syndromes Who Failed Prior Intensive Regimen: No Negative Impact of Prior Therapy

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2010 .

Phase I/II Study of the Oral Isotype-Selective Histone Deacetylase (HDAC) Inhibitor MGCD0103 in Combination with Azacitidine in Patients (pts) with High-Risk Myelodysplastic Syndrome (MDS) or Acute Myelogenous Leukemia (AML).

J. Issa, A. Yang, H. Kantarjian, 2006 .

Efficacy and Safety of the Bruton Tyrosine Kinase Inhibitor Ibrutinib in Patients with Hairy Cell Leukemia: Stage 1 Results of a Phase 2 Study

Jeffrey A Jones, M. Grever, G. Lozanski, 2016 .

Phase I study of BP1001 (Liposomal Grb2 Antisense) in patients with hematologic malignancies.

M. Konopleva, M. Andreeff, G. Garcia-Manero, 2016 .

Measurable residual disease monitoring in patients with acute myeloid leukemia treated with lower-intensity therapy: Roadmap from an ELN-DAVID expert panel.

K. Döhner, M. Heuser, C. Hourigan, 2023, American journal of hematology.

Phenotypic subtypes of leukaemic transformation in chronic myelomonocytic leukaemia.

G. Garcia-Manero, T. Kadia, F. Ravandi, 2023, British journal of haematology.

Updated Phase IIb Results of Venetoclax with FLAG-IDA in Relapsed or Refractory Acute Myeloid Leukemia

M. Konopleva, M. Andreeff, G. Garcia-Manero, 2022, Blood.

Final Results of Phase I/II Study of Selinexor (SEL) with Sorafenib in Patients (pts) with Relapsed and/or Refractory (R/R) FLT3 Mutated Acute Myeloid Leukemia (AML)

M. Konopleva, Z. Estrov, M. Andreeff, 2018, Blood.

Prognostic significance of the Medical Research Council cytogenetic classification compared with the European LeukaemiaNet risk classification system in acute myeloid leukaemia

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2015, British journal of haematology.

A Randomized Trial of High-Dose (HD) Imatinib Mesylate (IM) with or without Peg-Interferon (PEG-IFN) and GM-CSF as Frontline Therapy for Patients with Chronic Myeloid Leukemia (CML) in Early Chronic Phase (CP).

Z. Estrov, M. Andreeff, H. Kantarjian, 2005 .

In Vivo Response to Sequential Tyrosine Kinase Inhibitors (TKI) in Chronic Myeloid Leukemia (CML) Modeled Based on In Vitro Properties of Particular BCR-ABL Kinase Domain (KD) Mutations.

Z. Estrov, H. Kantarjian, J. Cortes, 2007 .

Acute myeloid leukemia (AML) in adolescents and young adults (AYA): The M. D. Anderson Cancer Center (MDACC) experience.

H. Kantarjian, J. Cortes, F. Ravandi, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Evaluating measurable residual disease in acute myeloid leukemia.

F. Ravandi, R. Walter, S. Freeman, 2018, Blood advances.

Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin.

E. Estey, Z. Estrov, H. Kantarjian, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Acute myeloid leukemia with t(9;11)(p21-22;q23): common properties of dysregulated ras pathway signaling and genomic progression characterize de novo and therapy-related cases.

H. Kantarjian, G. Garcia-Manero, F. Ravandi, 2010, American Journal of Clinical Pathology.

Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia

H. Kantarjian, J. Cortes, F. Ravandi, 2013, Cancer.

Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study.

H. Kantarjian, J. Cortes, F. Ravandi, 2012, The Lancet. Oncology.

Acute myeloid leukemia clinical practice guidelines in oncology.

J. Byrd, E. Estey, M. Millenson, 2006, Journal of the National Comprehensive Cancer Network : JNCCN.

Toward Individualized Therapy in Acute Myeloid Leukemia: A Contemporary Review.

H. Kantarjian, J. Cortes, T. Kadia, 2015, JAMA oncology.

Lack of association of IDH1, IDH2 and DNMT3A mutations with outcome in older patients with acute myeloid leukemia treated with hypomethylating agents

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2014, Leukemia & lymphoma.

Genomic Landscape of Mixed Phenotype Acute Leukemia (MPAL)

M. Konopleva, M. Andreeff, Chang-Jiun Wu, 2017 .

Monoclonal antibodies in acute lymphoblastic leukemia.

H. Kantarjian, F. Ravandi, E. Jabbour, 2015, Blood.

A Phase I/II Study of the mTOR Inhibitor Everolimus in Combination with HyperCVAD Chemotherapy in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia

K. Baggerly, M. Konopleva, Wenbin Liu, 2015, Clinical Cancer Research.

Phase I study of sorafenib in patients with refractory or relapsed acute leukemias

M. Konopleva, M. Andreeff, H. Kantarjian, 2011, Haematologica.

Prognostic impact of CD20 and CD25 expression in patients with Philadelphia-positive (Ph + ) acute lymphoblastic leukemia (ALL)

H. Kantarjian, J. Cortes, F. Ravandi, 2010 .

Prognostic Impact of CD20 and CD25 Expression in Patients with Philadelphia-Positive (Ph + ) Acute Lymphoblastic Leukemia (ALL).

H. Kantarjian, J. Cortes, F. Ravandi, 2009 .

Conditional survival in patients with chronic myeloid leukemia in chronic phase in the era of tyrosine kinase inhibitors

M. Konopleva, H. Kantarjian, J. Cortes, 2016, Cancer.

Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2011, Blood.

Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia.

H. Kantarjian, J. Cortes, F. Ravandi, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Next-Generation Sequencing of DDX41 in Myeloid Neoplasms Leads to Increased Detection of Germline Alterations

K. Bhalla, H. Kantarjian, G. Garcia-Manero, 2021, Frontiers in Oncology.

Ruxolitinib in combination with lenalidomide as therapy for patients with myelofibrosis

H. Kantarjian, J. Cortes, S. Verstovsek, 2015, Haematologica.

The history of oral decitabine/cedazuridine and its potential role in acute myeloid leukemia

H. Kantarjian, G. Garcia-Manero, F. Ravandi, 2023, Therapeutic Advances in Hematology.

10-day vs 5-day decitabine: equivalence cannot be concluded - Authors' reply.

F. Ravandi, N. Short, 2019, The Lancet. Haematology.

Cladribine and low-dose cytarabine alternating with decitabine as front-line therapy for elderly patients with acute myeloid leukaemia: a phase 2 single-arm trial.

M. Konopleva, Z. Estrov, H. Kantarjian, 2018, The Lancet. Haematology.

Incidence of secondary neoplasms in patients with acute promyelocytic leukemia treated with all-trans retinoic acid plus chemotherapy or with all-trans retinoic acid plus arsenic trioxide

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2015, Leukemia & lymphoma.

Initial Results of a Phase 2 Study of Guadecitabine (SGI-110), a Novel Subcutaneous (sc) Hypomethylating Agent, for Patients with Previously Untreated Intermediate-2 or High Risk Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML)

M. Andreeff, H. Kantarjian, G. Garcia-Manero, 2016 .

Phase I Study of the Akt-Inhibitor Triciribine Phosphate Monohydrate in Patients with Advanced Hematologic Malignancy

H. Kantarjian, G. Garcia-Manero, S. Verstovsek, 2008 .

Minimal residual disease assessed by multi‐parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2016, British journal of haematology.

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2008, Blood.

Acute myeloid leukemia: Clinical Practice Guidelines in Oncology

M. Millenson, F. Appelbaum, K. Gregory, 2006 .

Patterns of Molecular Response to and Relapse After Combination of Sorafenib, Idarubicin, and Cytarabine in Patients with Newly Diagnosed FLT3-Mutant Acute Myeloid Leukemia (AML).

M. Konopleva, M. Andreeff, H. Kantarjian, 2009 .

FLT3 Inhibitor Therapy for Patients with Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML): Impact On Survival According to FLT3 Status.

M. Konopleva, M. Andreeff, H. Kantarjian, 2009 .

Phase II Study of Vorinostat in Combination with Idarubicin (Ida) and Cytarabine (ara-C) as Front Line Therapy in Acute Myelogenous Leukemia (AML) or Higher Risk Myelodysplastic Syndrome (MDS).

M. Konopleva, Z. Estrov, H. Kantarjian, 2009 .

Peripheral blood blast clearance is an independent prognostic factor for survival and response to acute myeloid leukemia induction chemotherapy

P. Qiu, M. Konopleva, M. Andreeff, 2016, American journal of hematology.

Single-Cell Atlas of Driver Mutations in Acute Myeloid Leukemia (AML)

Erika J. Thompson, M. Konopleva, M. Andreeff, 2018, Blood.

Long‐term durable remission by cladribine followed by rituximab in patients with hairy cell leukaemia: update of a phase II trial

H. Kantarjian, P. Jain, F. Ravandi, 2016, British journal of haematology.

Clinical outcomes in adult patients with aplastic anemia: A single institution experience

S. Parmar, H. Kantarjian, G. Garcia-Manero, 2017, American journal of hematology.

Single-Center Experience of Immunosuppressive Therapy with or without Eltrombopag in Patients with Aplastic Anemia

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2015 .

A phase II study of hyper-CVAD with blinatumomab (blina) and inotuzumab ozogamicin (INO) for newly diagnosed Philadelphia chromosome (Ph)–negative B-cell acute lymphoblastic leukemia (ALL).

H. Kantarjian, T. Kadia, F. Ravandi, 2023, Journal of Clinical Oncology.

P369: A PHASE II STUDY OF MINI-HYPER-CVD PLUS VENETOCLAX IN PATIENTS WITH PHILADELPHIA CHROMOSOME-NEGATIVE ACUTE LYMPHOBLASTIC LEUKEMIA

T. Kadia, F. Ravandi, E. Jabbour, 2022, HemaSphere.

Updated Results from a Phase II Study of Mini-Hyper-CVD Plus Inotuzumab Ozogamicin, with or without Blinatumomab, in Older Adults with Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2021, Blood.

Ph-like acute lymphoblastic leukemia: a high-risk subtype in adults.

C. Mullighan, M. Konopleva, H. Kantarjian, 2017, Blood.

S118: A CHEMOTHERAPY-FREE COMBINATION OF PONATINIB AND BLINATUMOMAB FOR PATIENTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA: SUBGROUP ANALYSIS FROM A PHASE II STUDY

M. Konopleva, Xuelin Huang, T. Kadia, 2023, HemaSphere.

A phase II trial of ponatinib and blinatumomab in adults with newly diagnosed Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL).

H. Kantarjian, Xuelin Huang, T. Kadia, 2023, Journal of Clinical Oncology.

Allogeneic Hematopoietic Stem Cell Transplant Versus No Transplant in Adult Patients with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia in First Complete Remission and Complete Molecular Remission

F. Gao, P. Westervelt, J. Dipersio, 2020 .

Replacing Gemtuzumab Ozogamicin With Idarubicin In Frontline Fludarabine, Cytarabine and G-CSF Based Regimen Does Not Compromise Outcome In Core Binding Factor Acute Myelogenous Leukemia

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2013 .

Effect of fludarabine, cytarabine, filgrastim, and gemtuzumab ozogamicin (FLAG-GO) on relapse-free survival in patients with newly diagnosed core-binding factor acute myelogenous leukemia.

Z. Estrov, H. Kantarjian, J. Cortes, 2012 .

Clofarabine, Idarubicin, and Cytarabine (CIA) As Frontline Therapy for Patients <= 60 Years with Newly Diagnosed Acute Myeloid Leukemia (AML)

M. Konopleva, Z. Estrov, M. Andreeff, 2011 .

Inotuzumab Ozogamicin (IO) Is An Effective Salvage Therapy That Allows for Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Remission in Patients with Advanced Acute Lymphoblastic Leukemia (ALL)

H. Kantarjian, F. Ravandi, S. O'brien, 2011 .

Incidence of and risk factors for involvement of the central nervous system in acute myeloid leukemia

Z. Estrov, G. Garcia-Manero, J. Cortes, 2015, Leukemia & lymphoma.

Tyrosine kinase inhibitors as initial therapy for patients with chronic myeloid leukemia in accelerated phase.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2014, Clinical lymphoma, myeloma & leukemia.

Neurologic complications associated with intrathecal liposomal cytarabine given prophylactically in combination with high-dose methotrexate and cytarabine to patients with acute lymphocytic leukemia.

H. Kantarjian, G. Garcia-Manero, F. Ravandi, 2007, Blood.

Chronic myeloid leukemia 2011: Successes, challenges, and strategies—Proceedings of the 5th annual BCR‐ABL1 positive and BCR‐ABL1 negative myeloproliferative neoplasms workshop

J. Radich, G. Martinelli, R. V. van Etten, 2011, American journal of hematology.

Dasatinib early intervention after cytogenetic or hematologic resistance to imatinib in patients with chronic myeloid leukemia

H. Kantarjian, J. Cortes, F. Ravandi, 2009, Cancer.

Importance of Early Intervention with Dasatinib at Cytogenetic Rather Than Hematologic Resistance to Imatinib.

H. Kantarjian, J. Cortes, F. Ravandi, 2007 .

A phase I dose-escalation study of the novel KSP inhibitor ARRY-520 in advanced leukemias.

Z. Estrov, G. Garcia-Manero, T. Kadia, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Report of a phase 1/2 study of a combination of azacitidine and cytarabine in acute myelogenous leukemia and high-risk myelodysplastic syndromes

D. Berry, J. Issa, H. Kantarjian, 2010, Leukemia & lymphoma.

Long-Term Follow up of a Phase II Study of Guadecitabine (SGI-110) in Patients with Higher-Risk Myelodysplastic Syndrome (MDS)

H. Kantarjian, G. Garcia-Manero, T. Kadia, 2020 .

A Phase II Study of Double Immune Checkpoint Inhibitor Blockade with Nivolumab and Ipilimumab with or without Azacitidine in Patients with Myelodysplastic Syndrome (MDS)

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2020 .

Preliminary Results from the Phase II Study of the IDH2-Inhibitor Enasidenib in Patients with High-Risk IDH2-Mutated Myelodysplastic Syndromes (MDS)

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2019, Blood.

Early Results of the Phase I/II Study Investigating the All-Oral Combination of the Menin Inhibitor Revumenib (SNDX-5613) with Decitabine/Cedazuridine (ASTX727) and Venetoclax in Acute Myeloid Leukemia (SAVE)

H. Kantarjian, G. Garcia-Manero, T. Kadia, 2023, Blood.

A phase Ib/II study of ivosidenib with venetoclax +/- azacitidine in IDH1-mutated myeloid malignancies.

P. Vyas, M. Konopleva, H. Kantarjian, 2023, Blood cancer discovery.

Venetoclax combined with FLAG‐IDA induction and consolidation in newly diagnosed acute myeloid leukemia

M. Konopleva, M. Andreeff, H. Kantarjian, 2022, American journal of hematology.

The mutational landscape of cold agglutinin disease: CARD11 and CXCR4 mutations are correlated with lower hemoglobin levels

M. Konopleva, H. Kantarjian, T. Kadia, 2021 .

5-Azacytidine (AZA) in Combination with Ruxolitinib (RUX) As Therapy for Patients (pts) with Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPNs)

M. Konopleva, Z. Estrov, H. Kantarjian, 2015 .

Phase 2 Trial of Mini-Hyper-CVD Plus Inotuzumab Ozogamicin, with or without Blinatumomab, in Older Patients with Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia

H. Kantarjian, T. Kadia, F. Ravandi, 2023, Blood.

Chemotherapy-Free Combination of Blinatumomab and Ponatinib in Adults with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Updates from a Phase II Trial

H. Kantarjian, Xuelin Huang, T. Kadia, 2023, Blood.

S119: COMBINATION OF MINI-HYPER-CVD AND INOTUZUMAB (INO) FOLLOWED BY BLINATUMOMAB (BLINA) CONSOLIDATION IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL): A PHASE II TRIAL

G. Garcia-Manero, Xuelin Huang, T. Kadia, 2023, HemaSphere.

P358: HYPER-CVAD WITH BLINATUMOMAB AND INOTUZUMAB OZOGAMICIN FOR PATIENTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-NEGATIVE B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA: A PHASE II STUDY

T. Kadia, F. Ravandi, E. Jabbour, 2023, HemaSphere.

A phase II trial of a chemotherapy-free combination of ponatinib and blinatumomab in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).

H. Kantarjian, T. Kadia, F. Ravandi, 2022, Journal of Clinical Oncology.

A Phase II Study of Low-Intensity Chemotherapy (Mini-Hyper-CVD) and Ponatinib Followed By Blinatumomab and Ponatinib in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

H. Kantarjian, F. Ravandi, E. Jabbour, 2023, Blood.

P576: A PHASE I/II STUDY OF MILADEMETAN (DS3032B) IN COMBINATION WITH LOW DOSE CYTARABINE WITH OR WITHOUT VENETOCLAX IN ACUTE MYELOID LEUKEMIA

S. Kornblau, M. Andreeff, F. Ravandi, 2022, HemaSphere.

Evaluation of Romyelocel-L Myeloid Progenitor Cells to Decrease Infections in De Novo AML Patients Receiving High-Dose Ara-C-Based Induction Therapy

S. Kambhampati, H. Kantarjian, T. Kadia, 2018, Blood.

Addition of All-Trans Retinoic Acid (ATRA) to the Combination of Fludarabine, Cytarabine, Idarubicin, with or without GCSF in Older, Higher Risk Patients with AML and High-Risk MDS Does Not Improve the Outcome in Those with NPM1 Mutation.

E. Estey, H. Kantarjian, J. Cortes, 2012 .

Treatment of older adults with FLT3-mutated AML: Emerging paradigms and the role of frontline FLT3 inhibitors

F. Ravandi, N. Short, Daniel Nguyen, 2023, Blood cancer journal.

Activity of Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib (PCI-32765) in B-Cell Acute Lymphoblastic Leukemia (B-ALL).

Z. Estrov, H. Kantarjian, F. Ravandi, 2012 .

Phase 1 Results of Bromodomain and Extraterminal Inhibitor PLX51107 in Combination with Azacitidine in Patients with Relapsed/Refractory Myeloid Malignancies.

K. Bhalla, G. Garcia-Manero, T. Kadia, 2023, Clinical cancer research : an official journal of the American Association for Cancer Research.

Survival is poorer in patients with secondary core‐binding factor acute myelogenous leukemia compared with de novo core‐binding factor leukemia

H. Kantarjian, J. Cortes, F. Ravandi, 2009, Cancer.